Hydrocortisone hemisuccinate is a synthetic corticosteroid that is a derivative of hydrocortisone. It is a prodrug that is rapidly converted to hydrocortisone in the body. Hydrocortisone hemisuccinate is used to treat a variety of inflammatory conditions, including allergic reactions, inflammatory bowel disease, and rheumatoid arthritis. It is also used to suppress the immune system in patients who have received organ transplants. Hydrocortisone hemisuccinate is typically administered intravenously or intramuscularly. It is a highly effective medication, but it can have serious side effects, including high blood pressure, weight gain, and osteoporosis. The synthesis of hydrocortisone hemisuccinate involves the reaction of hydrocortisone with succinic anhydride. This reaction produces a hemisuccinate ester that is more water-soluble than hydrocortisone itself. The increased water solubility allows for easier administration of the drug and faster absorption into the bloodstream. Hydrocortisone hemisuccinate is an important medication because it is effective in treating a wide range of inflammatory conditions. It is also used to suppress the immune system in patients who have received organ transplants. The study of hydrocortisone hemisuccinate is ongoing, and researchers are constantly looking for ways to improve its efficacy and safety. One area of research is the development of new formulations of the drug that have fewer side effects. Another area of research is the development of new uses for hydrocortisone hemisuccinate, such as in the treatment of cancer.'
hydrocortisone succinate : A derivative of succinic acid in which one of the carboxy groups is esterified by the C-21 hydroxy group of cortisol (hydrocortisone). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 16623 |
| CHEMBL ID | 977 |
| CHEBI ID | 31677 |
| SCHEMBL ID | 7664 |
| MeSH ID | M0050132 |
| Synonym |
|---|
| MLS002207249 |
| AC-6828 |
| MLS001146928 , |
| nsc-7576 |
| LMST02030126 |
| 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione 21-succinate |
| hydrocortisone succinate |
| 11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-(hydrogensuccinate) |
| 2203-97-6 |
| cortisol succinate |
| LOPAC0_000623 |
| aftasome |
| oralsome |
| saxizon |
| hydrocortisone roussel |
| hydrocortisone hydrogen succinate |
| hydrocortisone leurquin |
| cortisol 21-hemisuccinate |
| preg-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11-beta)- |
| cortisol, 21-(hydrogen succinate) |
| hydrocortisonum hemisuccinatum |
| hydrocortisone 21-hemisuccinate |
| (11-beta)-21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxypreg-4-ene-3,20-dione |
| hydrocortisone 21-succinate |
| einecs 218-612-3 |
| aacicortisol |
| cortisol, hydrogen succinate |
| hydrocortisone 21-(hydrogen succinate) |
| 4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethoxy]-4-oxo-butanoic acid |
| cortisol hemisuccinate |
| 4-((11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl)oxy)-4-oxobutanoic acid |
| solucortef |
| pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11, 17-dihydroxy- |
| hydrocortisone succinate (jp17) |
| D01442 |
| smr000058328 |
| MLS000028530 , |
| CHEMBL977 |
| chebi:31677 , |
| 4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid |
| bdbm50016931 |
| HMS3259A14 |
| 4-{2-[(1r,3as,3bs,9ar,9bs,10s,11as)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid |
| EN300-55845 |
| ihv1vp592v , |
| hydrocortisone succinate [jan] |
| unii-ihv1vp592v |
| 3-{[2-((1s,10s,11s,15s,17s,2r,14r)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyc lo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-14-yl)-2-oxoethyl]oxycarbonyl}propanoic acid |
| ST075193 |
| A815861 |
| 4-[2-[(8s,9s,10r,11s,13s,14s,17r)-10,13-dimethyl-11,17-bis(oxidanyl)-3-oxidanylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxidanylidene-ethoxy]-4-oxidanylidene-butanoic acid |
| 4-{2-[(1s,2r,10s,11s,14r,15s,17s)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl]-2-oxoethoxy}-4-oxobutanoic acid |
| HMS2235G13 |
| AKOS015969742 |
| hydrocortisone hydrogen succinate [who-dd] |
| hydrocortisone hydrogen succinate [ep monograph] |
| hydroxycortisone succinate [inci] |
| hydroxycortisone succinate |
| cortisol 21-(hydrogen succinate) |
| S5972 |
| NC00567 |
| hydrocortisone 21-hemisuccinate*free acid |
| SCHEMBL7664 |
| W-107508 |
| OPERA_ID_1732 |
| DTXSID40872905 |
| GS-6198 |
| hydrocortisone hydrogen succinate, european pharmacopoeia (ep) reference standard |
| hydrocortisone 21-hemisuccinate, analytical standard |
| hydrocortisone hydrogen succinate, british pharmacopoeia (bp) reference standard |
| hydrokortison-21-hemisuccinat |
| DB14545 |
| 4-(2-((8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-4-oxobutanoic acid |
| Q27104202 |
| CS-0013125 |
| hydrocortisone-hemisuccinate |
| hydrocortisone 21-he |
| pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11b)- |
| HY-B1402 |
| (11beta)-21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxypregn-4-ene-3,20-dione |
| Class | Description |
|---|---|
| dicarboxylic acid monoester | A monoester of a dicarboxylic acid. |
| hemisuccinate | A succinate ester in which only one of the carboxy groups of succinic acid has been esterified. |
| tertiary alpha-hydroxy ketone | An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Smad3 | Homo sapiens (human) | Potency | 3.1623 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 0.7943 | 0.0013 | 7.7625 | 44.6684 | AID914; AID915 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 0.2662 | 0.0041 | 9.9848 | 25.9290 | AID504444; AID720524 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.2589 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Mus musculus (house mouse) | Kd | 0.1900 | 0.1900 | 0.1900 | 0.1900 | AID1150111 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protease | Human immunodeficiency virus 1 | ID50 | 27.0000 | 0.0014 | 0.8549 | 1.7000 | AID162539 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleoplasm | Glucocorticoid receptor | Mus musculus (house mouse) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588461 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588460 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588459 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID358767 | Inhibition of scrapie form PrP production in mouse GT1-7 cells infected with human transmissible spongiform encephalopathies agent Fukuoka1 by Western blot | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 104, Issue:29 | Hot spots in prion protein for pathogenic conversion. |
| AID1273986 | Inhibition of TNFalpha production in C57Bl/6 mouse BMDM cells at 1.6 to 6.4 uM pretreated prior to LPS-stimulation measured on day 7 by ELISA | 2015 | Journal of natural products, Dec-24, Volume: 78, Issue:12 | Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages. |
| AID162539 | Evaluated for the inhibition of HIV-1 Protease. | 1996 | Journal of medicinal chemistry, May-10, Volume: 39, Issue:10 | Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching. |
| AID1273988 | Inhibition of IL-1beta production in C57Bl/6 mouse BMDM cells at 1.6 to 6.4 uM pretreated for 1 hr prior to ATP-stimulation by ELISA | 2015 | Journal of natural products, Dec-24, Volume: 78, Issue:12 | Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages. |
| AID1273987 | Inhibition of IL-6 production in C57Bl/6 mouse BMDM cells at 1.6 to 6.4 uM pretreated prior to LPS-stimulation measured on day 7 by ELISA | 2015 | Journal of natural products, Dec-24, Volume: 78, Issue:12 | Serrulatane Diterpenoid from Eremophila neglecta Exhibits Bacterial Biofilm Dispersion and Inhibits Release of Pro-inflammatory Cytokines from Activated Macrophages. |
| AID358768 | Cytotoxicity against mouse GT1-7 cells at 1 uM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 104, Issue:29 | Hot spots in prion protein for pathogenic conversion. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1150111 | Displacement of 1 x 10'-8 M of [1,2,3-3H]-triamcinolone acetonide from glucocorticoid receptor in soluble fraction of mouse L929 cells after 20 hrs | 1977 | Journal of medicinal chemistry, Sep, Volume: 20, Issue:9 | Synthesis and biological action of two glucocorticoid alkylating agents. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1224864 | HCS microscopy assay (F508del-CFTR) | 2016 | PloS one, , Volume: 11, Issue:10 | Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (55.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Pilot Study of Ifosfamide, Carboplatin and Etoposide Therapy (ICE) and SGN-30 (NSC# 731636, IND#) in Children With CD30+ Recurrent Anaplastic Large Cell Lymphoma [NCT00354107] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2007-01-31 | Terminated | ||
| Single Centre, Subject and Observer Blinded, Placebo Controlled, Cross-over Study of the Effect of Oral Ibuprofen and Topical Hydrocortisone-21-acetate on Ultraviolet Radiation (UVR) Induced Pain and Inflammation in Healthy Volunteers [NCT01055249] | Phase 1 | 24 participants (Anticipated) | Interventional | 2010-01-31 | Completed | ||
| Monocentric, Double-blind Placebo-Controlled, Randomized Cross-Sectional Clinical Trial of Hydrocortisone (10 and 30 mg/d) in Outpatients With Posttraumatic-Stress-Disorder (PTSD) [NCT01108146] | 30 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1) [NCT05008146] | Early Phase 1 | 80 participants (Anticipated) | Interventional | 2020-12-31 | Recruiting | ||
| The Role of Stress Neuromodulators in Decision Making Under Risk [NCT04359147] | 167 participants (Actual) | Interventional | 2019-11-01 | Completed | |||
| Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis. [NCT03422159] | Phase 2 | 140 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [NCT03813147] | Phase 1 | 12 participants (Actual) | Interventional | 2019-05-17 | Active, not recruiting | ||
| Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia [NCT02096510] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2014-08-31 | Recruiting | ||
| Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. [NCT01941589] | Phase 4 | 149 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse [NCT04546399] | Phase 2 | 550 participants (Anticipated) | Interventional | 2020-12-04 | Suspended(stopped due to Other - FDA Partial Clinical Hold) | ||
| Assessment of Application Order When Utilizing Locoid Lotion and Hylatopic Plus Cream in the Treatment of Atopic Dermatitis [NCT02153762] | 41 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma [NCT02043587] | Phase 2 | 31 participants (Actual) | Interventional | 2014-01-31 | Terminated(stopped due to Original investigator for the trial has left) | ||
| Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) [NCT00096135] | 168 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| A Multi-center, Randomized, Placebo-controlled, Double-blind, Adaptive Clinical Trial of Vitamin C, Thiamine and Steroids as Combination Therapy in Patients With Sepsis. [NCT03509350] | Phase 3 | 501 participants (Actual) | Interventional | 2018-08-22 | Completed | ||
| Phase IV Study to Evaluate the Neuropsychological Effects of Hydrocortisone Substitution in Patients With Partial Adrenal Insufficiency After Traumatic Brain Injury or Subarachnoidal Haemorrhage [NCT01089075] | Phase 4 | 32 participants (Actual) | Interventional | 2010-02-28 | Terminated(stopped due to Insufficient recruitment of suitable patients.) | ||
| The VitamIn C, HydrocorTisone and ThiAMINe in Patients With Septic Shock Trial (VITAMINS Trial) - A Prospective, Feasibility, Pilot, Multi-centre, Randomised, Open-label Controlled Trial [NCT03333278] | Phase 2 | 216 participants (Actual) | Interventional | 2018-05-02 | Completed | ||
| A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations [NCT04293562] | Phase 3 | 1,400 participants (Anticipated) | Interventional | 2020-07-21 | Recruiting | ||
| Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter [NCT03165344] | 66 participants (Actual) | Interventional | 2017-02-10 | Completed | |||
| A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen [NCT02481310] | Phase 1/Phase 2 | 38 participants (Actual) | Interventional | 2015-10-28 | Active, not recruiting | ||
| Effect of Modified-release Compared to Conventional Hydrocortisone on Fatigue, Measured by Ecological Momentary Assessments; a Pilot Study. [NCT02282150] | Phase 4 | 30 participants (Anticipated) | Interventional | 2016-10-31 | Enrolling by invitation | ||
| Randomized Cross-over Trial in Patients Treated With Both Insulin & Hydrocortisone [NCT05716607] | 16 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | |||
| Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial [NCT03358082] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | ||
| Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions [NCT02230930] | Phase 2 | 20 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial [NCT02266264] | Phase 4 | 80 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916] | Phase 3 | 847 participants (Actual) | Interventional | 2014-10-04 | Active, not recruiting | ||
| International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147] | Phase 3 | 475 participants (Anticipated) | Interventional | 2017-08-08 | Recruiting | ||
| Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853] | Phase 3 | 669 participants (Actual) | Interventional | 2014-12-17 | Active, not recruiting | ||
| Single-center, Double-masked, Placebo-controlled Parallel-group Study of Pregnancy-related Hormones Estradiol and Medroxyprogesterone, in Conjunction With Hydrocortisone and Growth Hormone to Stimulate C-peptide Secretion in Women With T1DM [NCT01265017] | Phase 1 | 0 participants (Actual) | Interventional | 2012-07-31 | Withdrawn(stopped due to Insufficient funding) | ||
| Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study [NCT01230983] | Phase 3 | 573 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| Stress Hydrocortisone In Pediatric Septic Shock [NCT03401398] | Phase 3 | 1,032 participants (Anticipated) | Interventional | 2019-03-11 | Recruiting | ||
| Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS): a Prospective Randomized Double-blinded Clinical Trial [NCT04301479] | Phase 3 | 140 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis (Steroids in Paediatric Sepsis, StePS) - a Randomised Pilot Study [NCT00732277] | Phase 2 | 21 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| ASSESSMENT OF ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS USING CONCENTRATION OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL [NCT02859584] | 111 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Protein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Adrenal Insufficiency [NCT02152553] | 11 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) [NCT03110198] | Phase 4 | 528 participants (Anticipated) | Interventional | 2017-05-31 | Recruiting | ||
| The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression [NCT02837432] | Early Phase 1 | 192 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Open Label Randomised 3 Period Crossover Study to Evaluate Bioavailability of Modified Release Hydrocortisone (HC) Under Fasting & Fed Conditions & Immediate Release HC Tablets Under Fasting Conditions in Dexamethasone-suppressed Subjects [NCT02408068] | Phase 1 | 18 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study [NCT05354778] | 180 participants (Anticipated) | Interventional | 2022-10-16 | Recruiting | |||
| The Influence of Psychobiological Adversity to Children and Adolescents With Type 1 Diabetes [NCT02575001] | 207 participants (Actual) | Observational | 2015-07-31 | Completed | |||
| A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer [NCT06136598] | Phase 1 | 14 participants (Anticipated) | Interventional | 2023-12-25 | Not yet recruiting | ||
| Effect Of Hydrocortisone Phonophoresis Versus Iontophoresis In Patients With Subacromial Impingement Syndrome [NCT05919121] | 60 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) [NCT00098839] | Phase 1/Phase 2 | 134 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB T [NCT00057811] | Phase 2 | 97 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707] | Phase 3 | 10,000 participants (Anticipated) | Interventional | 2016-04-11 | Recruiting | ||
| Impact of Obesity on the Pharmacokinetics of Anticancer Therapy in Children With High Risk Acute Lymphoblastic Leukemia (ALL) [NCT00900445] | 0 participants (Actual) | Observational | 2008-03-24 | Withdrawn | |||
| A Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) Versus Paclitaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients With a Rising PSA After Hormonal Therapy f [NCT00027859] | Phase 3 | 0 participants | Interventional | 2003-10-08 | Completed | ||
| A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids [NCT02689856] | Phase 2 | 211 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception: A Randomized Controlled Trial [NCT02691858] | 80 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | |||
| A Comparative Clinical Trial to Evaluate the Efficacy and Safety of Tacrolimus Versus Hydrocortisone in Treatment of Children With Atopic Dermatitis [NCT05324618] | Phase 4 | 200 participants (Actual) | Interventional | 2022-05-15 | Completed | ||
| Randomized, Open Label, Crossover Study Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Administered as a Suppository With the Sephure® Rectal Suppository Applicator Compared With Cortenema in Healthy Subjects [NCT02671058] | Phase 1 | 16 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| A Phase II Pilot Trial of Bortezomib (PS-341, Velcade) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT00873093] | Phase 2 | 148 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| An Open-label, Prospective, Randomized, Controlled Clinical Trial of the Use of Reduced Duration Versus Standard Duration Steroid Replacement Therapy for Acute Adrenal Insufficiency in Patients With Septic Shock [NCT00842933] | Phase 4 | 32 participants (Anticipated) | Interventional | 2007-05-31 | Terminated(stopped due to Unable to meet enrollment goal prior to PI transfer) | ||
| DFCI ALL Adult Consortium Protocol: Adult ALL Trial [NCT01005758] | Phase 2 | 180 participants (Anticipated) | Interventional | 2009-01-31 | Not yet recruiting | ||
| A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410] | Phase 3 | 1,875 participants (Anticipated) | Interventional | 2023-05-11 | Recruiting | ||
| A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625] | Phase 3 | 6,720 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers [NCT01064986] | Phase 1 | 12 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Randomized, Double-Blind, Active-Controlled, Phase 3 Study of Chronocort Compared With Immediate-Release Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia [NCT05063994] | Phase 3 | 150 participants (Anticipated) | Interventional | 2021-12-13 | Active, not recruiting | ||
| Hair Cortisol and the Risk of Acute Myocardial Infarction [NCT00682487] | 120 participants (Actual) | Observational | 2008-06-30 | Completed | |||
| Pilot Study of Chinese Medicine Medicated Bath as Complementary Medicine for Mild to Moderate Plaque -Type Psoriasis Patient. [NCT04117919] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-05 | Recruiting | ||
| RESCUE - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency; A Multicentre, Randomised, Double Blinded, Placebo-controlled Clinical Trial on Health-related Quality of Life in Patients With Polymyalgia Rheumat [NCT05435781] | Phase 4 | 250 participants (Anticipated) | Interventional | 2022-06-07 | Recruiting | ||
| A Double Blind, Multicentre, Randomised, Parallel Group Study to Demonstrate the Equivalence of the Response to Vaccination of a Tacrolimus Ointment Regimen to a Steroid Ointment Regimen in Children With Moderate to Severe Atopic Dermatitis [NCT00801957] | Phase 2 | 260 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock. [NCT02768740] | Phase 4 | 120 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) [NCT01186328] | Phase 1 | 6 participants (Actual) | Interventional | 2010-08-24 | Terminated(stopped due to Enzon Pharmaceuticals decided to end its development of EZN-3042.) | ||
| A Phase I, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability Profile of Topical Cream SNG100 for 14 Days of Treatment in Moderate Atopic Dermatitis Subjects. [NCT04615962] | Phase 1 | 66 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| Interval Bolus Delivery of Subcutaneous Hydrocortisone Via Infusion Pump in Children With Congenital Adrenal Hyperplasia [NCT03718234] | Phase 1 | 11 participants (Actual) | Interventional | 2019-01-01 | Completed | ||
| Randomized, Placebo-Controlled Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids vs. Low-Potency Corticosteroid Mono-therapy [NCT00871208] | Phase 4 | 0 participants (Actual) | Interventional | 2009-05-31 | Withdrawn(stopped due to Funding withdrawn) | ||
| Phase III Study of Hydrocortisone in Patients With Severe H1N1 Related Pneumonia [NCT01014364] | Phase 3 | 40 participants (Actual) | Interventional | 2010-03-31 | Terminated(stopped due to the H1N1 pandemic is now over, and fewer cases than expected were observed) | ||
| Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2008-07-14 | Completed | ||
| Glucocorticoid Treatment in Addison's Disease [NCT01063569] | Phase 2/Phase 3 | 33 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation [NCT00460031] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-01 | Completed | ||
| Effect of Estrogen on the Stress Response for Postmenopausal Women [NCT00220454] | Phase 2 | 40 participants | Interventional | 2002-12-31 | Completed | ||
| Withholding Hydrocortisone vs Routine Use of Hydrocortisone During Peri-operation in Pituitary Adenoma Patients With Intact Hypothalamus-Pituitary-Adrenal Axis: Randomized Controlled Trial to Assess Safety and Complications [NCT04621565] | 436 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | |||
| [NCT01608945] | 60 participants (Actual) | Observational | 2008-04-30 | Suspended | |||
| Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis [NCT00693693] | Phase 4 | 26 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase I/II Study of Oral Calcitriol in Combination With Ketoconazole in Androgen Independent Prostate Cancer [NCT00536991] | Phase 1/Phase 2 | 51 participants (Actual) | Interventional | 2006-10-31 | Terminated(stopped due to difficult to recruit) | ||
| A Phase 2 Study of SNDX-5613 in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia [NCT05761171] | Phase 2 | 78 participants (Anticipated) | Interventional | 2023-11-20 | Recruiting | ||
| A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies [NCT05292664] | Phase 1 | 92 participants (Anticipated) | Interventional | 2023-03-29 | Recruiting | ||
| A Phase III Study of Efficacy, Safety and Tolerability of Chronocort® Compared With Standard Glucocorticoid Replacement Therapy in the Treatment of Congenital Adrenal Hyperplasia [NCT02716818] | Phase 3 | 122 participants (Actual) | Interventional | 2016-02-22 | Completed | ||
| A Phase 1 Study Of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, In Combination With Chemotherapy In Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Or Lymphoblastic Lymphoma (LL) [NCT03792256] | Phase 1 | 15 participants (Anticipated) | Interventional | 2019-04-11 | Active, not recruiting | ||
| Prospective, Randomized, Double-blind, Cohort Study of Hydrocortisone vs Placebo in Systemic Low Blood Pressure During Hypothermia Treatment in Asphyxiated Newborns [NCT02700828] | Phase 2/Phase 3 | 32 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Retrospective Study of Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome [NCT01423864] | Phase 2 | 29 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Hemodynamic and Biological Effects of Fludrocortisone and Hydrocortisone, in Healthy Volunteers With Aldosterone Induced Suppression [NCT00673270] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2008-05-31 | Terminated | ||
| A Randomized Pilot Trial of a Steroid-free Immunosuppressant Regimen in Pediatric Liver Transplantation [NCT00694408] | Phase 3 | 15 participants (Actual) | Interventional | 2008-06-30 | Terminated(stopped due to Study terminated due to withdrawal from market of Daclizumab) | ||
| Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis [NCT02602210] | Phase 3 | 100 participants (Actual) | Interventional | 2015-01-31 | Terminated(stopped due to low inclusion rate) | ||
| Gleevec (Imatinib) Plus Multi-Agent Chemotherapy For Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT00618501] | Phase 2 | 50 participants (Anticipated) | Interventional | 2005-10-31 | Completed | ||
| International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992] | 445 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | |||
| A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358] | Phase 2 | 78 participants (Actual) | Interventional | 2017-04-01 | Active, not recruiting | ||
| A Novel Therapeutic Modality for Congenital Adrenal Hyperplasia [NCT00529841] | 7 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193] | Phase 3 | 218 participants (Actual) | Interventional | 2008-01-15 | Active, not recruiting | ||
| Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial [NCT00623740] | Phase 3 | 523 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia [NCT05320380] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2023-08-01 | Withdrawn(stopped due to Withdrawn per CS0150757) | ||
| Effect of Oral Ketoconazole on the Pharmacokinetics of Oral Dexamethasone and Oral Hydrocortisone in Patients With Androgen Independent Prostate Cancer [NCT00559481] | 0 participants (Actual) | Interventional | 2007-10-31 | Withdrawn(stopped due to Withdrawn due to low accrual) | |||
| An Open-label, Randomized, Titration-blinded, Phase III Study of Efficacy, Safety and Tolerability Of Chronocort® Compared With Standard Glucocorticoid REeplacement Therapy in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hy [NCT03532022] | Phase 3 | 0 participants (Actual) | Interventional | 2018-10-04 | Withdrawn(stopped due to Protocol re-design required following EU Phase III results) | ||
| The Effects of Epinephrine and Cortisol on Emotion in Depression [NCT04148261] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn(stopped due to Principal Investigator left lab before study start) | ||
| A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700] | Phase 3 | 392 participants (Anticipated) | Interventional | 1995-08-31 | Completed | ||
| A PHASE III TWO-ARM RANDOMIZED STUDY COMPARING ANTIANDROGEN WITHDRAWAL ALONE VERSUS ANTIANDROGEN WITHDRAWAL COMBINED WITH KETOCONAZOLE AND HYDROCORTISON IN PATIENTS WITH ADVANCED PROSTAGE CANCER [NCT00002760] | Phase 3 | 260 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
| A Phase II Study of Compound 506U78 in Patients With Refractory T-Cell Malignancies-POG/CCG Intergroup Study [NCT00002970] | Phase 2 | 148 participants (Actual) | Interventional | 1997-06-30 | Completed | ||
| Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant [NCT00005802] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates - a Pharmacokinetic Study [NCT05836610] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-09-21 | Recruiting | ||
| Hemophagocytic Lymphohistiocytosis [NCT00334672] | Phase 3 | 288 participants (Anticipated) | Interventional | 2006-03-31 | Active, not recruiting | ||
| Influence of Hydrocortisone on Humoral and Cellular Immunologic Markers in High Risk Patients After Cardiac Surgery [NCT00490828] | Phase 4 | 120 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease [NCT00507832] | Phase 2 | 30 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma [NCT04759586] | Phase 3 | 244 participants (Anticipated) | Interventional | 2021-10-05 | Recruiting | ||
| The Safety of Proctofoam-HC in the Third Trimester of Pregnancy [NCT00405288] | 408 participants (Actual) | Observational | 2006-11-30 | Completed | |||
| Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas [NCT00691002] | Phase 3 | 1,245 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Treatment of Acute Lymphoblastic Leukemia in Children [NCT00400946] | Phase 3 | 800 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Phase III of Recombinant Human Activated Protein C and Low Dose of Hydrocortisone and Fludrocortisone in Adult Septic Shock [NCT00625209] | Phase 3 | 1,241 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A, Randomised, Controlled, Two-armed, Two-period Cross-over, Multi-centre Phase II/III Study to Assess the Safety and Pharmacokinetics of Once-daily Oral Modified-release Hydrocortisone in Patients With Adrenal Insufficiency [NCT00915343] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 2007-08-21 | Completed | ||
| Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia [NCT00002744] | Phase 3 | 1,970 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| Induction Intensification in Infant ALL: A Children's Oncology Group Study [NCT00002756] | Phase 2 | 221 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| "A Phase II Trial of Early Medical Adrenalectomy for D0.5 Prostate Cancer" [NCT00006371] | Phase 2 | 2 participants (Actual) | Interventional | 2000-05-31 | Terminated(stopped due to low accrual) | ||
| A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia [NCT00019409] | Phase 3 | 0 participants (Actual) | Interventional | 1999-10-31 | Withdrawn | ||
| Intensive Induction Therapy for Children With Acute Lymphoblastic Leukemia (ALL) Who Experience a Bone Marrow Relapse [NCT00049569] | 126 participants (Anticipated) | Interventional | 2003-01-31 | Completed | |||
| The Effect of Glucocorticoid Pre-Treatment on the Systemic Cytokine Response to Endotoxin in Human Volunteers [NCT00396344] | 36 participants (Anticipated) | Interventional | 2006-10-31 | Completed | |||
| Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study [NCT00147004] | Phase 3 | 500 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in Adrenal Insufficiency [NCT05222152] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-11-23 | Active, not recruiting | ||
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in the Treatment of Symptomatic Internal Hemorrhoids. [NCT03335774] | Phase 2 | 103 participants (Actual) | Interventional | 2019-02-12 | Completed | ||
| Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache: a Randomized Double-blind Study [NCT02760862] | Phase 4 | 50 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| An Open Label Pilot Study to Investigate the Effects of Two Preparations of Hydrocortisone (Hydrocortisone 100mg/ml and Solu-Cortef) Injected Intramuscularly Into the Deltoid and Upper Thigh Muscle During the State of Hypocortisolaemia [NCT05350020] | Phase 4 | 8 participants (Anticipated) | Interventional | 2022-03-14 | Recruiting | ||
| Phase II Trial to Assess the Activity of Ketoconazole Plus GM-CSF in Patients With Prostate Cancer Progressive After Androgen Deprivation [NCT00309894] | Phase 2 | 49 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Congenital Adrenal Hyperplasia: Innovative Once Daily Dual Release Hydrocortisone Treatment [NCT03760835] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-08-11 | Recruiting | ||
| Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia [NCT01771328] | Phase 2 | 20 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study. [NCT01817153] | Phase 2/Phase 3 | 10 participants (Actual) | Interventional | 2013-11-05 | Terminated(stopped due to not enough recruitment) | ||
| Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes [NCT01840189] | Phase 2 | 2 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma [NCT01700946] | Phase 2 | 80 participants (Actual) | Interventional | 2013-04-15 | Completed | ||
| A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia [NCT01859312] | Phase 2 | 8 participants (Actual) | Interventional | 2013-05-06 | Completed | ||
| FAB LMB 96 -- Treatment of Mature B-CELL Lymphoma/Leukemia: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 Cooperative Study [NCT00002757] | Phase 3 | 1,148 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock [NCT01448109] | Phase 4 | 3,800 participants (Actual) | Interventional | 2012-06-13 | Completed | ||
| A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma [NCT01614197] | Phase 1 | 16 participants (Actual) | Interventional | 2015-07-03 | Completed | ||
| Low-dose Cortisol in Chronic Posttraumatic Stress Disorder [NCT00362661] | 20 participants (Anticipated) | Interventional | 2007-06-30 | Terminated(stopped due to Recruitment: Insufficient number of patients eligible for enrollment) | |||
| Prevalence of Neuroendocrine Dysfunction in the Pediatric Cardiopulmonary Bypass Patient [NCT00850720] | 3 participants (Actual) | Observational | 2009-03-31 | Terminated(stopped due to Inability to recruit / logistic problems.) | |||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN [NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
| TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704] | Phase 2 | 156 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 [NCT00003436] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1998-07-31 | Completed | ||
| A Phase 2, Open Label, Crossover Pharmacokinetic and Pharmacodynamic Study to Compare Chronocort Versus Cortef in Patients With CAH [NCT00519818] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Glucocorticoids After Traumatic Birth and the Associated Risk of Developing Posttraumatic Stress Disorder (PTSD): an Open Label Pilot Trial [NCT04852458] | Phase 1 | 133 participants (Actual) | Interventional | 2021-05-21 | Completed | ||
| ALL Adult Consortium Trial: Adult ALL Trial [NCT00476190] | Phase 2 | 112 participants (Anticipated) | Interventional | 2007-04-30 | Active, not recruiting | ||
| Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone [NCT05534334] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery [NCT01559675] | 121 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| Combined Use of Dexmedetomidine and Hydrocortisone to Prevent New Onset Atrial Fibrillation After Coronary Artery Bypass Grafting Surgery [NCT05674253] | Early Phase 1 | 248 participants (Anticipated) | Interventional | 2022-12-25 | Recruiting | ||
| An Open Label, Partially Randomised, Single Dose, Crossover Study to Evaluate the PK, Oral Bioavailability and Relationship to Metabolic Parameters of Hydrocortisone and Infacort® in Healthy Adult Male Volunteers. [NCT01960530] | Phase 1 | 14 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Phase 3 Study of Corticotherapy (Hydrocortisone Alone Versus Hydrocortisone Plus Fludrocortisone) Versus Corticotherapy Plus Intensive Insulin Therapy for Septic Shock [NCT00320099] | Phase 3 | 508 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| AUTOLOGOUS, ALLOGENEIC, OR SYNGENEIC BONE MARROW TRANSPLANTATION IN HODGKIN'S DISEASE, NON-HODGKIN'S LYMPHOMA, AND MULTIPLE MYELOMA [NCT00002552] | Phase 2 | 40 participants (Anticipated) | Interventional | 1993-10-31 | Completed | ||
| A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) [NCT00002798] | Phase 3 | 880 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
| EXTRAMEDULLARY RELAPSE AND OCCULT BONE MARROW INVOLVEMENT IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE III GROUP-WIDE STUDY [NCT00002816] | Phase 3 | 120 participants (Anticipated) | Interventional | 1996-12-31 | Completed | ||
| Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785] | Phase 2 | 0 participants | Interventional | 1996-07-31 | Completed | ||
| The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728] | Phase 3 | 1,500 participants (Anticipated) | Interventional | 1998-12-31 | Active, not recruiting | ||
| PHASE III TRIAL OF ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE + SURAMIN + HYDROCORTISONE VS ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER [NCT00002881] | Phase 3 | 0 participants | Interventional | 1996-10-31 | Completed | ||
| A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients [NCT01867294] | Phase 2 | 19 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471] | Phase 2 | 0 participants | Interventional | 1990-02-28 | Completed | ||
| Evaluation of Suramin in Advanced Adrenal Cortical Carcinoma, Phase II [NCT00002921] | Phase 2 | 13 participants (Actual) | Interventional | 1997-03-31 | Terminated(stopped due to Permanently Closed Due to Lack of Accrual) | ||
| HYdrocortisone and VAsopressin in Post-REsuscitation Syndrome [NCT04591990] | Phase 3 | 380 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | ||
| Effect of Postoperative Hydrocortisone on Cardiovascular and Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass [NCT01595386] | 40 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Acute Myeloid Leukemia Salvage Therapy for Patients in First Relapse or Who Fail to Achieve an Initial Remission or Who Develop AML as a Second Malignant Neoplasm [NCT00002805] | Phase 2 | 115 participants (Actual) | Interventional | 1997-08-31 | Completed | ||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR RELAPSED OR REFRACTORY ALL: A PHASE II STUDY OF A MULTIDRUG REGIMEN [NCT00002865] | Phase 2 | 25 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| Physiologic Effects of Stress Dose Corticosteroids in the Management of Inhospital Cardiac Arrest - CORTICA [NCT02790788] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2016-11-04 | Completed | ||
| Effect of Stress-dose Steroids on Post-resuscitation Infectious (Septic) Complications After In-hospital Cardiac Arrest. Individual Patient Data-based Re-analysis of Synthesized Prior Randomized Clinical Trial Data [NCT02408939] | 191 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Hormonal Mechanisms of Sleep Restriction - Axis Study [NCT03142893] | Phase 1 | 80 participants (Anticipated) | Interventional | 2017-05-08 | Active, not recruiting | ||
| The Use of Perioperative Steroids in Patients Undergoing Transsphenoidal Resection of Pituitary Tumors or Cysts [NCT02084134] | 43 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| An Open-label, Single-arm, Single-center Study Evaluating the Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock [NCT06122987] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor [NCT00084838] | Phase 2 | 25 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Pharmacokinetics of Hydrocortisone After Subcutaneous Administration Compared With Intramuscular Injection in Chronic Adrenal Insufficiency [NCT01450930] | Phase 2 | 12 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies [NCT00185692] | Phase 2 | 16 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| 3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Applicator in Subjects With Ulcerative Colitis [NCT04469686] | Phase 3 | 618 participants (Anticipated) | Interventional | 2020-12-10 | Recruiting | ||
| A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049] | Phase 3 | 5,937 participants (Actual) | Interventional | 2012-02-29 | Active, not recruiting | ||
| A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intert [NCT00640822] | Phase 3 | 782 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Effect of Steroids Given Over 24 Hours on Cytokine Release, Urinary Desmosine Level and Thrombogenic Markers in Patients Undergoing Unilateral Total Hip Replacement [NCT01782859] | 40 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial [NCT04348305] | Phase 3 | 30 participants (Actual) | Interventional | 2020-04-17 | Completed | ||
| A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157] | Phase 3 | 680 participants (Anticipated) | Interventional | 2024-01-22 | Not yet recruiting | ||
| A Phase 3 Trial of Androgen Ablation Alone vs. Chemo/Hormonal Therapy as Initial Treatment of Unresectable/Metastatic Adenocarcinoma of the Prostate [NCT00002855] | Phase 3 | 306 participants (Actual) | Interventional | 1996-08-31 | Completed | ||
| Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215] | Phase 3 | 400 participants (Anticipated) | Interventional | 1997-04-30 | Completed | ||
| Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study [NCT00003593] | Phase 3 | 254 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma [NCT00392834] | Phase 2 | 34 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085] | Phase 3 | 4,772 participants (Anticipated) | Interventional | 2019-10-31 | Recruiting | ||
| A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial. [NCT02277587] | Phase 4 | 89 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale andDesign of A Randomized Study (I-PADUA) [NCT03449797] | 200 participants (Anticipated) | Interventional | 2018-04-01 | Not yet recruiting | |||
| International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma [NCT00006455] | Phase 3 | 885 participants (Actual) | Interventional | 1999-11-26 | Completed | ||
| Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women [NCT04037605] | Early Phase 1 | 5 participants (Actual) | Interventional | 2020-02-09 | Active, not recruiting | ||
| Hormonal Mechanisms of Sleep Restriction [NCT02256865] | Early Phase 1 | 40 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Difference in Mortality and Evolution in Septic Patients Treated With Vitamin C, Tiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone Treated at the ICU of General Hospital Zone 11 IMSS Piedras Negras Coahuila. [NCT04197115] | Phase 3 | 19 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study (STRIPES) [NCT02044159] | Phase 4 | 57 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Effects of Glucocorticoid Combined With Vitamin C and Vitamin B1 Versus Hydrocortisone Alone on Microcirculation in Severe Septic Shock [NCT03821714] | 22 participants (Actual) | Interventional | 2019-02-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Implementation of the toxic death rate stopping rule, a death must be possibly, probably or definitely attributable to Rituximab and/or chemotherapy to be considered a toxic death. (NCT00057811)
Timeframe: Up to 1 year
| Intervention | participants (Number) | |
|---|---|---|
| Toxic death | No toxic death | |
| Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) | 0 | 45 |
| Group C (Chemotherapy, Monoclonal Antibody Therapy) | 2 | 38 |
Response includes both complete and partial responses. Per protocol, complete Response is defined as the complete disappearance of all clinical evidence of disease by physical examination, by imaging studies, by bone marrow biopsy (where indicated), by CNS evaluation (where indicated) and by biopsy where there is a residual abnormality on an imaging study. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present. Partial response is defined as: at least a 50% reduction in the size of all measurable tumor areas. Each site is to be defined by the product of the maximum length, width and depth (3 dimensions). No lesion may progress. No new lesion may appear. Bone marrow must contain <5% blasts. CSF WBC must be <5/μL with no blasts or lymphomatous cells present.. (NCT00057811)
Timeframe: Up to 5 years
| Intervention | percentage of participants analyzed (Number) |
|---|---|
| Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) | 88 |
| Group C (Chemotherapy, Monoclonal Antibody Therapy) | 83 |
The presence or absence of tumor cells at the end of induction assessed by studying tissue and/or blood/marrow. Details of methods and criteria used can be found in Shiramizu at al. BJH 153:758-763, 2011 (full citation in the citation section). (NCT00057811)
Timeframe: Not Provided
| Intervention | percentage of samples analyzed (Number) |
|---|---|
| Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) | 22 |
| Group C (Chemotherapy, Monoclonal Antibody Therapy) | 70 |
The incidence of grade ≥ 3 stomatitis. Grade 3 stomatitis: Confluent ulcerations or pseudomembranes; bleeding with minor trauma. Grade 4 stomatitis: Tissue necrosis; Significant spontaneous bleeding; life-threatening consequences (NCT00057811)
Timeframe: Up to 1 year
| Intervention | participants (Number) | |
|---|---|---|
| Incidence of grade ≥ 3 stomatitis | No incidence of grade ≥ 3 stomatitis | |
| Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.) | 4 | 41 |
| Group C (Chemotherapy, Monoclonal Antibody Therapy) | 6 | 34 |
All Grade 3-4 Gastrointestinal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 139 |
All Grade 3-4 Hemorrhage events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 1 |
All Grade 3-4 Hepatic events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 8 |
Overall survival is defined as the time from date of diagnosis to death or date of last follow-up. 2-year overall survival is the probability of patients remaining alive at 2-years from study entry estimated using Kaplan-Meier (KM) methods which censors patients at date of last follow-up. Precision of this conditional probability estimate was measured in terms of standard error. Median OS, the original primary endpoint, was not estimable based on the Kaplan-Meier method because of insufficient follow-up. (NCT00084838)
Timeframe: Patients are followed for survival up to 5 yrs post-therapy completion or death; As of this analysis, median follow-up among survivors was 31 months with the longest follow-up being 40 months.
| Intervention | probability (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Modified IRS | 0.70 |
All Grade 3-4 Infection/Febrile Neutropenia events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 49 |
All Grade 3-4 Metabolic/Laboratory events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 128 |
All Grade 3-4 Muscloskeletal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 8 |
All Grade 3-4 Neurology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 45 |
All Grade 3-4 Pain events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 31 |
All Grade 3-4 events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 1021 |
All Grade 3-4 Dermatology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 3 |
All Grade 3-4 Pulmonary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 4 |
All Grade 3-4 Renal/Genitourinary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 4 |
All Grade 3-4 Constitutional events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 22 |
All Grade 3-4 Cardiovascular events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 6 |
"All Grade 3-4 Blood/Bone Marrow events based on CTCAEv2 as reported on case report forms.~Arm Name" (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 564 |
All Grade 3-4 Auditory/Hearing events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 8 |
All Grade 3-4 Allergy/Immunology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.
| Intervention | adverse events (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III) | 1 |
"Response pre-RT/post-CT was defined as follows with overall response defined as achieving PR or CR.~Complete Response (CR): Complete resolution of all initially demonstrable tumor on MRI or CT evaluation w/o appearance of any new areas of disease; negative CSF cytology. Partial Response (PR): >/= 50% decrease in the sum of the products of the maximum perpendicular diameters of the tumor (sum LD) relative to baseline w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Stable Disease (SD): <50% decrease in the sum LD w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Progressive Disease (PD): >/= 25% increase in the sum LD relative to baseline, or the appearance of any new areas of disease or appearance of positive cytology after two consecutive negative samples." (NCT00084838)
Timeframe: Assessed at study entry and pre-RT/post-CT at week 7.
| Intervention | proportion of evaluable patients (Number) |
|---|---|
| Multi-agent Intrathecal and Systemic CT With RT (Modified IRS | 0.58 |
Monitoring of efficacy results will be performed in comparison with historical results. (NCT00096135)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| CNS Patients - Treatment (Combination Chemotherapy) | 64.9 |
| Testicular Relapse Patients (Combination Chemotherapy) | 70 |
The proportion of patients who achieved complete response at the end Block 1 of re-induction therapy. Complete Remission (CR) - Attainment of M1 bone marrow (<5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (ANC >1000/uL and platelet count >100,000/uL). Partial Remission (PR) - Complete disappearance of circulating blasts and achievement of M2 marrow status (5% or < 25% blast cells and adequate cellularity). Partial Remission Cytolytic (PRCL) - Complete disappearance of circulating blasts and achievement of at least 50% reduction from baseline in bone marrow blast count. Minimal Response Cytolytic (MRCL) - 50% reduction in the peripheral blast count with no increase in peripheral white blood cell count. (NCT00098839)
Timeframe: At the end of Block 1 of re-induction therapy (day 36)
| Intervention | proportion of participants (Number) |
|---|---|
| Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly | .646 |
| Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly | .660 |
Mean trough serum concentration measured before final dose of epratuzumab. (NCT00098839)
Timeframe: Up to day 36
| Intervention | ug/mL (Mean) |
|---|---|
| Twice Weekly Dosing Schedule | 501 |
Proportion of patients (evaluable and had MRD measured at the end of Block 1) who had MRD < 0.01%. (NCT00098839)
Timeframe: At the end of Block 1 of re-induction therapy (day 36)
| Intervention | Proportion of participants (Number) |
|---|---|
| Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly | .195 |
| Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly | .295 |
Proportion of patients who were event free at 4 months (NCT00098839)
Timeframe: At 4 months after enrollment
| Intervention | Proportion of participants (Number) |
|---|---|
| Reinduction Chemoimmunotherapy With Epratuzumab Once Weekly | .604 |
| Reinduction Chemoimmunotherapy With Epratuzumab Twice Weekly | .640 |
GVHD grading system goes from 0-4 where grade 4 is the most severe. Grade 0 and 1 do not require systemic treatment, Grade 2-4 require treatment. This trial evaluated the risk of developing acute GVHD grades 2-4 within 90 days of transplant. (NCT00185692)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Transplantation of CD34+ Cells | 1 |
number achieving donor cell engraftment (>95%) by day 90 after transplant. (NCT00185692)
Timeframe: 100 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Transplantation of CD34+ Cells | 4 |
Anti tumor activity as assessed by computed tomography of neck/chest/abdomen/pelvis, positron emission tomography scan and/or gallium scan. Assessed by physical examination appropriate imaging studies. Bone marrow aspirate/biopsy must be normal and any macroscopic nodules in any organs detectable on imaging techniques should no longer be present. Gallium scans must be negative if initially positive. (NCT00354107)
Timeframe: Week 4
| Intervention | percent (Number) |
|---|---|
| Treatment (Monoclonal Antibody Therapy, Chemotherapy) | 50 |
(NCT00392834)
Timeframe: 1 year post treatment
| Intervention | Cumulative proportion surviving at 1 yr (Number) |
|---|---|
| Regimen A (R-CODOX-M Chemotherapy) | 1.0 |
| Regimen B (Rituximab and IVAC Chemotherapy) | 0.82 |
Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy. (NCT00400946)
Timeframe: Assessed daily during remission induction days 4-32.
| Intervention | percentage of participants (Number) |
|---|---|
| Overall | 26 |
Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.
| Intervention | percentage of participants (Number) |
|---|---|
| Intramuscular Native E Coli L-asparaginase (IM-EC) | 71 |
| Intravenous PEG-asparaginase (IV-PEG) | 99 |
Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Day 4 NSAA Rate | Day 11 NSAA Rate | Day 18 NSAA Rate | Day 25 NSAA Rate | |
| Overall | 97 | 96 | 87 | 12 |
Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.
| Intervention | IU/mL (Mean) | ||||
|---|---|---|---|---|---|
| Week 5 NSAA Level | Week 11 NSAA Level | Week 17 NSAA Level | Week 23 NSAA Level | Week 29 NSAA Level | |
| Intramuscular Native E Coli L-asparaginase (IM-EC) | 0.129 | 0.143 | 0.159 | 0.180 | 0.123 |
| Intravenous PEG-asparaginase (IV-PEG) | 0.726 | 0.773 | 0.787 | 0.757 | 0.806 |
Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.
| Intervention | probability (Number) |
|---|---|
| M1 Day 18 Bone Marrow Status | .89 |
| M2/M3 Day 18 Bone Marrow Status | .78 |
| Hypocellular Day 18 Bone Marrow Status | .88 |
Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.
| Intervention | probability (Number) |
|---|---|
| CNS-1 | .89 |
| CNS-2 | .89 |
| CNS-3 | 1.00 |
| Traumatic Tap With Blasts | .84 |
| Traumatic Tap Without Blasts | .87 |
Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.
| Intervention | probability (Number) |
|---|---|
| Low Day 32 MRD Level | .79 |
| High Day 32 MRD Level | .90 |
Asparaginase-related toxicity rate is defined as the percentage of patients who experience allergy (all grades), symptomatic pancreatitis (grade 2 or worse), thrombotic or bleeding complications requiring intervention (grade 2 or worse) with treatment attribution of possibly, probably or definite based on CTCAEv3. (NCT00400946)
Timeframe: 30-week post-induction asparaginase treatment period
| Intervention | percentage of participants (Number) |
|---|---|
| Intramuscular Native E Coli L-asparaginase (IM-EC) | 26 |
| Intravenous PEG-asparaginase (IV-PEG) | 28 |
Serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.
| Intervention | IU/mL (Median) | |||
|---|---|---|---|---|
| Day 4 NSAA Level | Day 11 NSAA Level | Day 18 NSAA Level | Day 25 NSAA Level | |
| Overall | .694 | .505 | .211 | .048 |
Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.
| Intervention | probability (Number) |
|---|---|
| Intramuscular Native E Coli L-asparaginase (IM-EC) | .89 |
| Intravenous PEG-asparaginase (IV-PEG) | .90 |
Neonatal health at birthyes=need for medical attention or intervention after birth, abnormalities detected, no= no need for medical attention, no abnormalities detected at birth (NCT00405288)
Timeframe: at birth
| Intervention | participants (Number) | |
|---|---|---|
| Yes (present neonatal health concerns) | No (absent neonatal health concerns) | |
| Control | 24 | 154 |
| Proctofoam-HC® | 28 | 171 |
Infections occuring in the neonatal period (NCT00405288)
Timeframe: neonatal period
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Urinary tract infections | Streptococcus B infection | Pneumonia | Leucocytosis | |
| Control | 0 | 2 | 2 | 0 |
| Proctofoam-HC® | 2 | 0 | 0 | 2 |
birth at <37 gestational weeks (NCT00405288)
Timeframe: at birth
| Intervention | participants (Number) | |
|---|---|---|
| yes | no | |
| Control | 10 | 180 |
| Proctofoam-HC® | 8 | 193 |
(NCT00405288)
Timeframe: neonatal period
| Intervention | participants (Number) | ||
|---|---|---|---|
| Pulmonary aspiration | Mild asthma | Tachypnea | |
| Control | 0 | 2 | 2 |
| Proctofoam-HC® | 4 | 2 | 0 |
(NCT00405288)
Timeframe: neonatal period
| Intervention | participants (Number) | ||
|---|---|---|---|
| Rash | Eczema | Acne | |
| Control | 2 | 2 | 2 |
| Proctofoam-HC® | 2 | 0 | 0 |
(NCT00405288)
Timeframe: neonatal period
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Conjuctivitis | Myopia | Colic | Milk allergy | Hypoglycemia | Poor feeding | Poor weight gain | Anemia | Renal calculi | |
| Control | 0 | 2 | 4 | 2 | 0 | 0 | 2 | 2 | 2 |
| Proctofoam-HC® | 4 | 0 | 0 | 0 | 4 | 2 | 2 | 0 | 0 |
Weight of the baby measured in grams at time of birth. (NCT00405288)
Timeframe: until delivery
| Intervention | grams (Mean) |
|---|---|
| Proctofoam-HC® | 3406.9 |
| Control | 3487.7 |
Fetal gestational age at delivery (NCT00405288)
Timeframe: until delivery
| Intervention | gestational weeks (Mean) |
|---|---|
| Proctofoam-HC® | 39.4 |
| Control | 39.1 |
Assessment of neonate's morphology and function of cardiovascular system in the first two weeks after birth (NCT00405288)
Timeframe: neonatal period
| Intervention | participants (Number) | ||
|---|---|---|---|
| Cardiovascular anomalies | Heart murmur | Premature atrial contraction | |
| Control | 0 | 4 | 2 |
| Proctofoam-HC® | 2 | 6 | 0 |
Presence of fetal distress at birth: heart deceleration/acceleration, meconium/amniotic fluid (NCT00405288)
Timeframe: at birth
| Intervention | participants (Number) | |
|---|---|---|
| Fetal distress | No fetal distress | |
| Control | 31 | 142 |
| Proctofoam-HC® | 36 | 163 |
Low birth weight (birth weights <2500 grams) (NCT00405288)
Timeframe: at birth
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Control | 3 | 198 |
| Proctofoam-HC® | 6 | 194 |
Method of delivery for both groups: vaginal or caesarean section (NCT00405288)
Timeframe: at birth
| Intervention | participants (Number) | ||
|---|---|---|---|
| Vaginal delivery | Caesarean section | Unknown | |
| Control | 146 | 55 | 3 |
| Proctofoam-HC® | 173 | 31 | 0 |
Patients will be evaluated for clinical benefit monthly with PSA values.Patients who are benefiting from treatment are eligible for additional cycles of treatment. Thereafter, therapy will continue until criteria for progressive disease are met. Response is based on the RECIST criteria from the National Cancer institute. Complete Response (CR) disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diameter of target lesions from baseline; Progressive Disease (PD) >= increase in the sum of the longest diameter of target lesions from baseline; Stable Disease (SD) neither sufficient for partial response nor sufficient increase for progressive disease. (NCT00460031)
Timeframe: 28 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Partial Response | Progressive Disease | Stable Disease | |
| Ketoconazole Plus Lenalidomide | 7 | 7 | 9 |
Patients will be evaluated for clinical benefit monthly with PSA values.Patients who are benefiting from treatment are eligible for additional cycles of treatment. Thereafter, therapy will continue until criteria for progressive disease are met. Response is based on the RECIST criteria from the National Cancer institute. Complete Response (CR) disappearance of all target lesions; Partial Response (PR) >= 30% decrease in the sum of the longest diameter of target lesions from baseline; Progressive Disease (PD) >= increase in the sum of the longest diameter of target lesions from baseline; Stable Disease (SD) neither sufficient for partial response nor sufficient increase for progressive disease. (NCT00460031)
Timeframe: One year (12 months) after start of treatment
| Intervention | Months (Median) |
|---|---|
| Ketoconazole Plus Lenalidomide | 3 |
The pattern of immune response by assessing T cell and dendritic cell markers, specifically by measuring the ratio of BDCA-2 to BDCA-1 cells (NCT00460031)
Timeframe: Week 8
| Intervention | ratio (Mean) |
|---|---|
| Ketoconazole Plus Lenalidomide | -0.39 |
The pattern of immune response by assessing T cell and dendritic cell markers, specifically by measuring the levels of CD4+ FoxP3+ Regulatory T cells (NCT00460031)
Timeframe: Week 8
| Intervention | cells/ul (Mean) |
|---|---|
| Ketoconazole Plus Lenalidomide | 0.18 |
Patients will be evaluated for toxicity every 2 weeks during the first cycle. Thereafter, evaluations will be done every 28 days or more frequently if clinically indicated. (NCT00460031)
Timeframe: Up to 30 days after discontinuation of treatment
| Intervention | participants (Number) |
|---|---|
| Ketoconazole Plus Lenalidomide | 19 |
(NCT00519818)
Timeframe: Cortef after one week compared with Chronocort after one month
| Intervention | nmol/l (Mean) |
|---|---|
| Cortef | 16.4 |
| Chronocort | 86.9 |
(NCT00519818)
Timeframe: Cortef after one week, Chronocort after one month
| Intervention | h*nmol/l (Mean) |
|---|---|
| Cortef | 5380 |
| Chronocort | 3973 |
Determine the maximum tolerated dose (MTD) of oral calcitriol daily x 3 consecutive days a week in combination with oral ketoconazole (400 mg thrice daily [TID]) + oral hydrocortisone (20 mg AM, 10 mg PM) (NCT00536991)
Timeframe: up to 11 years
| Intervention | mcg (Number) |
|---|---|
| Treatment (Calcitriol, Ketoconazole, Hydrocortisone) | 10 |
Count of participants with serious adverse event. Please refer to the adverse event reporting for more detail. (NCT00536991)
Timeframe: Up to 11 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I/II: Oral Calcitriol, Ketoconazole, Hydrocortisone | 14 |
Judged by monthly physical exam and radiographic evaluation. Patients will be considered evaluable for tumor response if they have at least two post-baseline tumor assessments at least 4 weeks apart, received study medication for 8 weeks or if they have evidence of disease progression. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00536991)
Timeframe: Up to 11 years
| Intervention | percentage of participants (Number) |
|---|---|
| Phase I/II: Oral Calcitriol, Ketoconazole, Hydrocortisone | 24 |
Patients will be considered evaluable for PSA response if they have at least two post-baseline PSA measurements at least 4 weeks apart, or if they have other evidence of disease progression. A PSA response will be considered a PSA decline of at least 50% must be confirmed by a second PSA value four or more weeks later. The reference PSA for these declines should be a PSA measured within 2 weeks prior to the initiation of therapy. (NCT00536991)
Timeframe: Up to 11 years
| Intervention | percentage of participants (Number) |
|---|---|
| Phase I/II: Oral Calcitriol, Ketoconazole, Hydrocortisone | 35 |
Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status. (NCT00557193)
Timeframe: 3 Years from end of Induction)
| Intervention | percent probability (Number) |
|---|---|
| Arm A (MRD Negative) | 86.05 |
| Arm A (MRD Positive) | 87.5 |
| Arm B (MRD Negative) | 47.37 |
| Arm B (MRD Positive) | 22.73 |
| Arm C (MRD Negative) | 51.85 |
| Arm C (MRD Positive) | 27.03 |
Summarized with mean and standard deviation for those with available data in Arm C (NCT00557193)
Timeframe: Sampled between weeks 6-12 from start of induction
| Intervention | Activity percentage (Mean) |
|---|---|
| Arm C (Safety/Efficacy Dose Level 2) | 69.00 |
Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years.
| Intervention | percent probability (Number) |
|---|---|
| Arm B (IR/HR MLL-R Chemotherapy) | 38.89 |
| Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib) | 35.82 |
EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years
| Intervention | percentage probability (Number) |
|---|---|
| Arm C (Safety/Efficacy Dose Level 2) | 35.82 |
EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years
| Intervention | percentage probability (Number) |
|---|---|
| Arm A (Standard Risk MLL-G) | 86.67 |
Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients. (NCT00557193)
Timeframe: Up to 12 weeks from start of induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib-Dose Level 1) | 0 |
| Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib-Dose Level 2) | 1 |
Described via means and standard deviations in samples which have primary resistance to lestaurtinib (NCT00557193)
Timeframe: Sampled at the start of induction
| Intervention | Proportion of cells that are viable (Median) |
|---|---|
| Arm A (Standard Risk MLL-G) | 0.75 |
| Arm B (IR/HR MLL-R Chemotherapy) | 0.48 |
| Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib) | 0.47 |
Described via means and standard deviations in samples which have acquired resistance to lestaurtinib (NCT00557193)
Timeframe: At relapse (up to 3 years)
| Intervention | Proportion of cells that are viable (Mean) |
|---|---|
| Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib) | 0.69 |
Described via means and standard deviations in available Arm C relapse samples (NCT00557193)
Timeframe: At relapse (up to 3 years)
| Intervention | qPCR fold expression ratio (Mean) |
|---|---|
| Arm C (Safety/Efficacy Dose Level 2) | 5.73 |
Described via mean and standard deviation by group. (NCT00557193)
Timeframe: Sampled at the start of induction
| Intervention | qPCR fold expression ratio (Mean) |
|---|---|
| Arm A (Standard Risk MLL-G) | 1.25 |
| Arm B (IR/HR MLL-R Chemotherapy) | 7.85 |
| Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib) | 5.83 |
(NCT00640822)
Timeframe: Week 8
| Intervention | Participants (Number) |
|---|---|
| Calcipotriol Plus Hydrocortisone Ointment | 183 |
| Tacalcitol Ointment | 147 |
| Calcipotriol Plus Hydrocortisone Ointment Vehicle | 37 |
"The assessment of the disease severity of the face was made using the 6-category scale below.~Clear Almost clear Mild Moderate Severe Very severe~The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.~For subjects with a baseline severity of moderate or worse - controlled disease of the face was defined as clear or almost clear according to the IGA of disease severity of the face.~For subjects with a baseline severity of mild - controlled disease of the face was defined as clear according to the IGA of disease severity of the face." (NCT00691002)
Timeframe: At Week 4
| Intervention | Participants (Count of Participants) |
|---|---|
| LEO 80190 | 101 |
| Calcipotriol | 66 |
| Hydrocortisone | 61 |
| LEO 80190 Vehicle | 14 |
"The severity of the subject's psoriasis vulgaris on the intertriginous areas was evaluated in terms of the three clinical signs: redness, thickness and scaliness. All the defined intertriginous areas were rated separately using the same scale as for the investigator's assessment of clinical signs (redness, thickness and scaliness) of the face.~For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:~Redness 0 = none~= mild~= moderate~= severe~= very severe~Thickness 0 = none~= mild~= moderate~= severe~= very severe~Scaliness 0 = none~= mild~= moderate~= severe~= very severe~A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS.~Success was defined as a TSS score of 0 or 1." (NCT00691002)
Timeframe: At Week 8 (end of treatment for double-blind phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| LEO 80190 | 82 |
| Calcipotriol | 81 |
| Hydrocortisone | 59 |
| LEO 80190 Vehicle | 15 |
"Success was defined as a TSS score of 0 or 1.~For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the face was determined according to the scale below:~Redness 0 = none (no erythema) 1 = mild (faint erythema, pink to very light red) 2 = moderate (definite light red erythema) 3 = severe (dark red erythema) 4 = very severe (very dark red erythema) Thickness 0 = none (no plaque elevation) 1 = mild (slight, barely perceptible elevation) 2 = moderate (definite elevation but not thick) 3 = severe (definite elevation, thick plaque with sharp edge) 4 = very severe (very thick plaque with sharp edge) Scaliness 0 = none (no scaling) 1 = mild (sparse, fine-scale lesions, only partially covered) 2 = moderate (coarser scales, most of lesions covered) 3 = severe (entire lesion covered with coarse scales) 4 = very severe (very thick coarse scales, possibly fissured)~The sum of the three scores constituted a TSS ranging from 0 to 12" (NCT00691002)
Timeframe: At Week 8 (end of treatment for double-blind phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| LEO 80190 | 171 |
| Calcipotriol | 136 |
| Hydrocortisone | 131 |
| LEO 80190 Vehicle | 42 |
"The (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.~Clear, Almost clear, Mild, Moderate, Severe, Very severe~The assessment was made considering the condition of psoriasis vulgaris of the face at the time of the evaluation, not in relation to the condition at a previous visit.~For subjects with a baseline (Visit 1) severity of moderate or worse - controlled disease of the face was defined as clear or almost clear according to the IGA of disease severity of the face.~For subjects with a baseline (Visit 1) severity of mild - controlled disease of the face was defined as clear according to the IGA of disease severity of the face." (NCT00691002)
Timeframe: At Week 8 (end of treatment for double-blind phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| LEO 80190 | 158 |
| Calcipotriol | 135 |
| Hydrocortisone | 115 |
| LEO 80190 Vehicle | 41 |
"The (sub)investigator made an assessment of the disease severity of the intertriginous areas using the 6-category scale below.~Clear, Almost clear, Mild, Moderate, Severe, Very severe The assessment was made considering the condition of psoriasis vulgaris of the intertrigi-nous areas at the time of the evaluation, not in relation to the condition at a previous visit.~For subjects with a baseline severity of moderate or worse - controlled disease of the intertriginous areas was defined as clear or almost clear according to the IGA of disease severity of the intertriginous areas.~For subjects with a baseline severity of mild - controlled disease of the intertriginous areas was defined as clear according to the IGA of disease severity of the intertriginous areas." (NCT00691002)
Timeframe: At Week 8 (end of treatment for double-blind phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| LEO 80190 | 80 |
| Calcipotriol | 55 |
| Hydrocortisone | 48 |
| LEO 80190 Vehicle | 14 |
Adherence measured by MEMS cap as the % of days that the two total prescribed doses were applied (NCT00693693)
Timeframe: 2 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Cream | .55 |
| Ointment | .60 |
| Lipocream | .50 |
A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used. (NCT00720109)
Timeframe: At end of consolidation (at 11 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 10.5 |
| Standard-risk | 0 |
| High-risk | 66.7 |
Percent of patients MRD Positive (MRD > 0.01%) at End of Induction. (NCT00720109)
Timeframe: At the end of induction therapy (at 5 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 40.7 |
| Standard-risk | 29.2 |
| High-risk | 100.0 |
Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay) (NCT00720109)
Timeframe: Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)
| Intervention | Pts with DLTs (Number) |
|---|---|
| Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 1 |
An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death. (NCT00720109)
Timeframe: From the time entry on study to first event or date of last follow-up, assessed up to 7 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 79.8 |
| Standard-risk | 83.2 |
| High-risk | 66.7 |
Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed. (NCT00720109)
Timeframe: At 3 years
| Intervention | Percent probability (Number) |
|---|---|
| Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy) | 79.8 |
| Standard-risk | 83.2 |
| High-risk | 66.7 |
Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 1. (NCT00873093)
Timeframe: End of Block 1 (Day 36 of Block 1) of re-induction therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs | 35.4 |
| Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs | 25 |
Percentage of patients who were event free at 4 months (NCT00873093)
Timeframe: 4 months after enrollment
| Intervention | Percentage of participants (Number) |
|---|---|
| Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs | 68.5 |
| Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs | 37.8 |
The proportion of toxic death rate among all eligible patients. (NCT00873093)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall | 2.1 |
The proportion of SAE rate among all eligible patients (NCT00873093)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall | 8.2 |
The percentage of eligible and evaluable patients who have achieved complete response at the end Block 1 of re-induction therapy. (NCT00873093)
Timeframe: The outcome is measured the end of Block 1 (Day 36 of Block 1) of re-induction therapy.
| Intervention | Percentage of participants (Number) |
|---|---|
| Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs | 72.2 |
| Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs | 63 |
Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 3. (NCT00873093)
Timeframe: End of Block 3 (Day 36 of Block 3) of re-induction therapy
| Intervention | Percentage of participants (Number) |
|---|---|
| Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs | 80 |
| Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs | 63.6 |
Percentage of eligible and evaluable patients with MRD < 0.01% among those who had successful MRD determination at the end of Block 2. (NCT00873093)
Timeframe: End of Block 2 (Day 36 of Block 2) of re-induction therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-B ALL Relapse 18-36 Mths From Dx (Chemotherapy)Age<=21 Yrs | 66.7 |
| Pre-B ALL Relapse <18 Mths From Dx (Chemotherapy) Age <=21 Yrs | 42.1 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. AUCtau is defined as AUC during a dosing interval at steady state. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour*nanomole per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 3962.0 |
| Hydrocortisone Tablet TID - Part A | 4879.6 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. Participants in Arm 1 underwent standardised in-house PK sampling during 14 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.048 |
| Hydrocortisone Tablet TID - Part A | 0.061 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.041 |
| Hydrocortisone Tablet TID - Part A | 0.046 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The data for combined arm 1+2 after multiple doses were reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour*nanomole per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 3962.0 |
| Hydrocortisone Tablet TID - Part A | 4879.6 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.047 |
| Hydrocortisone Tablet TID - Part A | 0.060 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.025 |
| Hydrocortisone Tablet TID - Part A | 0.024 |
Css,av was calculated as the area under the S-cortisol concentration versus time curve during a dosing interval at steady state (AUCtau) divided by dosing interval (tau). Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | nanomoles per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 165.1 |
| Hydrocortisone Tablet TID - Part A | 203.3 |
Css,av was calculated as the area under the S-cortisol concentration versus time curve during a dosing interval at steady state (AUCtau) divided by dosing interval (tau). Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.002 |
| Hydrocortisone Tablet TID - Part A | 0.003 |
Diurnal fatigue was assessed at 8 ante meridian (AM), at 12 AM and at 4 post meridian (PM) by a visual analogue scale (VAS) based on 8 domains (energy, relaxed, less alert, moody, mental fatigue, intellectually slow, difficulty focusing, physical activity). Mean values were calculated for the morning (8 AM), the day (12 AM), the evening (4 PM) and mean per day (mean of 8 AM, 12 AM and 4 PM) were analyzed with score range from 0 to 100. A lower value corresponds to better well-being. (NCT00915343)
Timeframe: Baseline (week 0), Week 12
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | -3.1 |
Diurnal fatigue scores (Visual Analog Scale [VAS] scores of energy, relaxed, less alert, moody, mental fatigue, intellectually slow, difficulty focusing, physical activity) were analyzed with score range from 0 to 100. A lower value corresponds to better well-being. (NCT00915343)
Timeframe: Baseline (week 0), month 6
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part B (All 6 Months) | -0.180 |
FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in participants. It consisted of 40 statements that measure fatigue in 3 areas: physical, cognitive, and psychosocial. This 40-item scale evaluates the construct of perceived impact of fatigue on everyday life. Respondents rated each statement using a 5-point Likert-type scale ranging from 0 (no problem) to 4 (extreme problem). A total score ranged from 0 to 160. A lower value corresponds to better well-being. (NCT00915343)
Timeframe: Baseline (week 0), month 6
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part B (All 6 Months) | -1.09 |
The PGWB consists of 22 self-administered items rated on a scale from 1 (worst level of well-being) to 6 (maximum level of well-being) with a total score ranging from 22 to 132. A higher score represents better well-being. (NCT00915343)
Timeframe: Baseline (week 0), month 6
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part B (All 6 Months) | -0.739 |
FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in participants. It consisted of 40 statements that measure fatigue in 3 areas: physical, cognitive, and psychosocial. This 40-item scale evaluates the construct of perceived impact of fatigue on everyday life. Respondents rated each statement using a 5-point Likert-type scale ranging from 0 (no problem) to 4 (extreme problem). A total score ranged from 0 to 160. A lower value corresponds to better well-being. (NCT00915343)
Timeframe: 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 22.6 |
| Hydrocortisone Tablet TID - Part A | 26.4 |
The PGWB consists of 22 self-administered items rated on a scale from 1 (worst level of well-being) to 6 (maximum level of well-being) with a total score ranging from 22 to 132. A higher score represents better well-being. (NCT00915343)
Timeframe: 12 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 110.5 |
| Hydrocortisone Tablet TID - Part A | 107.7 |
(NCT00915343)
Timeframe: 12 weeks
| Intervention | nanomoles per 24 hours (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 385.7 |
| Hydrocortisone Tablet TID - Part A | 425.9 |
Compliance was calculated as actual consumption/expected consumption Compliance = (Number of dispensed tablets - Number of returned tablets)/(Number of days during the study period x daily Number of hydrocortisone tablets when taking the ordinary daily dose). (NCT00915343)
Timeframe: Weeks 4 up to 28
| Intervention | percentage use (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 104.8 |
| Hydrocortisone Tablet TID - Part A | 103.1 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | nanomoles per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 278.5 |
| Hydrocortisone Tablet TID - Part A | 426.7 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | nanomoles per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 214.1 |
| Hydrocortisone Tablet TID - Part A | 322.4 |
t1/2[5-14h] is the time taken for the blood plasma concentration of a drug to halve from 5 to 14 hours. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hours (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 4.60 |
| Hydrocortisone Tablet TID - Part A | 18.4 |
t1/2[5-24h] is the time taken for the blood plasma concentration of a drug to halve from 5 to 24 hours. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hours (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 7.32 |
| Hydrocortisone Tablet TID - Part A | 1.84 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | nanomoles per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 229.0 |
| Hydrocortisone Tablet TID - Part A | 295.1 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.003 |
| Hydrocortisone Tablet TID - Part A | 0.004 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. Cmax1 is the Cmax after first dose of study drug. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | nanomoles per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 690.7 |
| Hydrocortisone Tablet TID - Part A | 802.8 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. Cmax2 is the Cmax after second dose of study drug. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | nanomoles per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 553.8 |
| Hydrocortisone Tablet TID - Part A | 446.9 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. Cmax1 is the Cmax after first dose of study drug. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | per liter (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.008 |
| Hydrocortisone Tablet TID - Part A | 0.010 |
Compliance was calculated as actual consumption/expected consumption Compliance = (Number of dispensed tablets - Number of returned tablets)/(Number of days during the study period x daily Number of hydrocortisone tablets when taking the ordinary daily dose). (NCT00915343)
Timeframe: Up to Month 6 follow-up
| Intervention | percentage use (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part B (All 6 Months) | 102.3 |
The percentage of AUC0-inf that is due to extrapolation from Tlast to infinity (AUC%Extrapolation) was calculated by using the formula AUC%extrapolation = 100*(AUC0-inf minus AUC0-t)/AUC0-inf. The function of this parameter was to provide information about what percentage of the theoretical curve (AUC0-inf) was possible to determine experimentally (AUC0-t). Therefore, on average, it is expected that the residual area (AUCextrapolation) is not greater than 20%. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | percentage of AUC (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 10.1 |
| Hydrocortisone Tablet TID - Part A | 9.26 |
Percentage of fluctuation was calculated by using formula 100*(Cmax-minimum plasma concentration [Cmin])/Cavg,ss. It was peak trough fluctuation within one dosing interval at steady state. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | percentage of fluctuation (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 429.7 |
| Hydrocortisone Tablet TID - Part A | 396.2 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hours (Median) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.229 |
| Hydrocortisone Tablet TID - Part A | 0.208 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | (hour per nanomole)*10^6 (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 2.26 |
| Hydrocortisone Tablet TID - Part A | 2.32 |
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached. Tmax1 is the Tmax after first dose of study drug. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hours (Median) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 1.00 |
| Hydrocortisone Tablet TID - Part A | 0.750 |
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached. Tmax2 is the Tmax after second dose of study drug. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hours (Median) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 5.00 |
| Hydrocortisone Tablet TID - Part A | 6.00 |
Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hours (Median) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 0.250 |
| Hydrocortisone Tablet TID - Part A | 0.167 |
"AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. AUC between specified timepoints included AUC0-4h, AUC4-12h, AUC6-12h, AUC12-24h, AUC0-10h, AUC4-10h, AUC6-10h, AUC10-24h, AUC(0-inf), AUC(24h-inf). Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. Here, Nsignifies the number of participants evaluable for this outcome." (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | hour*nanomole per liter (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AUC0-4h (N=61, 61) | AUC4-12h (N=61, 61) | AUC6-12h (N=61, 61) | AUC12-24h (N=61, 61) | AUC0-10h (N=61, 61) | AUC4-10h (N=61, 61) | AUC6-10h (N=61, 61) | AUC10-24h (N=61, 61) | AUC(0-inf) (N=52, 52) | AUC(24h-inf) (N=52, 52) | |
| Hydrocortisone MR Tablet OD - Part A | 2053.7 | 1491.8 | 808.2 | 306.2 | 3388.4 | 1334.7 | 651.1 | 465.0 | 3972.6 | 195.3 |
| Hydrocortisone Tablet TID - Part A | 1929.7 | 2302.5 | 1607.6 | 576.6 | 3768.7 | 1839.0 | 1144.1 | 1058.0 | 5162.8 | 410.4 |
The SF-36 was a questionnaire used to assess physical functioning and is made up of eight domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Transforming and standardizing these domains lead to the calculation of the physical and mental component summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A higher value in the SF-36 questionnaire corresponds to better well-being. (NCT00915343)
Timeframe: Baseline (week 0), month 6
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Physical component | Mental component | |
| Hydrocortisone MR Tablet OD - Part B (All 6 Months) | 0.390 | -0.896 |
"Overall patient tolerability score assessed by patient and investigator, ranged from 1 (feeling poor on treatment) to 5 (feeling very well on treatment). The average total score ranges from 1 to 5 with a higher score representing better tolerability of the treatment. Questionnaire assessed by patient were I have been very poorly on the treatment, I haven't been very well (or less well) on the treatment, I have been acceptably well on the treatment, I have been well on the treatment and I have been very well on the treatment. Questionnaire assessed by investigator were The patient has been feeling very poorly on the treatment, The patient has not tolerated the treatment well, The patient has tolerated the treatment less well, The patient has tolerated the treatment well and The patient has tolerated the treatment very well." (NCT00915343)
Timeframe: 12 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Patient | Investigator | |
| Hydrocortisone MR Tablet OD - Part A | 4.28 | 4.26 |
| Hydrocortisone Tablet TID - Part A | 4.36 | 4.33 |
The SF-36 was a questionnaire used to assess physical functioning and is made up of eight domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. Transforming and standardizing these domains lead to the calculation of the physical and mental component summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A higher value corresponds to better well-being. (NCT00915343)
Timeframe: 12 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Physical component | Mental component | |
| Hydrocortisone MR Tablet OD - Part A | 49.3 | 51.1 |
| Hydrocortisone Tablet TID - Part A | 50.0 | 49.8 |
Participant Preference Questionnaire consisted of the following set of questions: 1. How large was the benefit with OD compared to TID and the responses were recorded as considerably poorer, somewhat poorer, comparable, large, very large; 2. How strongly concur with the following statement: I prefer novel OD to conventional TID and the responses were recorded as strongly disagree, disagree, neutral, strongly, very strongly; 3. How strongly concur with the following statement: I prefer conventional TID to novel OD and the responses were recorded as strongly disagree, disagree, neutral, strongly, very strongly. (NCT00915343)
Timeframe: Weeks 16 up to 28
| Intervention | percentage of preference (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benefit compared OD to TID: Considerably poorer | Benefit compared OD to TID: Somewhat poorer | Benefit compared OD to TID: Comparable | Benefit compared OD to TID: Large | Benefit compared OD to TID: Very large | Prefer OD to TID: Strongly disagree | Prefer OD to TID: Disagree | Prefer OD to TID: Neutral | Prefer OD to TID: Strongly | Prefer OD to TID: Very strongly | Prefer TID to OD: Strongly disagree | Prefer TID to OD: Disagree | Prefer TID to OD: Neutral | Prefer TID to OD: Strongly | Prefer TID to OD: Very strongly | |
| Hydrocortisone OD Versus TID | 3.8 | 5.7 | 5.7 | 20.8 | 64.2 | 3.7 | 3.7 | 5.6 | 25.9 | 61.1 | 39.6 | 35.4 | 12.5 | 4.2 | 8.3 |
Patient tolerability questionnaire was assessed by both patient and investigator, the responses were as follows: improvement, no change, worsening and were reported. (NCT00915343)
Timeframe: Baseline (week 0), month 6
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Improvement (Patient) | Improvement (Investigator) | No change (Patient) | No change (Investigator) | Worsening (Patient) | Worsening (Investigator) | |
| Hydrocortisone MR Tablet OD - Part B (All 6 Months) | 10.7 | 14.0 | 73.2 | 70.0 | 16.1 | 16.0 |
The Rac was calculated as area under the S-cortisol concentration versus time curve during a dosing interval at steady state (AUCtau) on Day 28 divided by AUC0-24h on Day 1. Participants in Arm 1 underwent standardised in-house PK sampling during 24 hours in order to assess single-dose PK of OD or TID regimen at the start of each study treatment period while participants in Arm 2 had a reduced PK sampling scheme of single dose PK on Days 1-2 and returned for multiple-dose PK sampling on Days 7-8. The average of single and multiple dosing for combined arm 1+2 was reported. (NCT00915343)
Timeframe: Arm 1: Week 4, Week 16, Week 16 + 1 day, Week 28; Arm 2: Week 4, Week 4 + 7 days, Week 16, Week 16 + 7 days
| Intervention | ratio (Mean) |
|---|---|
| Hydrocortisone MR Tablet OD - Part A | 1.11 |
| Hydrocortisone Tablet TID - Part A | 1.03 |
(NCT01559675)
Timeframe: Postoperative Day 1
| Intervention | participants (Number) |
|---|---|
| High Dose Steroid | 2 |
| Low Dose Steroid | 2 |
Average inotrope score over first 48 hours after Cardiac Intensive Care Unit admission was used as a secondary outcome. Inotrope Score is calculated based on the dose of inotropes currently infusing at a given time points. The formula for calculation is as follows: Epinephrine/Norepinephrine (mcg/kg/min) dose x100, plus Dopamine/Dobutamine (mcg/kg/min) dose x 1, plus Neosynephrine (mcg/kg/min) dose x10, plus Vasopressin (units/kg/hr) [(dose x60)/10,000] = Inotrope Score. Our institution does not include Milrinone in our inotrope score calculation because every patient receives a continuous infusion in the immediate post-operative period. The higher the inotrope score the more cardiac support the patient is requiring or the worse their cardiac function is becoming. (NCT01595386)
Timeframe: first 48 hours post-op
| Intervention | Inotrope Score (Median) | ||
|---|---|---|---|
| Inotrope Score at 12 hours post bypass | Inotrope Score 24 hours post bypass | Inotrope Score 48 hours post bypass | |
| Hydrocortisone | 4.7 | 4 | 0 |
| Normal Saline-Placebo | 5.3 | 0 | 0 |
CICU length of stay will be calculated from the time the subject is admitted to the CICU post-op until they are discharged from the unit. This will be used as a secondary outcome. (NCT01595386)
Timeframe: approximately 1 week
| Intervention | hours (Median) |
|---|---|
| Normal Saline-Placebo | 162 |
| Hydrocortisone | 213 |
Respiratory values such as changes in baseline arterial-venous oxygen saturation difference at admission to the pediatric cardiac intensive care unit will be used as a secondary outcome. (NCT01595386)
Timeframe: admit to the CICU
| Intervention | percentage of arterial-venous saturation (Median) |
|---|---|
| Normal Saline-Placebo | 14 |
| Hydrocortisone | 9.5 |
Low Cardiac Output Syndrome (LCOS) within the first 48 hours after post-operative admission to the Pediatric Cardiac Intensive Care Unit was used as the primary outcome. This was defined as a double in inotropic support from post-operative admit, requiring Extracorporeal Membrane Oxygenation (ECMO) support, receiving Cardiopulmonary Resuscitation, or death. (NCT01595386)
Timeframe: first 48 hours after cardiac intensive care unit (CICU) admission post-op
| Intervention | percentage of patients (Number) |
|---|---|
| Normal Saline-Placebo | 57 |
| Hydrocortisone | 26 |
Changes in pre-op inflammatory mediators will be assessed at 0, 4, 12, 24 and 48 hours post bypass and used as a secondary outcome. (NCT01595386)
Timeframe: 0, 4,12, 24, and 48 hours post bypass
| Intervention | pg/mL (Median) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-op Il-10 | 0 hr post bypass Il-10 | 4 hr post bypss Il-10 | 12 hr post bypass Il-10 | 24 hr post bypass Il-10 | 48 hr post bypass Il-10 | Pre-op Il-1 beta | 0 hr post bypass Il-1 beta | 4 hr post bypass Il-1 beta | 12 hr post bypss Il-1 beta | 24 hr post bypass Il-1 beta | 48 hr post bypass Il-1 beta | Pre-op Il-6 | 0 hr post bypass IL-6 | 4 hr post bypsas Il-6 | 12 hr post bypass Il-6 | 24 hr post bypass Il-6 | 48 hr post bypass Il-6 | Pre-op Il-8 | 0 hr post bypass Il-8 | 4 hr post bypss IL-8 | 12 hr post bypass IL-8 | 24 hr post bypass Il-8 | 48 hr post bypass Il-8 | Pre-op tumor necrosis factor (TNF)-alpha | 0 hr post bypass TNF-alpha | 4 hr post bypass TNF-alpha | 12 hr post bypss TNF-alpha | 24 hr post bypass TNF-alpha | 48 hr post bypass TNF-alpha | |
| Hydrocortisone | 4.3 | 164 | 92.2 | 20.1 | 10.7 | 9.4 | 0.53 | 0.5 | 1.2 | 0.33 | 0.77 | 0.29 | 5.8 | 12.4 | 65.2 | 50.4 | 45.5 | 15.3 | 23.5 | 99.8 | 261.5 | 97 | 103 | 50.3 | 4.3 | 2.9 | 5.5 | 4.2 | 4.1 | 3 |
| Normal Saline-Placebo | 4 | 225 | 53.5 | 17.5 | 11.4 | 7.9 | 0.49 | 0.44 | 0.83 | 0.49 | 1.71 | 0.76 | 3.6 | 13.6 | 58 | 93.7 | 110 | 40.1 | 27.1 | 118 | 212 | 153 | 129 | 67.3 | 4.7 | 3.6 | 6.4 | 6.6 | 5.8 | 5.1 |
AdrenoCorticoTropic Hormone stimulation test will be performed at least 24 hours pre-bypass and immediately after successful discontinuation of bypass and compared. These outcomes will be used as a secondary outcome. (NCT01595386)
Timeframe: 24 hours prebypass and 0 hours post-bypass
| Intervention | microg/dL (Median) | |||||
|---|---|---|---|---|---|---|
| Pre-op ACTH | Pre-op Pre-stimulation cortisol | Pre-op Post-stimulation cortisol | Post-op ACTH | Post-op Pre-Stimulation cortisol | Post-op Post-stimulation cortisol | |
| Hydrocortisone | 31 | 23.3 | 47.1 | 7.5 | 87.2 | 118.8 |
| Normal Saline-Placebo | 24.5 | 18.2 | 43.6 | 10.5 | 89.4 | 112.3 |
Respiratory values such as duration of intubation will be used as a secondary outcome. (NCT01595386)
Timeframe: Until discharge from hospital, approximately 2 weeks
| Intervention | hours (Median) |
|---|---|
| Normal Saline-Placebo | 55 |
| Hydrocortisone | 51 |
Subject mortality will in the CICU will be used as a secondary outcome. (NCT01595386)
Timeframe: Duration of CICU stay, approximately 1 week
| Intervention | percentage of patients (Number) |
|---|---|
| Normal Saline-Placebo | 14 |
| Hydrocortisone | 0 |
Respiratory variables include such as alive, ventilator free days at 28 days post-op will be used as secondary outcome. The mean number of days subjects were live and ventilator free up to the 28 days after surgery. (NCT01595386)
Timeframe: up to 28 days post op
| Intervention | days (Median) |
|---|---|
| Normal Saline-Placebo | 24 |
| Hydrocortisone | 25 |
The average length of hospital stay from the time the subject is admitted to the CICU post-op until they are discharged will be used as a secondary outcome. (NCT01595386)
Timeframe: Admit to CICU till hospital discharge, approximately 3 weeks
| Intervention | days (Median) |
|---|---|
| Normal Saline-Placebo | 13.5 |
| Hydrocortisone | 19 |
Hemodynamic variable such as total fluid balance within the first 48 hours post-op will be used as a secondary outcome. Fluid balance is a calculation of the overall fluid status for a given time period. The total input (fluid, medications, etc) that are given to a patient during a given time frame (24 hours) minus the total output (urine, stool, drainage, etc. ) that comes out of a patient during a given time frame. (NCT01595386)
Timeframe: 1st 48 hours post-op
| Intervention | mL/kg (Median) |
|---|---|
| Normal Saline-Placebo | -64 |
| Hydrocortisone | -114 |
"MRD positive is defined as > or = to 0.1% MRD MRD negative is define as < 0.1% MRD~All these analyses will be descriptive and exploratory and hypotheses generating in nature." (NCT01614197)
Timeframe: Cycle 1 (a minimum of 4 weeks and a max of 8 weeks)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| MRD positive | MRD negative | |
| Dose Level 1 | 3 | 0 |
| Dose Level 2 | 2 | 1 |
| Dose Level 3 | 5 | 1 |
| Dose Level 4 | 2 | 1 |
Estimate the 3-year survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy. (NCT01700946)
Timeframe: 3 years of follow-up since the on-study date
| Intervention | percentage of participants (Number) |
|---|---|
| STANDARD RISK | 94.4 |
| HIGH RISK | 55.5 |
| All Patients Enrolled on the Study | 72.63 |
To estimate mean levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block I of remission induction therapy for relapsed precursor B-cell ALL. (NCT01700946)
Timeframe: Baseline and at the end of Block I (approximately 5 weeks after the on-study date)
| Intervention | percentage of CD20 Antigen (Mean) | |
|---|---|---|
| At Baseline | At Block I | |
| All Patients Enrolled on the Study | 36.23 | 19.43 |
| HIGH RISK | 39.82 | 20.10 |
| STANDARD RISK | 31.10 | 18.54 |
Estimate the 3-year event-free survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy. (NCT01700946)
Timeframe: 3 years of follow-up since the on-study date
| Intervention | percentage of participants (Number) |
|---|---|
| STANDARD RISK | 83.3 |
| HIGH RISK | 55.7 |
| All Patients Enrolled on the Study | 67.83 |
To estimate median levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block I of remission induction therapy for relapsed precursor B-cell ALL. (NCT01700946)
Timeframe: Baseline and at the end of Block I (approximately 5 weeks after the on-study date)
| Intervention | percentage of CD20 Antigen (Median) | |
|---|---|---|
| At Baseline | At Block 1 | |
| All Patients Enrolled on the Study | 22.0 | 15.58 |
| HIGH RISK | 23.13 | 19.58 |
| STANDARD RISK | 16.40 | 11.83 |
(NCT01782859)
Timeframe: First 24 hours after surgery
| Intervention | pmol/mL (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Wound Closure | 4 hours postoperatively | 6 hours postoperatively | 24 hours postoperatively | |
| Placebo | 334.15 | 778.33 | 1306.76 | 1175.71 | 356.79 |
| Prednisone/Hydrocortisone | 298.12 | 619.21 | 1138.65 | 1032.52 | 422.61 |
(NCT01782859)
Timeframe: First 24 hours after surgery
| Intervention | mcg/L (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Wound Closure | 4 hours postoperatively | 6 hours postoperatively | 24 hours postoperatively | |
| Placebo | 924.67 | 1361.23 | 2251.33 | 2283.18 | 996.39 |
| Prednisone/Hydrocortisone | 1011.17 | 2251.33 | 2455.71 | 2379.57 | 914.16 |
The time frame of the study for each patient covers the period between time of surgery and until discharge from the hospital. (NCT01782859)
Timeframe: Participants will be followed from the time of surgery until discharge, expected average of 3-5 days
| Intervention | picograms/milliliter (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Wound closure | 4 hours postoperatively | 6 hours postoperatively | 24 hours postoperatively | |
| Placebo | 2.98 | 4.46 | 89.21 | 115.17 | 176.79 |
| Prednisone/Hydrocortisone | 5.69 | 4.47 | 56.72 | 64.4 | 68.51 |
At 3 months postoperatively, patients were asked to rate their pain on a scale of 0-10, with 0 being no pain and 10 being worst pain. (NCT01782859)
Timeframe: 3 months postoperatively
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.92 |
| Prednisone/Hydrocortisone | 0.54 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - Midday (1500 - 2300). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 458 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - Nighttime (2300 - 0700). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 841 |
Participants Mean Level of ACTH at 0700. (NCT01859312)
Timeframe: At 6 months
| Intervention | pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 139 |
Participants Mean Level of ACTH at 0700. (NCT01859312)
Timeframe: At baseline
| Intervention | pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 405 |
Participants Mean Level of Androstenedione area under the curve (AUC) - 24 hours. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 5.2 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - 24 hours. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 12.7 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Daytime (0700-1500). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 1.8 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Daytime (0700-1500). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 5.3 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Midday (1500 - 2300). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 1.6 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Midday (1500 - 2300). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 3.7 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Nighttime (2300 - 0700). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 1.8 |
Participants Mean Level of Progesterone area under the curve (AUC) - Nighttime (2300 - 0700). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 28.2 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - Nighttime (2300 - 0700). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaenous Hydrocortisone Infusion | 564 |
Participants Mean Level of Androstenedione Area Under the Curve (AUC) - Nighttime (2300 - 0700). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 3.7 |
Participants Mean Level of Androstenedione at 0700. (NCT01859312)
Timeframe: At 6 months
| Intervention | ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 317 |
Participants Mean Level of Androstenedione at 0700. (NCT01859312)
Timeframe: At baseline
| Intervention | ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 748 |
Participants Mean Level of Progesterone area under the curve (AUC) - 24 hours. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 13.7 |
Participants Mean Level of Progesterone area under the curve (AUC) - 24 hours. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 101.1 |
Participants Mean Level of Progesterone area under the curve (AUC) - Daytime (0700-1500). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 4.2 |
Participants Mean Level of Progesterone area under the curve (AUC) - Daytime (0700-1500). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 42.2 |
Participants Mean Level of Progesterone area under the curve (AUC) - Midday (1500 - 2300). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 5.5 |
Participants Mean Level of Progesterone area under the curve (AUC) - Midday (1500 - 2300). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 30.7 |
Participants Mean Level of Progesterone area under the curve (AUC) - Nighttime (2300 - 0700). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 4.0 |
Participants Mean Level of Progesterone at 0700 (NCT01859312)
Timeframe: At baseline
| Intervention | ng/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 9.5 |
Participants Mean Level of Progesterone at 0700 (NCT01859312)
Timeframe: At 6 months
| Intervention | ng/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 0.8 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (NCT01859312)
Timeframe: At 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 3 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (NCT01859312)
Timeframe: At baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 0 |
lean body mass measured by DEXA, Hologic Discovery-A (NCT01859312)
Timeframe: At 6 months
| Intervention | kg (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 64.3 |
lean body mass measured by DEXA, Hologic Discovery-A (NCT01859312)
Timeframe: At baseline
| Intervention | kg (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 60.7 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 25.7 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 98.5 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 6.8 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 48.6 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficienc. AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 20.5 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 7.5 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 11.4 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour nighttime level, samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*mcg/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 29.5 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (NCT01859312)
Timeframe: At 6 months
| Intervention | ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 2150 |
17-OHP (17-hydroxyprogesterone) is a laboratory blood test to test for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (NCT01859312)
Timeframe: At baseline
| Intervention | ng/dL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 8313 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - 24 Hours. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 1087 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - 24 Hours. AUC was calculated using the linear-up log-down trapezoidal rule for the entire 24 hours and samples were obtained every 2 hours beginning at 2300, 0100, 0300, 0500, 0700, 0900, 1100, 1300, 1500, 1700, 1900, 2100, 2300.Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 2538 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - Daytime (0700-1500). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 340 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - Daytime (0700-1500). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour daytime level, samples were obtained every 2 hours beginning at 0700, 0900, 1100, 1300, 1500. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At baseline
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 1239 |
Participants Mean Level of ACTH Area Under the Curve (AUC) - Midday (1500 - 2300). AUC was calculated using the linear-up log-down trapezoidal rule for the 8 hour midday level, samples were obtained every 2 hours beginning at 1500, 1700, 1900, 2100, 2300. Actual collection times were used to define peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax). (NCT01859312)
Timeframe: At 6 months
| Intervention | h*pg/mL (Mean) |
|---|---|
| Continuous Subcutaneous Hydrocortisone Infusion | 183 |
The number of patients able to complete the 4-week study intervention and the 4-week observation period are reported. (NCT01867294)
Timeframe: At 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study I: Spironolactone | 4 |
| Study I: Placebo | 0 |
Adverse events were collected at the end of one 4-week cycle and one 4-week observation period according to the Common Terminology Criteria for Adverse Events (CTCAE) CTEP Version 4.0. The number of patients reporting a grade 2+ adverse event attributed to spironolactone is reported here. (NCT01867294)
Timeframe: At 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study I: Spironolactone | 0 |
| Study I: Placebo | 0 |
Adverse events were collected at the end of each 4-week cycle according to the Common Terminology Criteria for Adverse Events (CTCAE) CTEP Version 4.0. The number of patients reporting a truncal/extremity adverse event is reported here. The treatment will be considered feasible if at least 50% of patients in the spironolactone arm develop a truncal/extremity rash of any grade at the end of 4 weeks. (NCT01867294)
Timeframe: At 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study I: Spironolactone | 6 |
| Study I: Placebo | 6 |
Patients will be dichotomously categorized as a success if no rash is reported and a failure if rash exists at the end of 4 weeks. The number of patients that successfully completed 4 weeks of treatment and reported no rash on the Brief Pictorial Rash Incidence Questionnaire are reported. (NCT01867294)
Timeframe: At 4 weeks
| Intervention | participants (Number) |
|---|---|
| Study I: Spironolactone | 1 |
| Study I: Placebo | 2 |
Blood: Serum cortisol under physiological conditions and after administration of dexamethasone and Infacort® Granules, Hydrocortisone Tablets and i.v Hydrocortisone Injection. (NCT01960530)
Timeframe: Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period
| Intervention | nmol/L (Mean) |
|---|---|
| Endogenous Cortisol | 447.355 |
| Dexamethasone | 19.349 |
| Infacort® | 963.134 |
| Hydrocortisone Tablet | 893.077 |
| i.v Hydrocortisone Injection | 1580.337 |
Derived PK for Serum Cortisol: Maximum serum concentration (Cmax) (NCT01960530)
Timeframe: Hourly from 0 to 24 hours
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Infacort® | 940.012 |
| Hydrocortisone Tablet | 896.489 |
| i.v Hydrocortisone Injection | 1563.479 |
A standardised mixed meal elevates blood glucose and provides a reproducible stimulation of insulin release. Lower levels of insulin secretion, whilst maintaining normoglycaemia would indicate enhanced insulin sensitivity and glucose disposal; higher insulin levels will reflect insulin resistance. (NCT01960530)
Timeframe: Blood samples on Day 1 and/or Day 2 of each Study Period
| Intervention | uIU/mL (Mean) |
|---|---|
| Endogenous Cortisol | 70.529 |
| Dexamethasone | 80.668 |
| Infacort® | 77.575 |
| Hydrocortisone Tablet | 70.650 |
| i.v Hydrocortisone Injection | 70.121 |
Cortisol protein binding under physiological conditions and after the administration of dexamethasone and hydrocortisone. (NCT01960530)
Timeframe: Blood samples on Day 1 and/or Day 2 of each Study Period
| Intervention | ug/mL (Mean) |
|---|---|
| Endogenous Cortisol | 22.950 |
| Dexamethasone | 23.441 |
| Infacort® | 22.386 |
| Hydrocortisone Tablet | 21.757 |
| i.v Hydrocortisone Injection | 21.482 |
Derived PK for Serum Cortisol: Area under the curve from 0-24 hours (NCT01960530)
Timeframe: Hourly from 0 to 24 hours
| Intervention | nmol*h/L (Geometric Mean) |
|---|---|
| Infacort® | 2543.24 |
| Hydrocortisone Tablet | 2896.73 |
| i.v Hydrocortisone Injection | 2923.46 |
Number of subjects with adverse events throughout the study. (NCT01960530)
Timeframe: Days 1-2 during each Study Period
| Intervention | participants (Number) |
|---|---|
| Endogenous Cortisol | 3 |
| Dexamethasone | 3 |
| Infacort® | 0 |
| Hydrocortisone Tablet | 1 |
| i.v Hydrocortisone Injection | 2 |
The specific adverse events that will be measured include: severe bleeding, secondary infections and the use of insulin infusions. The incidence of adverse events and mortality rate was measured in aggregate (i.e. the whole cohort) in order to provide a better baseline estimate of these outcomes in our study population. (NCT02044159)
Timeframe: Daily during hospital admission (up to 28 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Cohort | 24 |
This objective is a measure of protocol adherence. The goal is to discontinue study drug within 12 to 18 hours of vasoactive medications being stopped. We will consider adherence to the protocol adequate if secondary outcomes 1a to 1c are met in 80% of enrolled patients. (NCT02044159)
Timeframe: 7 days
| Intervention | % of doses administered correctly (Number) |
|---|---|
| Full Cohort | 97.6 |
This objective is a measure of protocol adherence. The goal is to have patients randomized within 6 hours, and study drug administration completed within 8 hours of starting a vasoactive medication. We will consider adherence to our protocol to be adequate if secondary outcomes 1a to 1c are met in 80% of enrolled patients. (NCT02044159)
Timeframe: 8 hours from starting vasoactive medication
| Intervention | hours (Mean) |
|---|---|
| Full Cohort | 3.8 |
This objective is a measure of protocol adherence. The goal is weaning of study drug to q8h within 12 hours of no escalation of therapy. We will consider adherence to our protocol to be adequate if secondary outcomes 1a to 1c are met in 80% of enrolled patients. (NCT02044159)
Timeframe: 7 days
| Intervention | % of doses administered correctly (Number) |
|---|---|
| Full Cohort | 97.6 |
A total of 3 ml of blood in a red top tube will be collected within 24 hours of hospital admission. Patients with access for blood sampling and for whom consent has been obtained will have blood samples collected. The samples will be separated at each centre, stored until the end of the recruitment period, and then shipped to the principal investigators's centre as per the specific test requirements. The free cortisol and stratification biomarker samples will be batched and then shipped to Cincinnati for analysis at the end of the study. The number of samples collected, and the number of samples successfully received and analyzed at the principal investigator's site and at the Cincinnati lab will be determined at the end of the recruitment phase. (NCT02044159)
Timeframe: End of the study recruitment phase (up to 1.5 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Cohort | 44 |
The time to discontinuation of vasoactive agents will be used to better estimate the sample size for the full study. (NCT02044159)
Timeframe: Daily during hospital admission (up to 28 days)
| Intervention | hours (Median) |
|---|---|
| Hydrocortisone | 38.2 |
| Placebo | 33.1 |
We will consider the number of patients started on open label steroids by the treating physician to be acceptable if it occurs in less than 10% of patients. We will also collect information on the clinical parameters of patients when open label steroids are given. (NCT02044159)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Full Cohort | 6 |
The total number of participants recruited over the recruitment period to both arms (this was a feasibility outcome that was analyzed for the full cohort and, as stated a priori in the study protocol was not compared between study arms). Our goal is to recruit 72 patients over one year . However, we will consider patient accrual rate to be adequate if we recruit 60 patients from seven sites within this time period. (NCT02044159)
Timeframe: 1 year
| Intervention | percentage of target sample size (Number) |
|---|---|
| Full Cohort | 82 |
Patient charts were reviewed to identify patients who were discharged on prednisone (NCT02084134)
Timeframe: 1 day (Day of hospital discharge)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Treatment Arm | 8 |
| Non-steroid Treatment | 2 |
Adrenal insufficiency was defined by a 30 or 60 min cortisol < 18 during a cosyntropin stimulation test (NCT02084134)
Timeframe: 6 weeks following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Treatment Arm | 2 |
| Non-steroid Treatment | 1 |
OS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Three-year OS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm C (LR Control) | 88.29 |
| Arm D (LR Blinatumomab) | 90.37 |
DFS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (HR and IR Control) | 39.04 |
| Arm B (HR and IR Blinatumomab) | 54.44 |
DFS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm C (LR Control) | 58.94 |
| Arm D (LR Blinatumomab) | 67.00 |
OS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Two-year OS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (HR and IR Control) | 58.40 |
| Arm B (HR and IR Blinatumomab) | 71.33 |
EFS for very high risk (VHR) T-LLy patients treated with HR Berlin-Frankfurt-Munster (BFM) intensification blocks who have complete or partial remission and those who do not respond (NCT02112916)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| VHR T-LLy (CR/PR) | 0 |
EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| AALL1231 T-ALL Patients | 88.3 |
| AALL0434 T-ALL Patients | 88.8 |
EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. Three-year EFS rates will be calculated for both groups. (NCT02112916)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A (Combination Chemotherapy) | 81.7 |
| Arm B (Combination Chemotherapy, Bortezomib) | 85.1 |
EFS will be calculated as time from the end of the three high-risk blocks of therapy to first event (relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| VHR T-ALL MRD Undetectable | 25.0 |
| VHR T-ALL MRD Detectable | 88.9 |
Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (NCT02112916)
Timeframe: 3 years from start of therapy by patient
| Intervention | Percentage of participants (Number) |
|---|---|
| Total Patients | 78.0 |
Cumulative incidence of isolated CNS relapse adjusting for competing risks using the method of: Gray R, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141:1154, 1988 (NCT02112916)
Timeframe: 3 years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Isolated CNS Relapse | Isolated Bone Marrow Relapse | Combined Bone Marrow Relapse | |
| AALL0434 T-ALL Patients | 2.2 | 3.0 | 1.8 |
| AALL1231 T-ALL Patients | 3.6 | 1.4 | 1.3 |
"Area under the curve from 0 to 24 hours for serum cortisol. Please note that the AUC0-t will be presented as a single figure (geometric mean) to represent exposure over time.~N.B., the sampling points for Hydrocortisone are as follows: 0h, 0.25h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h and 12h post-dose. However, the results for Hydrocortisone will not be incorporated into the analysis for this outcome measure." (NCT02408068)
Timeframe: 24 hours (at 0h, then 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 6.5h, 7h, 7.5h, 8h, 9h, 10h, 11h, 12h, 13h, 14h, 15h, 16h, 18h, 20h, 22h and 24h post-dose.)
| Intervention | h*nmol/L (Geometric Mean) |
|---|---|
| Chronocort Fed | 3229.26 |
| Chronocort Fasted | 2980.85 |
| Immediate-Release Hydrocortisone | 2466.90 |
Comparison of fed and fasted Chronocort Cmax for serum cortisol. (NCT02408068)
Timeframe: 24 hours
| Intervention | nmol/L (Geometric Least Squares Mean) |
|---|---|
| Chronocort Fed | 549.49 |
| Chronocort Fasted | 708.46 |
| Immediate-Release Hydrocortisone | 856.36 |
To evaluate the relative bioavailability of Chronocort® and immediate release hydrocortisone at a single dose of 20 mg in the fasted state using area under the curve (NCT02408068)
Timeframe: 24 hours
| Intervention | h*nmol/L (Geometric Mean) |
|---|---|
| Chronocort Fasted | 2980.85 |
| Immediate-Release Hydrocortisone | 2466.90 |
| Chronocort Fed | 3229.26 |
Evaluation of the relative bioavailability of Chronocort® and immediate release hydrocortisone at a single dose of 20 mg in the fasted state by Cmax (NCT02408068)
Timeframe: 24 hours
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Chronocort Fasted | 708.45 |
| Immediate-Release Hydrocortisone | 856.36 |
| Chronocort Fed | 549.49 |
To evaluate the relative bioavailability of Chronocort® and immediate release hydrocortisone at a single dose of 20 mg in the fasted state using Tmax. (NCT02408068)
Timeframe: 24 hours
| Intervention | hours (Median) |
|---|---|
| Chronocort Fasted | 4.5 |
| Immediate-Release Hydrocortisone | 0.87 |
| Chronocort Fed | 6.75 |
Comparison of Fed and Fasted Chronocort based on the time to achive the maximum concentration of serum cortisol (NCT02408068)
Timeframe: 24 hours
| Intervention | hours (Median) |
|---|---|
| Chronocort Fed | 6.75 |
| Chronocort Fasted | 4.5 |
| Immediate-Release Hydrocortisone | 0.87 |
12-month PFS will be defined as the percentage of patients alive and progression free 12 months from start of therapy. Patients lost to follow up will be censored from last point of contact. PFS was calculated using a Kplan-meier estimation with the probability of patients being progression free at 12 months, presented as the percentage based on this probability. (NCT02481310)
Timeframe: Up to 12 months from initiation of treatment
| Intervention | probability (%) of patients alive (Number) |
|---|---|
| Treatment (Combination Chemotherapy, Rituximab, Ixazomib) | 75.84 |
"The RP2D will be determined by the evaluation of dose-limiting toxicities (DLT) to find the Maximum Tolerated Dose (MTD) which will constitute the RP2D. DLTs will be defined as the occurrence of ≥ Grade 3 toxicity experienced during the first cycle (3 weeks or 21 days) of study treatment, will be determined, except for cytopenias.~The dose of ixazomib will start at 2.3 mg weekly (for phase I patients) when given concurrently with DA-EPOCH-R. Single-subject cohorts (escalating in ixazomib dose) will be enrolled until the MTD is encountered, after which expansion to 3-subject cohorts will be undertaken. The MTD from phase I will equate the RP2D for ixazomib given in conjunction with DA-EPOCH-R." (NCT02481310)
Timeframe: The first 21 days of treatment
| Intervention | mg (Number) |
|---|---|
| Treatment (Combination Chemotherapy, Rituximab, Ixazomib) | 3 |
"17-OHP and A4 levels at 09:00 at the week 24 visit, as a responder analysis (i.e. the number of participants achieving results in the optimal range).~Optimal range for 17-OHP (male) = 1.2* - 6.7 nmol/L (female) = 1.2* - 8.6 Optimal range for A4 (male) = 1.4 - 5.2 nmol/L (female) = 1.0 - 7.0 nmol/L~* = There is no lower reference range available for 17-OHP, hence the lower limit of the optimal range was used in the derivation of the average Standard Deviation Score. This enabled calculation of an 'unsigned' SDS score which was used to assess potential over-treatment as well as under-treatment." (NCT02716818)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Chronocort - 09:00h Response - 17-OHP | 30 |
| Chronocort - 09:00h Response - A4 | 25 |
| Standard Glucocorticoid Therapy - 09:00h Response - 17-OHP | 30 |
| Standard Glucocorticoid Therapy - 09:00h Response - A4 | 30 |
Changes relative to Standard glucocorticoid therapy in body composition (DEXA - bone mineral density only) - measured at all sites except Germany. (NCT02716818)
Timeframe: Baseline and 24 weeks
| Intervention | g/cm^2 (Mean) |
|---|---|
| Chronocort - DEXA - Bone Mineral Density | -0.001 |
| Standard Glucocorticoid Therapy - DEXA - Bone Mineral Density | -0.008 |
Change from baseline to 24 weeks of the mean of the 24-hour standard deviation score (SDS) - also referred to as a z-score - profile for A4 (androstenedione). This secondary efficacy variable was calculated as follows: the natural logarithm of the mean of the 24-hour SDS for the natural logarithm of A4. The mean of the 24-hour SDS profile for each visit was the arithmetic mean of all the SDSs with the first and last (13th) weighted one half relative to the intermediate SDSs. For each of the 13 log-transformed A4 values at each visit, an SDS was calculated by counting the number of SDs that were above or below the mean of the log-transformed range. A negative z-score indicated greater control of A4 when compared to baseline (0). (NCT02716818)
Timeframe: 24 weeks
| Intervention | Z-score (Mean) |
|---|---|
| Chronocort® | 0.113 |
| Standard Glucocorticoid Therapy | -0.041 |
Change from baseline to 24 weeks of the mean of the 24-hour standard deviation score (SDS) - also referred to as a z-score - profile for 17-OHP (17-Hydroxyprogesterone). The primary efficacy variable was the natural logarithm of the mean of the 24-hour SDS for the natural logarithm of 17-OHP. The mean of the 24-hour SDS profile for each visit was the arithmetic mean of all the SDSs with the first and last (13th) weighted one half relative to the intermediate SDSs. For each of the 13 log-transformed 17-OHP values at each visit, an SDS was calculated by counting the number of SDs that were above or below the mean of the log-transformed range. A negative z-score indicated greater control of 17-OHP when compared to baseline (0). (NCT02716818)
Timeframe: 24 weeks
| Intervention | Z-score (Mean) |
|---|---|
| Chronocort® | -0.403 |
| Standard Glucocorticoid Therapy | -0.172 |
17-OHP and A4 by individual baseline treatment strata presented in the same manner as the primary endpoint (using 24-hour SDS profile at 24 weeks). Change from baseline to 24 weeks of the mean of the 24-hour standard deviation score (SDS) - also referred to as a z-score - profile for 17-OHP and A4. This secondary efficacy variable was calculated as follows: the natural logarithm of the mean of the 24-hour SDS for the natural logarithm of 17-OHP and A4. The mean of the 24-hour SDS profile for each visit was the arithmetic mean of all the SDSs with the first and last (13th) weighted one half relative to the intermediate SDSs. For each of the 13 log-transformed 17-OHP and A4 values at each visit, an SDS was calculated by counting the number of SDs that were above or below the mean of the log-transformed range. A negative z-score indicated greater control of 17-OHP and A4 when compared to baseline (0). (NCT02716818)
Timeframe: 24 weeks
| Intervention | Z-score (Mean) |
|---|---|
| Pre-Baseline - Hydrocortisone - 17-OHP | -0.248 |
| Pre-Baseline - Prednisone/Prednisolone - 17-OHP | -0.061 |
| Pre-Baseline - Dexamethasone - 17-OHP | -0.245 |
| Pre-Baseline - Chronocort vs. Hydrocortisone - 17-OHP | -0.431 |
| Pre-Baseline - Chronocort vs. Prednisone/Prednisolone - 17-OHP | -0.320 |
| Pre-Baseline - Chronocort vs. Dexamethasone - 17-OHP | -0.565 |
| Pre-Baseline - Hydrocortisone - A4 | -0.211 |
| Pre-Baseline - Prednisone/Prednisolone - A4 | 0.100 |
| Pre-Baseline - Dexamethasone - A4 | 0.368 |
| Pre-Baseline - Chronocort vs. Hydrocortisone - A4 | 0.015 |
| Pre-Baseline - Chronocort vs. Prednisone/Prednisolone - A4 | 0.328 |
| Pre-Baseline - Chronocort vs. Dexamethasone - A4 | -0.092 |
Changes relative to Standard glucocorticoid therapy in body composition (DEXA) (fat mass and lean mass) - measured at all sites except Germany. (NCT02716818)
Timeframe: Baseline and 24 weeks
| Intervention | kilograms (Mean) |
|---|---|
| Chronocort - DEXA - Fat Mass | -0.575 |
| Standard Glucocorticoid Therapy - DEXA - Fat Mass | 0.445 |
| Chronocort - DEXA - Lean Mass | 0.640 |
| Standard Glucocorticoid Therapy - DEXA - Lean Mass | 0.234 |
(NCT02760862)
Timeframe: within 48 hours after starting of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Group (I) (N=25) | 25 |
| Group (II) (N=25) | 25 |
Results on early postresuscitation, mean arterial blood pressure (mmHg) are provided for the second, pre-specified time point of measurement, i.e. at 4 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 4 hours after ROSC.
| Intervention | mmHg (Mean) |
|---|---|
| Steroids Group | 83.9 |
| Control Group | 78.9 |
Results on postresuscitation, mean arterial blood pressure (mmHg) are provided for the fifth, pre-specified time point of measurement, i.e. at 72 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 72 hours after ROSC.
| Intervention | mmHg (Mean) |
|---|---|
| Steroids Group | 85.2 |
| Control Group | 84.7 |
Results on postresuscitation, mean arterial blood pressure (mmHg) are provided for the fourth, pre-specified time point of measurement, i.e. at 48 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 48 hours after ROSC.
| Intervention | mmHg (Mean) |
|---|---|
| Steroids Group | 80.2 |
| Control Group | 84.2 |
Results on postresuscitation, mean arterial blood pressure (mmHg) are provided for the third, pre-specified time point of measurement, i.e. at 24 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 24 hours after ROSC.
| Intervention | mmHg (Mean) |
|---|---|
| Steroids Group | 79.9 |
| Control Group | 81.9 |
RESULTS ARE PROVIDED FOR CARDIAC OUTPUT (CO) AT 4 HOURS AFTER ROSC. (NCT02790788)
Timeframe: Time points of measurement: 4 hours after ROSC.
| Intervention | L/min (Mean) |
|---|---|
| Steroids Group | 4.9 |
| Control Group | 5.0 |
Results are provided for CO at 24 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 24 hours after ROSC.
| Intervention | L/min (Mean) |
|---|---|
| Steroids Group | 5.6 |
| Control Group | 5.4 |
Results are provided for CO at 48 hours after ROSC (NCT02790788)
Timeframe: Time points of measurement: 48 hours after ROSC.
| Intervention | L/min (Mean) |
|---|---|
| Steroids Group | 5.8 |
| Control Group | 5.7 |
Results are provided for CO at 72 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 72 hours after ROSC.
| Intervention | L/min (Mean) |
|---|---|
| Steroids Group | 5.8 |
| Control Group | 5.6 |
Results on postresuscitation central venous oxygen saturation (%) are provided for the second, pre-specified time point of measurement, i.e., at 4 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 4 hours after ROSC.
| Intervention | Percent Hemoglobin Concentration (Mean) |
|---|---|
| Steroids Group | 67.4 |
| Control Group | 56.8 |
Results on postresuscitation central venous oxygen saturation (%) are provided for the fifth, pre-specified time point of measurement, i.e., at 72 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 72 hours after ROSC.
| Intervention | Percent Hemoglobin Saturation (Mean) |
|---|---|
| Steroids Group | 72.5 |
| Control Group | 70.4 |
Results on postresuscitation central venous oxygen saturation (%) are provided for the fourth, pre-specified time point of measurement, i.e., at 48 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 48 hours after ROSC.
| Intervention | Percent Hemoglobin Concentration (Mean) |
|---|---|
| Steroids Group | 73.3 |
| Control Group | 70.5 |
Results on postresuscitation central venous oxygen saturation (%) are provided for the third, pre-specified time point of measurement, i.e., at 24 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: 24 hours after ROSC.
| Intervention | Percent Hemoglobin Concentration (Mean) |
|---|---|
| Steroids Group | 71.1 |
| Control Group | 70.1 |
Number of organ failure-free days during days 1 through 60 postrandomization. Organ failure free=corresponding Sequential Organ Failure Assessment Subscore <3; each subscore can have the following values: 0, 1, 2, 3, and 4; increasing values indicate worsening organ failure. (NCT02790788)
Timeframe: Days 1 to 60 postrandomization.
| Intervention | Number of Days without Organ Failure (Median) |
|---|---|
| Steroids Group | 0 |
| Control Group | 0 |
Survival to hospital discharge with a Cerebral Performance Category (CPC) Score of 1 or 2. The CPC Score ranges can have the following values: 1, 2, 3, 4, and 5; lower Scores correspond to better outcomes, whereas higher Scores reflect worsening outcomes, e.g. a Score of 4 means Coma or Vegetative state, and a Score of 5 means Brain Death. (NCT02790788)
Timeframe: Up to 180 days postrandomization.
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroids Group | 2 |
| Control Group | 5 |
Results are reported for 2 pairs of cerebral blood flow index (CBFI) measurements performed each time at a lower and a higher level of mean arterial pressure (MAP) at the following time points: 1) at 4 hours after ROSC and 2) at 72 hours after ROSC (NCT02790788)
Timeframe: Time points of measurement: 4 and 72 hours postresuscitation.
| Intervention | nM/s (Mean) | |||
|---|---|---|---|---|
| CBFI 4 HOURS POST-ROSC MEAN MAP=75.5 MMHG | CBFI 4 HOURS POST-ROSC MEAN MAP=96.0 MMHG | CBFI 72 HOURS POST-ROSC MEAN MAP=75.5 MMHG | CBFI 72 HOURS POST-ROSC MEAN MAP= 97.0 MMHG | |
| Control Group | 3.3 | 3.5 | 3.4 | 3.8 |
| Steroids Group | 4.0 | 4.2 | 4.3 | 4.9 |
Logarithm (base 10)-transformed serum levels of tumor necrosis factor alpha (TNFa), interleukin (IL)-1 beta, IL-6, IL-8, and IL-10; blood samples were obtained by venipuncture. (NCT02790788)
Timeframe: Time points of measurement: 4, 24, 48, and 72 hours postresuscitation.
| Intervention | Log(10) transformed values of pg/mL (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IL-6 at 4 hours after ROSC | TNFα at 4 hours after ROSC | IL-1β at 4 hours after ROSC | IL-8 at 4 hours after ROSC | IL-10 at 4 hours after ROSC | IL-6 at 24 hours after ROSC | TNFα at 24 hours after ROSC | IL-1β at 24 hours after ROSC | IL-8 at 24 hours after ROSC | IL-10 at 24 hours after ROSC | IL-6 at 48 hours after ROSC | TNFα at 48 hours after ROSC | IL-1β at 48 hours after ROSC | IL-8 at 48 hours after ROSC | IL-10 at 48 hours after ROSC | IL-6 at 72 hours after ROSC | TNFα at 72 hours after ROSC | IL-1β at 72 hours after ROSC | IL-8 at 72 hours after ROSC | IL-10 at 72 hours after ROSC | |
| Control Group | 2.22 | 2.03 | 2.03 | 2.43 | 1.76 | 1.99 | 2.00 | 2.09 | 2.29 | 1.54 | 1.91 | 1.96 | 2.03 | 2.17 | 1.53 | 1.90 | 1.96 | 2.04 | 2.19 | 1.45 |
| Steroids Group | 2.19 | 1.97 | 2.07 | 2.39 | 1.76 | 2.06 | 2.02 | 2.06 | 2.27 | 1.69 | 1.87 | 1.99 | 2.09 | 2.15 | 1.56 | 1.93 | 2.00 | 2.05 | 2.15 | 1.66 |
"Eccentricity index (ECCI) is defined as the ratio of the left ventricular (LV) longitudinal (or anteroposterior) diameter to the LV transverse (or septo-lateral) diameter, measured at end diastole and end systole in a short-axis view. Pertinent results are provided for a first determination within 12 hours after ROSC and a second determination at 72 hours after ROSC." (NCT02790788)
Timeframe: Time points of measurement: Within the first 12 hours and at 72 hours postresuscitation.
| Intervention | ECCENTRICITY INDEX (Mean) | |||
|---|---|---|---|---|
| End-diastolic ECCI within 12 hours after ROSC | End-systolic ECCI within 12 hours after ROSC | End-diastolic ECCI at 72 hours after ROSC | End-systolic ECCI at 72 hours after ROSC | |
| Control Group | 1.3 | 1.3 | 1.3 | 1.3 |
| Steroids Group | 1.2 | 1.3 | 1.2 | 1.2 |
Results are provided on left ventricular end-diastolic area (LVEDA) and right ventricular diastolic area (RVEDA) by echocardiography within 12 hours and 72 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: Within the first 12 hours and at 72 hours postresuscitation.
| Intervention | cm^2 (Mean) | |||
|---|---|---|---|---|
| LVEDA within 12 hours after ROSC | RVEDA within 12 hours after ROSC | LVEDA at 72 hours after ROSC | RVEDA at 72 hours after ROSC | |
| Control Group | 22.8 | 13.0 | 18.5 | 12.6 |
| Steroids Group | 23.1 | 12.1 | 23.1 | 14.5 |
Episodes of 1) Hyperglycemia (defined as Blood Glucose >200 mg/dL), 2) Hypernatremia (defined as blood gas analysis-derived sodium ion concentration >150 mEq/L), and 3) Infections (defined as any microbiologically documented, intensive care unit-acquired, or hospital-acquired infection). (NCT02790788)
Timeframe: Up to 180 days postrandomization.
| Intervention | Number of Episodes per Patient (Median) | ||
|---|---|---|---|
| No. of Episodes of Hyperglycemia | No. of Episodes of Hypernatremia | No. of Episodes of Infections | |
| Control Group | 0 | 0 | 0 |
| Steroids Group | 0 | 0 | 0 |
Results are provided for core body temperature averaged over the following time intervals after ROSC: 1) 0-6 hours; 2) 6-12 hours; 3) 12-18 hours; 4) 18-24 hours; 5) 24-30 hours; 6) 30-36 hours; 7) 36-42 hours; and 42-48 hours. (NCT02790788)
Timeframe: Time points of measurement: Hourly from intensive care admission to 48 hours postresuscitation.
| Intervention | Degrees Celcius (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Temperature averaged over 0-6 hours after ROSC | Temperature averaged over 6-12 hours after ROSC | Temperature averaged over 12-18 hours after ROSC | Temperature averaged over 18-24 hours after ROSC | Temperature averaged over 24-30 hours after ROSC | Temperature averaged over 30-36 hours after ROSC | Temperature averaged over 36-42 hours after ROSC | Temperature averaged over 42-48 hours after ROSC | |
| Control Group | 35.6 | 36.6 | 36.5 | 36.3 | 36.2 | 36.2 | 36.2 | 36.3 |
| Steroids Group | 36.5 | 36.3 | 36.0 | 36.1 | 36.1 | 36.0 | 36.1 | 36.2 |
Results on early postresuscitation, mean arterial blood pressure (mmHg) are provided for the first, pre-specified time point of measurement, i.e. at 20 min after the return of spontaneous circulation (ROSC). (NCT02790788)
Timeframe: Time point of measurement: 20 min after the return of spontaneous circulation (ROSC).
| Intervention | mmHg (Mean) |
|---|---|
| Steroids Group | 78.4 |
| Control Group | 75.1 |
Results are provided on left ventricular ejection fraction (LVEF) and right ventricular ejection fraction (RVEF) within 12 hours and 72 hours after ROSC. (NCT02790788)
Timeframe: Time points of measurement: Within the first 12 hours and at 72 hours postresuscitation.
| Intervention | Percentage (Mean) | |||
|---|---|---|---|---|
| LVEF within 12 hours after ROSC | RVEF within 12 hours after ROSC | LVEF at 72 hours after ROSC | RVEF at 72 hours after ROSC | |
| Control Group | 45.9 | 42.7 | 50 | 44.7 |
| Steroids Group | 42.3 | 41.7 | 45 | 42.8 |
Will calculate the percentage of CpG site methylation for all patients after the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 5 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)
| Intervention | Percentage of CpG methylation (Mean) |
|---|---|
| KMT2A-Rearranged | 74.52 |
Proportion of KMT2A-Rearranged patients treated with azacitidine with Dose Limiting Toxicities (DLTs) from the first course of azacitidine administration up to fourth course of azacitidine administration. (NCT02828358)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| KMT2A-Rearranged | 6.45 |
Will calculate the percentage of CpG site methylation for all patients after the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 5 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)
| Intervention | Percentage of CpG methylation (Mean) |
|---|---|
| KMT2A-Rearranged | 75.54 |
Will calculate the percentage of CpG site methylation for all patients before the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 1 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)
| Intervention | Percentage of CpG methylation (Mean) |
|---|---|
| KMT2A-Rearranged | 76.5 |
Will calculate the percentage of CpG site methylation for all patients before the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 1 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)
| Intervention | Percentage of CpG methylation (Mean) |
|---|---|
| KMT2A-Rearranged | 78.17 |
"Reduction in the swelling of internal hemorrhoid was measured by anoscopy. Visual assessment of hemorrhoids was performed at end of treatment. Video of the procedure will be recorded for blinded central reading and assessment. Swelling was graded on a scale from 0 - None to 4 - Very Severe.~Numeric grades and their changes from baseline are summarized descriptively by visit and treatment group. Changes from baseline will be compared between the treatment groups. Mean difference between the groups and its 95% confidence interval will be displayed at Visit 4, along with the p-value from the two-sample t-test." (NCT03335774)
Timeframe: Day 15
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone Acetate Suppository, 25 mg | 2.3 |
| Placebo (Vehicle) Suppository | 2.0 |
"Patient-reported outcome (PRO) was collated and analyzed by deploying the Internal Hemorrhoid Sign and Symptom Assessment (IHSSA) questionnaire. The patients updated the questionnaire on a daily basis between visits 1-5. Responses to each item were averaged across each period.~The mean score from the Screening period was considered the baseline score.~Mean scores and their changes from baseline were summarized.~Itching was scored from on 0-4 scale (0 =No itching, 1 = A little itching, 2 =Moderate itching, 3 = A lot of itching, 4 = Worst itching that you could imagine" (NCT03335774)
Timeframe: Day 15
| Intervention | scores on a scale (Mean) |
|---|---|
| Hydrocortisone Acetate Suppository, 25 mg | 0.74 |
| Placebo (Vehicle) Suppository | 0.71 |
Number of days alive and off of the ventilator at day 28. (NCT03422159)
Timeframe: 28 Days post-randomization
| Intervention | Days (Mean) |
|---|---|
| Treatment Arm | 22 |
| Placebo Arm | 22.4 |
In-hospital mortality rate. (NCT03422159)
Timeframe: Survival until hospital discharge, up to 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 11 |
| Placebo Arm | 13 |
Defined as the day 4 post-randomization SOFA score minus the initial SOFA score. The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours SOFA score ranges from 0 (no organ dysfunction) to 24 (highest possible score / organ dysfunction). (NCT03422159)
Timeframe: 4 days post-randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm | 2.9 |
| Placebo Arm | 1.93 |
Time from admitting to discharge of hospital stay. (NCT03422159)
Timeframe: From admission to the hospital until final discharge, up to 28 days.
| Intervention | Days (Mean) |
|---|---|
| Treatment Arm | 11.5 |
| Placebo Arm | 11 |
Defined as the time from starting the active treatment/placebo to discontinuation of all pressors. (NCT03422159)
Timeframe: From start of vasopressor medication to final discontinuation of vasopressor medication, up to 7 days.
| Intervention | hours (Mean) |
|---|---|
| HAT Treatment | 27 |
| Comparator | 53 |
PCT at 96 hours minus initial PCT, divided by the initial PCT multiplied by 100. (NCT03422159)
Timeframe: 4 days post-randomization
| Intervention | Percent (Mean) |
|---|---|
| Treatment Arm | 63 |
| Placebo Arm | 58 |
ICU mortality rate (NCT03422159)
Timeframe: From admission to hospital until final discharge from the ICU, up to 28 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 6 |
| Placebo Arm | 10 |
Time from admitting to ICU to discharge. (NCT03422159)
Timeframe: From admission to the ICU until final discharge from the ICU, up to an average of 7 days.
| Intervention | days (Mean) |
|---|---|
| Treatment Arm | 4.76 |
| Placebo Arm | 4.66 |
Activities of daily living is assessed with the Katz ADL instrument. The Katz ADL has 6 items asking if participants can perform daily tasks independently. Responses are scored as 1 = yes and 0 = no. Total scores range from 0 to 6 with higher scores indicating greater independence. (NCT03509350)
Timeframe: Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Protocol | 2.8 |
| Control Protocol | 2.4 |
Executive function is assessed with the Hayling Test. The Hayling Test includes two parts of 15 items each where participants complete sentences by providing the missing word. The test is scored as the amount of time it takes, in seconds, to recite a correct response and the appropriateness of the response (in Part 2). Scaled scores range from 1 to 10 where 1 = impaired, 6 = average, and 10 = very superior. (NCT03509350)
Timeframe: Day 180
| Intervention | units on a scale (Mean) |
|---|---|
| Treatment Protocol | 4.2 |
| Control Protocol | 4.2 |
Instrumental activities of daily living is assessed with the Functional Activities Questionnaire (FAQ). The FAQ includes 10 items which are scored on a scale from 0 to 3 where 0 = normal and 3 = dependent. Total scores range from 0 to 30 and lower scores indicate that the respondent is able to perform daily activities. A score of 9 (where the person is dependent in 3 activities) is used as a cut-point indicating impairments with functioning. (NCT03509350)
Timeframe: Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Protocol | 9.5 |
| Control Protocol | 7.7 |
Quality of life is assessed with the Visual Analog Scale of the EuroQol, 5 dimension (EQ-5D) questionnaire. The EQ-5D asks about 5 dimensions of health (mobility, self-care, usual activities, pain, and depression). The questionnaire includes a visual analog scale where respondents rate their current health where 0 = worst health imaginable and 100 = best health imaginable. (NCT03509350)
Timeframe: Day 180
| Intervention | units on a scale (Mean) |
|---|---|
| Treatment Protocol | 66 |
| Control Protocol | 67 |
The Digit Span Test is used to assesses attention. In the Digit Span Test, participants are read a series of numbers and are asked to repeat them back in the same order. The Digit Span test is scored by the number of digits the participant is able to remember in each test. Higher scores indicate greater ability to pay attention and to remember sequences. The average adult can remember about 7 numbers, plus or minus two, without making an error. (NCT03509350)
Timeframe: Day 180
| Intervention | numbers recalled (Mean) |
|---|---|
| Treatment Protocol | 8.3 |
| Control Protocol | 9.5 |
Language is assessed with the Controlled Oral Word Association Test (COWAT). Participants generate words beginning with selected letters within 60 seconds. Generating a higher number of words indicates greater language skills. (NCT03509350)
Timeframe: Day 180
| Intervention | words (Mean) |
|---|---|
| Treatment Protocol | 40 |
| Control Protocol | 40 |
The number of days that participants were in the hospital is compared between study arms. (NCT03509350)
Timeframe: Day 30
| Intervention | days (Mean) |
|---|---|
| Treatment Protocol | 12.6 |
| Control Protocol | 13.5 |
The number of participants who died while in the ICU is compared between study arms. (NCT03509350)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Protocol | 52 |
| Control Protocol | 49 |
Memory is assessed with the Logical Memory subtest from the Wechsler Memory Scale III. Participants listened to two short paragraphs and were asked to recall details from each story after 30 minutes. Scores represent the number of correctly remembered details. Total scores range from 0 to 25 with higher scores reflecting better memory. (NCT03509350)
Timeframe: Day 180
| Intervention | correct story details (Mean) |
|---|---|
| Treatment Protocol | 6.9 |
| Control Protocol | 8.1 |
Reasoning is assessed with the WAIS-IV Similarities instrument. Participants were asked to explain how two words are alike. Responses are scored according to how correct they are, with a score of 0 for incorrect answers. After 3 consecutive scores of 0 the survey is stopped. Total raw scores vary depending on the number of word pairs presented. Higher scores indicate better performance. Scores will be compared between study arms. (NCT03509350)
Timeframe: Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Protocol | 7.7 |
| Control Protocol | 8.2 |
The primary outcome measure is VVFD in the first 30 days after the start of treatment. The endpoint was recorded to the nearest day. Participants who died are scored zero days, even if there was a period during which the participant was alive and free of vasopressors and mechanical ventilation. Participants who must return to ventilation and/or vasopressors had their counters reset at zero days. (NCT03509350)
Timeframe: Up to Day 30
| Intervention | days (Median) |
|---|---|
| Treatment Protocol | 25 |
| Control Protocol | 26 |
The Telephone Interview for Cognitive Status (TICS) is an 11-item instrument assessing orientation. Correct responses to the items are scored in a variety of ways, depending on how much of the response is correct. Total scores range from 0 to 41 with higher scores indicating increased cognitive orientation. (NCT03509350)
Timeframe: Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Protocol | 30.6 |
| Control Protocol | 31.2 |
Posttraumatic Stress Disorder (PTSD) is assessed with the Posttraumatic Stress Disorder - 8 instrument. The PTSD-8 includes 8 items which are answered on a 4 point scale where 01 = not at all and 3 = all of the time. Total scores range from 0 to 24 where higher scores indicate greater symptoms of PTSD. (NCT03509350)
Timeframe: Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Protocol | 5.7 |
| Control Protocol | 5.2 |
Depression is assessed with the PROMIS Depression 6 instrument. This tool includes 6 items with response options on a scale of 1 to 5. Total raw scores range from 6 to 30 with higher scores indicating greater symptoms of depression. (NCT03509350)
Timeframe: Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Protocol | 11.9 |
| Control Protocol | 11.9 |
The Telephone CAM evaluates dementia with 9-items, where additional questions are asked if symptoms are present. Rather than providing a summary score, if participants exhibit signs of a change in mental status which fluctuates and they experience inattention, along with disorganized thinking or altered level of consciousness, delirium is suggested. (NCT03509350)
Timeframe: Day 180
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Protocol | 0 |
| Control Protocol | 0 |
The Employment Questionnaire is a brief measure of the participant's employment history and ability or capacity to work. The number of participants who indicated being employed are presented here. (NCT03509350)
Timeframe: Day 180
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Protocol | 17 |
| Control Protocol | 25 |
The number of participants who did not survive until Day 30 is compared between study arms. (NCT03509350)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Protocol | 56 |
| Control Protocol | 60 |
The number of participants who did not survive until Day 180 is compared between study arms. (NCT03509350)
Timeframe: Day 180
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Protocol | 102 |
| Control Protocol | 94 |
The number of days that participants were in the ICU is compared between study arms. (NCT03509350)
Timeframe: Day 30
| Intervention | days (Mean) |
|---|---|
| Treatment Protocol | 6.7 |
| Control Protocol | 6.4 |
Median (Range) of the elimination half-life of MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level measured pre-dose, end of infusion, 4-6 hours, and 24 hours post-dose infusion on Days 1 and 5. (NCT03813147)
Timeframe: Up to 5 days
| Intervention | Hour (Median) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 4.7 |
| PK With 20 mg/m^2 | 5.5 |
Median (Range) of the area under the plasma concentration versus time curve of MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level measured pre-dose, end of infusion, 4-6 hours, and 24 hours post-dose infusion on Days 1 and 5. (NCT03813147)
Timeframe: Up to 5 days
| Intervention | hr*ng/mL (Median) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 1004.9 |
| PK With 20 mg/m^2 | 1047.4 |
Median (Range) of the maximum concentration of MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level measured pre-dose, end of infusion, 4-6 hours, and 24 hours post-dose infusion on Days 1 and 5. (NCT03813147)
Timeframe: Up to 5 days
| Intervention | ng/mL (Median) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 248.5 |
| PK With 20 mg/m^2 | 213 |
Frequency of participants with best overall response by dose level of PR or CR for MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction Per Response Evaluation Criteria for CR (M1 bone marrow (< 5% blasts) with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral blood counts (ANC > 1000/uL and platelet count > 100,000/uL), CRp (M1 bone marrow (< 5% blasts) and no evidence of circulating blasts or extramedullary disease and with recovery of ANC > 1000/uL and platelet transfusion independence), CRi (M1 bone marrow (<5% blasts) and no evidence of circulating blasts or extramedullary disease and with ANC < 1000/uL or platelet count < 100,000/uL without platelet transfusion independence), or PR (M2 marrow status (> 5% or < 25% blasts cells) and at least 50% decrease in bone marrow blast percent from baseline. (NCT03813147)
Timeframe: Up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 1 |
| PK With 20 mg/m^2 | 2 |
Frequency of patients with at least one grade 3 adverse event at least possibly attributable to MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level. (NCT03813147)
Timeframe: Up to 70 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 6 |
| PK With 20 mg/m^2 | 6 |
Frequency of patients with dose limiting toxicity in the first cycle of MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level among patients in the dose escalation cohort. (NCT03813147)
Timeframe: Up to 35 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 1 |
| PK With 20 mg/m^2 | 2 |
Median (Range) of the total plasma clearance of MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level measured pre-dose, end of infusion, 4-6 hours, and 24 hours post-dose infusion on Days 1 and 5. (NCT03813147)
Timeframe: Up to 5 days
| Intervention | L/h/m^2 (Median) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 20.1 |
| PK With 20 mg/m^2 | 19.2 |
Median (Range) of the maximum time to concentration of MLN4924 (pevonedistat) added to the 3-drug backbone of azacitidine (aza), fludarabine, and cytarabine re-induction for pediatric patients with recurrent/refractory AML and MDS by dose level measured pre-dose, end of infusion, 4-6 hours, and 24 hours post-dose infusion on Days 1 and 5. (NCT03813147)
Timeframe: Up to 5 days
| Intervention | Hour (Median) |
|---|---|
| Stratum 1 With 20 mg/m^2 | 1.2 |
| PK With 20 mg/m^2 | 1.1 |
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4. | 2.13 | 1 | 0 | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule |
| 9-xylosyladenine 9-xylosyladenine: RN given refers to cpd with unspecified isomeric designation; structure in first source | 2.13 | 1 | 0 | purine nucleoside | |
| coumarin 2H-chromen-2-one: coumarin derivative | 2.13 | 1 | 0 | coumarins | fluorescent dye; human metabolite; plant metabolite |
| salicylic acid Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL). | 2.13 | 1 | 0 | monohydroxybenzoic acid | algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite |
| malic acid malic acid : A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.. 2-hydroxydicarboxylic acid : Any dicarboxylic acid carrying a hydroxy group on the carbon atom at position alpha to the carboxy group. | 2.13 | 1 | 0 | 2-hydroxydicarboxylic acid; C4-dicarboxylic acid | food acidity regulator; fundamental metabolite |
| phosphonoacetic acid Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group. | 2.13 | 1 | 0 | monocarboxylic acid; phosphonic acids | antiviral agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor |
| histamine [no description available] | 2.13 | 1 | 0 | aralkylamino compound; imidazoles | human metabolite; mouse metabolite; neurotransmitter |
| naringenin [no description available] | 2.13 | 1 | 0 | 4'-hydroxyflavanones; trihydroxyflavanone | |
| niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. | 2.13 | 1 | 0 | pyridine alkaloid; pyridinecarboxamide; vitamin B3 | anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor |
| niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. | 2.13 | 1 | 0 | pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3 | antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent |
| pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis. | 2.13 | 1 | 0 | monocarboxylic acid amide; N-acylammonia; pyrazines | antitubercular agent; prodrug |
| pyrazinoic acid pyrazinoic acid: active metabolite of pyrazinamide; structure. pyrazine-2-carboxylic acid : The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide. | 2.13 | 1 | 0 | pyrazinecarboxylic acid | antitubercular agent; drug metabolite |
| 1,10-phenanthroline 1,10-phenanthroline: RN given refers to parent cpd; inhibits Zn-dependent metalloproteinases | 2.13 | 1 | 0 | phenanthroline | EC 2.7.1.1 (hexokinase) inhibitor; EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor |
| 1,3-dipropyl-8-cyclopentylxanthine DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group. | 2.13 | 1 | 0 | oxopurine | adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
| 2,2'-dipyridyl 2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'. | 2.13 | 1 | 0 | bipyridine | chelator; ferroptosis inhibitor |
| ro 5-4864 4'-chlorodiazepam: selectively binds peripheral benzodiazepine receptor | 2.13 | 1 | 0 | ||
| 4-aminopyridine [no description available] | 2.13 | 1 | 0 | aminopyridine; aromatic amine | avicide; orphan drug; potassium channel blocker |
| phenytoin [no description available] | 2.13 | 1 | 0 | imidazolidine-2,4-dione | anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent |
| 5,8,11,14-eicosatetraynoic acid 5,8,11,14-Eicosatetraynoic Acid: A 20-carbon unsaturated fatty acid containing 4 alkyne bonds. It inhibits the enzymatic conversion of arachidonic acid to prostaglandins E(2) and F(2a). | 2.13 | 1 | 0 | long-chain fatty acid | |
| 5-fluoroindole-2-carboxylic acid 5-fluoroindole-2-carboxylic acid: N-methyl-D-aspartate receptor antagonist | 2.13 | 1 | 0 | indolyl carboxylic acid | |
| etofylline etofylline: etophyllin appeared once in PubMed: Wien Med Wochenschr. 1986 May 15;136(9):213-8 as a combination drug with theophylline (spelt without e, theophllin) | 2.13 | 1 | 0 | oxopurine | |
| 7-nitroindazole 7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure | 2.13 | 1 | 0 | ||
| aa 861 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone: structure given in first source. docebenone : A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group. | 2.13 | 1 | 0 | 1,4-benzoquinones; acetylenic compound; primary alcohol | EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor |
| acetarsol [no description available] | 2.13 | 1 | 0 | acetamides; anilide | |
| acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | 2.13 | 1 | 0 | monocarboxylic acid amide; sulfonamide; thiadiazoles | anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor |
| altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine. | 2.13 | 1 | 0 | triamino-1,3,5-triazine | |
| theophylline [no description available] | 2.13 | 1 | 0 | dimethylxanthine | adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent |
| amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position. | 2.13 | 1 | 0 | dibenzooxazepine | adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor |
| aniracetam [no description available] | 2.13 | 1 | 0 | N-acylpyrrolidine; pyrrolidin-2-ones | |
| anisindione anisindione: structure. anisindione : A cyclic beta-diketone consisting of indane-1,3-dione having a 4-methoxyphenyl substituent at the 4-position. | 2.13 | 1 | 0 | aromatic ketone; beta-diketone | anticoagulant; vitamin K antagonist |
| astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. | 2.13 | 1 | 0 | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
| atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent. | 2.13 | 1 | 0 | ethanolamines; monocarboxylic acid amide; propanolamine | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic |
| azelaic acid nonanedioic acid : An alpha,omega-dicarboxylic acid that is heptane substituted at positions 1 and 7 by carboxy groups. | 2.13 | 1 | 0 | alpha,omega-dicarboxylic acid; dicarboxylic fatty acid | antibacterial agent; antineoplastic agent; dermatologic drug; plant metabolite |
| bay-k-8644 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.. Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644. methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6. | 2.13 | 1 | 0 | (trifluoromethyl)benzenes; C-nitro compound; dihydropyridine; methyl ester | |
| bendroflumethiazide Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group. | 2.13 | 1 | 0 | benzothiadiazine; sulfonamide | antihypertensive agent; diuretic |
| benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication. | 2.13 | 1 | 0 | 1-benzofurans; aromatic ketone | uricosuric drug |
| benzothiazide benzothiazide: structure. benzthiazide : 7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema. | 2.13 | 1 | 0 | benzothiadiazine; sulfonamide | antihypertensive agent; diuretic |
| bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1. | 2.13 | 1 | 0 | biphenyls; imidazoles | |
| bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871) | 2.13 | 1 | 0 | diarylmethane | |
| brimonidine [no description available] | 2.13 | 1 | 0 | imidazoles; quinoxaline derivative; secondary amine | adrenergic agonist; alpha-adrenergic agonist; antihypertensive agent |
| bufexamac Bufexamac: A benzeneacetamide with anti-inflammatory, analgesic, and antipyretic action. It is administered topically, orally, or rectally.. bufexamac : A hydroxamic acid derived from phenylacetamide in which the benzene moiety is substituted at C-4 by a butoxy group. It has anti-inflammatory, analgesic, and antipyretic properties. | 2.13 | 1 | 0 | aromatic ether; hydroxamic acid | antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| bumetanide [no description available] | 2.13 | 1 | 0 | amino acid; benzoic acids; sulfonamide | diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor |
| butacaine butacaine: was MH 1965-92; BUTAPROBENZ & BUTOCAIN were see BUTACAINE 1978-92; use 4-AMINOBENZOIC ACID to search BUTACAINE 1966-92 | 2.13 | 1 | 0 | benzoate ester | |
| butamben butamben: structure. butamben : An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for relief of pain and itching associated with some anorectal disorders. | 2.13 | 1 | 0 | amino acid ester; benzoate ester; primary amino compound; substituted aniline | local anaesthetic |
| carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. | 2.13 | 1 | 0 | dibenzoazepine; ureas | analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic |
| carisoprodol Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. | 2.13 | 1 | 0 | carbamate ester | muscle relaxant |
| chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. | 2.13 | 1 | 0 | aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent |
| chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification. | 2.13 | 1 | 0 | monochlorobenzenes; N-sulfonylurea | hypoglycemic agent; insulin secretagogue |
| chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. | 2.13 | 1 | 0 | isoindoles; monochlorobenzenes; sulfonamide | |
| chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm. | 2.13 | 1 | 0 | 1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound | muscle relaxant; sedative |
| cilostazol [no description available] | 2.13 | 1 | 0 | lactam; tetrazoles | anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent |
| cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach. | 2.13 | 1 | 0 | aliphatic sulfide; guanidines; imidazoles; nitrile | adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor |
| cinoxacin Cinoxacin: Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.. cinoxacin : A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections. | 2.13 | 1 | 0 | cinnolines; oxacycle; oxo carboxylic acid | antibacterial drug; antiinfective agent |
| 4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide [no description available] | 2.13 | 1 | 0 | sulfonamide | |
| dapsone [no description available] | 2.13 | 1 | 0 | substituted aniline; sulfone | anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug |
| deferiprone Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. | 2.13 | 1 | 0 | 4-pyridones | iron chelator; protective agent |
| diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. | 2.13 | 1 | 0 | benzothiadiazine; organochlorine compound; sulfone | antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent |
| dibucaine Dibucaine: A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006). cinchocaine : A monocarboxylic acid amide that is the 2-(diethylamino)ethyl amide of 2-butoxyquinoline-4-carboxylic acid. One of the most potent and toxic of the long-acting local anesthetics, its parenteral use was restricted to spinal anesthesia. It is now generally only used (usually as the hydrochloride) in creams and ointments and in suppositories for temporary relief of pain and itching associated with skin and anorectal conditions. | 2.13 | 1 | 0 | aromatic ether; monocarboxylic acid amide; tertiary amino compound | topical anaesthetic |
| dichlorophen Dichlorophen: Nontoxic laxative vermicide effective for taenia infestation. It tends to produce colic and nausea. It is also used as a veterinary fungicide, anthelmintic, and antiprotozoan. (From Merck, 11th ed.) | 2.13 | 1 | 0 | bridged diphenyl fungicide; diarylmethane | |
| diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. | 2.13 | 1 | 0 | monohydroxybenzoic acid; organofluorine compound | non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. | 2.13 | 1 | 0 | piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol | adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent |
| disulfiram [no description available] | 2.13 | 1 | 0 | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor |
| domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations. | 2.13 | 1 | 0 | benzimidazoles; heteroarylpiperidine | antiemetic; dopaminergic antagonist |
| droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. | 2.13 | 1 | 0 | aromatic ketone; benzimidazoles; organofluorine compound | anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic |
| dipropizine [no description available] | 2.13 | 1 | 0 | piperazines | |
| dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs. | 2.13 | 1 | 0 | oxopurine; propane-1,2-diols | bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent |
| ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase. | 2.13 | 1 | 0 | benzoselenazole | anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger |
| ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11. | 2.13 | 1 | 0 | indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene | antineoplastic agent; plant metabolite |
| epirizole Epirizole: 4-Methoxy-2-(5-methoxy-3-methylpyrazol-1-yl)-6-methylpyrimidine. A pyrimidinyl pyrazole with antipyretic, analgesic, and anti-inflammatory activity. | 2.13 | 1 | 0 | aromatic ether | |
| ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor. | 2.13 | 1 | 0 | aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic |
| myambutol [no description available] | 2.13 | 1 | 0 | amino alcohol | |
| ethoxzolamide Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic. | 2.13 | 1 | 0 | aromatic ether; benzothiazoles; sulfonamide | antiglaucoma drug; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor |
| etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. | 2.13 | 1 | 0 | monocarboxylic acid; organic heterotricyclic compound | antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy. | 2.13 | 1 | 0 | carbamate ester | anticonvulsant; neuroprotective agent |
| 4-biphenylylacetic acid biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis. | 2.13 | 1 | 0 | biphenyls; monocarboxylic acid | non-steroidal anti-inflammatory drug |
| felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris. | 2.13 | 1 | 0 | dichlorobenzene; dihydropyridine; ethyl ester; methyl ester | anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent |
| fenbufen fenbufen: structure; RN given refers to parent cpd | 2.13 | 1 | 0 | 4-oxo monocarboxylic acid; biphenyls | non-steroidal anti-inflammatory drug |
| fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE | 2.13 | 1 | 0 | aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes | antilipemic drug; environmental contaminant; geroprotector; xenobiotic |
| flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. | 2.13 | 1 | 0 | aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone | prodrug |
| flufenamic acid Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16). flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders. | 2.13 | 1 | 0 | aromatic amino acid; organofluorine compound | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose. | 2.13 | 1 | 0 | ethyl ester; imidazobenzodiazepine; organofluorine compound | antidote to benzodiazepine poisoning; GABA antagonist |
| flumequine flumequine: structure. flumequine : A racemate comprising equimolar amounts of R- and S-flumequine. A broad-spectrum antibiotic, formerly used in veterinary medicine for stock breeding and treatment of aquacultures.. 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid : A member of the class of pyridoquinolines that is 1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline carrying additional carboxy, methyl and fluoro substituents at positions 2, 5 and 9 respectively. | 2.13 | 1 | 0 | 3-oxo monocarboxylic acid; organofluorine compound; pyridoquinoline; quinolone antibiotic | |
| fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth. | 2.13 | 1 | 0 | nucleobase analogue; organofluorine compound | antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic |
| flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. | 2.13 | 1 | 0 | fluorobiphenyl; monocarboxylic acid | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| gemfibrozil [no description available] | 2.13 | 1 | 0 | aromatic ether | antilipemic drug |
| glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus. | 2.13 | 1 | 0 | aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue |
| glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. | 2.13 | 1 | 0 | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
| fluorometholone [no description available] | 2.13 | 1 | 0 | ||
| 1-(5-isoquinolinesulfonyl)-2-methylpiperazine 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group. | 2.13 | 1 | 0 | isoquinolines; N-sulfonylpiperazine | EC 2.7.11.13 (protein kinase C) inhibitor |
| haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. | 2.13 | 1 | 0 | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
| harmaline Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond. | 2.13 | 1 | 0 | harmala alkaloid | oneirogen |
| hexachlorophene Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union. | 2.13 | 1 | 0 | bridged diphenyl fungicide; polyphenol; trichlorobenzene | acaricide; antibacterial agent; antifungal agrochemical; antiseptic drug |
| hexamethylene bisacetamide N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208 | 2.13 | 1 | 0 | acetamides | |
| hycanthone Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel. | 2.13 | 1 | 0 | thioxanthenes | mutagen; schistosomicide drug |
| hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure. | 2.13 | 1 | 0 | benzothiadiazine; organochlorine compound; sulfonamide | antihypertensive agent; diuretic; environmental contaminant; xenobiotic |
| hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide. | 2.13 | 1 | 0 | benzothiadiazine; thiazide | antihypertensive agent; diuretic |
| ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine | 2.13 | 1 | 0 | monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic |
| lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline. | 2.13 | 1 | 0 | benzenes; monocarboxylic acid amide; tertiary amino compound | anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic |
| amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. | 2.13 | 1 | 0 | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
| indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine. | 2.13 | 1 | 0 | indoles; organochlorine compound; sulfonamide | antihypertensive agent; diuretic |
| indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. | 2.13 | 1 | 0 | aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole | analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic |
| indoprofen Indoprofen: A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21). indoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein. | 2.13 | 1 | 0 | gamma-lactam; isoindoles; monocarboxylic acid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| ipriflavone ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. | 2.13 | 1 | 0 | aromatic ether; isoflavones | bone density conservation agent |
| isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC). | 2.13 | 1 | 0 | carbohydrazide | antitubercular agent; drug allergen |
| itraconazole [no description available] | 2.13 | 1 | 0 | piperazines | |
| ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. | 2.13 | 1 | 0 | benzophenones; oxo monocarboxylic acid | antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic |
| khellin Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator. | 2.13 | 1 | 0 | furanochromone; organic heterotricyclic compound; oxacycle | anti-asthmatic agent; bronchodilator agent; cardiovascular drug; vasodilator agent |
| lamotrigine [no description available] | 2.13 | 1 | 0 | 1,2,4-triazines; dichlorobenzene; primary arylamine | anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic |
| lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers. | 2.13 | 1 | 0 | benzimidazoles; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor |
| leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. | 2.13 | 1 | 0 | (trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide | antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor |
| loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders. | 2.13 | 1 | 0 | benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide | anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist |
| ly 171883 LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity. | 2.13 | 1 | 0 | acetophenones; aromatic ether; phenols; tetrazoles | anti-asthmatic drug; leukotriene antagonist |
| edaravone [no description available] | 2.13 | 1 | 0 | pyrazolone | antioxidant; radical scavenger |
| mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR. | 1.95 | 1 | 0 | nitrogen mustard; organochlorine compound | alkylating agent |
| meclofenamate sodium anhydrous [no description available] | 2.13 | 1 | 0 | organic sodium salt | |
| mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. | 2.13 | 1 | 0 | aminobenzoic acid; secondary amino compound | analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic |
| vitamin k 3 Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo. | 2.13 | 1 | 0 | 1,4-naphthoquinones; vitamin K | angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical |
| methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | 2.13 | 1 | 0 | sulfonamide; thiadiazoles | |
| methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester. | 2.13 | 1 | 0 | aromatic ether; carbamate ester; secondary alcohol | |
| metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. | 2.13 | 1 | 0 | C-nitro compound; imidazoles; primary alcohol | antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic |
| minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6. | 2.13 | 1 | 0 | dialkylarylamine; tertiary amino compound | |
| moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression. | 2.13 | 1 | 0 | benzamides; monochlorobenzenes; morpholines | antidepressant; environmental contaminant; xenobiotic |
| acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine. | 2.13 | 1 | 0 | acetamides; benzamides | anti-arrhythmia drug |
| nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs. | 2.13 | 1 | 0 | methoxynaphthalene; methyl ketone | cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug |
| nalidixic acid [no description available] | 2.13 | 1 | 0 | 1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic | antibacterial drug; antimicrobial agent; DNA synthesis inhibitor |
| nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. | 2.13 | 1 | 0 | cyclopropanes; dipyridodiazepine | antiviral drug; HIV-1 reverse transcriptase inhibitor |
| nialamide Nialamide: An MAO inhibitor that is used as an antidepressive agent. | 2.13 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | 2.13 | 1 | 0 | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
| niflumic acid Niflumic Acid: An analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. | 2.13 | 1 | 0 | aromatic carboxylic acid; pyridines | |
| nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups. | 2.13 | 1 | 0 | aromatic ether; C-nitro compound; sulfonamide | cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
| nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm. | 2.13 | 1 | 0 | 2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester | antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent |
| nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension. | 2.13 | 1 | 0 | C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester | antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent |
| norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase. | 2.13 | 1 | 0 | fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone | antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic |
| cm 7116 norflutoprazepam: structure | 2.13 | 1 | 0 | benzodiazepine | |
| ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | 2.13 | 1 | 0 | 3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline | |
| omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5. | 2.13 | 1 | 0 | aromatic ether; benzimidazoles; pyridines; sulfoxide | |
| aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4. | 2.13 | 1 | 0 | aminobenzoic acid; phenols | antitubercular agent |
| pentoxifylline [no description available] | 2.13 | 1 | 0 | oxopurine | |
| perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10. | 2.13 | 1 | 0 | N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines | antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug |
| phenindione Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234) | 2.13 | 1 | 0 | aromatic ketone; beta-diketone | anticoagulant |
| phenolphthalein Phenolphthalein: An acid-base indicator which is colorless in acid solution, but turns pink to red as the solution becomes alkaline. It is used medicinally as a cathartic. | 2.13 | 1 | 0 | phenols | |
| 4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation. | 2.13 | 1 | 0 | monocarboxylic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug |
| phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position. | 2.13 | 1 | 0 | pyrazolidines | antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug |
| pinacidil Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed) | 2.13 | 1 | 0 | pyridines | |
| pipemidic acid Pipemidic Acid: Antimicrobial against Gram negative and some Gram positive bacteria. It is protein bound and concentrated in bile and urine and used for gastrointestinal, biliary, and urinary infections.. pipemidic acid : A pyridopyrimidine that is 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid substituted at position 2 by a piperazin-1-yl group and at position 8 by an ethyl group. A synthetic broad-spectrum antibacterial, it is used for treatment of gastrointestinal, biliary, and urinary infections. | 2.13 | 1 | 0 | amino acid; monocarboxylic acid; N-arylpiperazine; pyridopyrimidine; quinolone antibiotic | antibacterial drug; DNA synthesis inhibitor |
| piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent. | 2.13 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| pirenperone [no description available] | 2.13 | 1 | 0 | aromatic ketone | |
| praziquantel azinox: Russian drug | 2.13 | 1 | 0 | isoquinolines | |
| primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures. | 2.13 | 1 | 0 | pyrimidone | anticonvulsant; environmental contaminant; xenobiotic |
| probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups. | 2.13 | 1 | 0 | benzoic acids; sulfonamide | uricosuric drug |
| probucol Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood. | 2.13 | 1 | 0 | dithioketal; polyphenol | anti-inflammatory drug; anticholesteremic drug; antilipemic drug; antioxidant; cardiovascular drug |
| prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position. | 2.13 | 1 | 0 | N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines | alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic |
| proxyphylline [no description available] | 2.13 | 1 | 0 | oxopurine | |
| pyrimethamine Maloprim: contains above 2 cpds | 2.13 | 1 | 0 | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
| pf 5901 alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist | 2.13 | 1 | 0 | quinolines | |
| riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS. | 2.13 | 1 | 0 | benzothiazoles | |
| ritanserin Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action. | 2.13 | 1 | 0 | organofluorine compound; piperidines; thiazolopyrimidine | antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist |
| rolipram [no description available] | 2.13 | 1 | 0 | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
| ronidazole Ronidazole: Antiprotozoal and antimicrobial agent used mainly in veterinary practice.. ronidazole : A carbamate ester that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by methyl and (carbamoyloxy)methyl groups, respectively. An antiprotozoal agent, it is used in veterinary medicine for the treatment of histomoniasis and swine dysentery. | 2.13 | 1 | 0 | C-nitro compound; carbamate ester; imidazoles | antiparasitic agent; antiprotozoal drug |
| salicylamide salamide: a major impurity of hydrochlorothiazide; structure in first source | 2.13 | 1 | 0 | phenols; salicylamides | antirheumatic drug; non-narcotic analgesic |
| spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively. | 2.13 | 1 | 0 | aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound | alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist |
| aldactazide [no description available] | 2.13 | 1 | 0 | steroid lactone | |
| streptonigrin [no description available] | 2.13 | 1 | 0 | pyridines; quinolone | antimicrobial agent; antineoplastic agent |
| sulfabenzamide sulfabenzamide : A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation. | 2.13 | 1 | 0 | benzenes; sulfonamide antibiotic; sulfonamide | antibacterial drug; antimicrobial drug |
| sulfacetamide Sulfacetamide: An anti-bacterial agent that is used topically to treat skin infections and orally for urinary tract infections.. sulfacetamide : A sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen. | 2.13 | 1 | 0 | N-sulfonylcarboxamide; substituted aniline | antibacterial drug; antiinfective agent; antimicrobial agent; EC 2.5.1.15 (dihydropteroate synthase) inhibitor |
| sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. | 2.13 | 1 | 0 | aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide | antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic |
| sulfamerazine [no description available] | 2.13 | 1 | 0 | pyrimidines; sulfonamide antibiotic; sulfonamide | antiinfective agent; drug allergen |
| sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position. | 2.13 | 1 | 0 | pyrimidines; sulfonamide antibiotic; sulfonamide | antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic |
| sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2. | 2.13 | 1 | 0 | sulfonamide antibiotic; sulfonamide; thiadiazoles | antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor |
| sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position. | 2.13 | 1 | 0 | isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide | antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic |
| sulfamethoxypyridazine Sulfamethoxypyridazine: A sulfanilamide antibacterial agent.. sulfamethoxypyridazine : A sulfonamide consisting of pyridazine having a methoxy substituent at the 6-position and a 4-aminobenzenesulfonamido group at the 3-position. | 2.13 | 1 | 0 | pyridazines; sulfonamide antibiotic; sulfonamide | antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor |
| tegafur [no description available] | 2.13 | 1 | 0 | organohalogen compound; pyrimidines | |
| terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia | 2.13 | 1 | 0 | furans; piperazines; primary amino compound; quinazolines | alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent |
| terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. | 2.13 | 1 | 0 | diarylmethane | |
| thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate | 2.13 | 1 | 0 | 1,3-thiazoles; benzimidazole fungicide; benzimidazoles | antifungal agrochemical; antinematodal drug |
| tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. | 2.13 | 1 | 0 | imidazoles | antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug |
| tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus. | 2.13 | 1 | 0 | N-sulfonylurea | hypoglycemic agent; potassium channel blocker |
| tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position. | 2.13 | 1 | 0 | N-sulfonylurea | human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker |
| tolnaftate [no description available] | 2.13 | 1 | 0 | monothiocarbamic ester | antifungal drug |
| trapidil Trapidil: A coronary vasodilator agent. | 2.13 | 1 | 0 | triazolopyrimidines | |
| trichlormethiazide Trichlormethiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830). trichlormethiazide : A benzothiadiazine, hydrogenated at positions 2, 3 and 4 and substituted with an aminosulfonyl group at C-7, a chloro substituent at C-6 and a dichloromethyl group at C-3 and with S-1 as an S,S-dioxide. A sulfonamide antibiotic, it is used as a diuretic to treat oedema (including that associated with heart failure) and hypertension. | 2.13 | 1 | 0 | benzothiadiazine; sulfonamide antibiotic | antihypertensive agent; diuretic |
| trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge. | 2.13 | 1 | 0 | aminopyrimidine; methoxybenzenes | antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic |
| tyramine [no description available] | 2.13 | 1 | 0 | monoamine molecular messenger; primary amino compound; tyramines | EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter |
| vesamicol vesamicol: RN given refers to parent cpd; structure | 2.13 | 1 | 0 | piperidines | |
| xylazine Xylazine: An adrenergic alpha-2 agonist used as a sedative, analgesic and centrally acting muscle relaxant in VETERINARY MEDICINE.. xylazine : A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties. | 2.13 | 1 | 0 | 1,3-thiazine; methylbenzene; secondary amino compound | alpha-adrenergic agonist; analgesic; emetic; muscle relaxant; sedative |
| zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position. | 2.13 | 1 | 0 | monochloropyridine; pyrrolopyrazine | central nervous system depressant; sedative |
| hydrocortisone acetate hydrocortisone acetate: RN given refers to cpd without isomeric designation | 2.13 | 1 | 0 | cortisol ester; tertiary alpha-hydroxy ketone | |
| oxyphenonium bromide [no description available] | 2.13 | 1 | 0 | ||
| corticosterone [no description available] | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite |
| phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension. | 2.13 | 1 | 0 | imidazoles; phenols; substituted aniline; tertiary amino compound | alpha-adrenergic antagonist; vasodilator agent |
| floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | 2.13 | 1 | 0 | nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent |
| neostigmine methylsulfate [no description available] | 2.13 | 1 | 0 | arylammonium sulfate salt | EC 3.1.1.8 (cholinesterase) inhibitor |
| prednisolone acetate prednisolone acetate: RN given refers to cpd with locant for acetate group in position 21 & (11 beta)-isomer | 2.13 | 1 | 0 | corticosteroid hormone | |
| trichlorfon Trichlorfon: An organochlorophosphate cholinesterase inhibitor that is used as an insecticide for the control of flies and roaches. It is also used in anthelmintic compositions for animals. (From Merck, 11th ed). trichlorfon : A phosphonic ester that is dimethyl phosphonate in which the hydrogen atom attched to the phosphorous is substituted by a 2,2,2-trichloro-1-hydroxyethyl group. | 2.13 | 1 | 0 | organic phosphonate; organochlorine compound; phosphonic ester | agrochemical; anthelminthic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; insecticide |
| estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens. | 2.13 | 1 | 0 | 17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols | antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite |
| androsterone [no description available] | 2.13 | 1 | 0 | 17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid | androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone |
| promazine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | |
| azauridine Azauridine: A triazine nucleoside used as an antineoplastic antimetabolite. It interferes with pyrimidine biosynthesis thereby preventing formation of cellular nucleic acids. As the triacetate, it is also effective as an antipsoriatic. | 2.13 | 1 | 0 | N-glycosyl-1,2,4-triazine | antimetabolite; antineoplastic agent; drug metabolite |
| pilocarpine hydrochloride pilocarpine hydrochloride : The hydrochloride salt of (+)-pilocarpine, a medication used to treat increased pressure inside the eye and dry mouth. | 2.13 | 1 | 0 | hydrochloride | |
| dimethylphenylpiperazinium iodide Dimethylphenylpiperazinium Iodide: A selective nicotinic cholinergic agonist used as a research tool. DMPP activates nicotinic receptors in autonomic ganglia but has little effect at the neuromuscular junction. | 2.13 | 1 | 0 | N-arylpiperazine; organic iodide salt; piperazinium salt; quaternary ammonium salt | nicotinic acetylcholine receptor agonist |
| desoxycorticosterone acetate Desoxycorticosterone Acetate: The 21-acetate derivative of desoxycorticosterone. | 2.13 | 1 | 0 | corticosteroid hormone | |
| benzyltrimethylammonium chloride [no description available] | 2.13 | 1 | 0 | ||
| ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration. | 2.13 | 1 | 0 | 17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound | xenoestrogen |
| promethazine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; geroprotector; H1-receptor antagonist; local anaesthetic; sedative |
| uridine [no description available] | 2.13 | 1 | 0 | uridines | drug metabolite; fundamental metabolite; human metabolite |
| tolazoline hydrochloride [no description available] | 2.13 | 1 | 0 | benzenes | |
| acetylcholine chloride acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug. | 2.13 | 1 | 0 | quaternary ammonium salt | |
| methoxamine hydrochloride [no description available] | 2.13 | 1 | 0 | dimethoxybenzene | |
| papaverine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| bretylium tosylate Bretylium Tosylate: An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.. bretylium tosylate : The tosylate salt of bretylium. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. | 2.13 | 1 | 0 | organosulfonate salt; quaternary ammonium salt | adrenergic antagonist; anti-arrhythmia drug; antihypertensive agent |
| methacholine chloride Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116) | 2.13 | 1 | 0 | quaternary ammonium salt | |
| androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads. | 2.13 | 1 | 0 | 17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid | androgen; Daphnia magna metabolite; human metabolite; mouse metabolite |
| desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE | 2.13 | 1 | 0 | 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite |
| fluocinolone acetonide Fluocinolone Acetonide: A glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluocinolone acetonide : A fluorinated steroid that is flunisolide in which the hydrogen at position 9 is replaced by fluorine. A corticosteroid with glucocorticoid activity, it is used (both as the anhydrous form and as the dihydrate) in creams, gels and ointments for the treatment of various skin disorders. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; glucocorticoid; organic heteropentacyclic compound; primary alpha-hydroxy ketone | anti-inflammatory drug; antipruritic drug |
| norethynodrel Norethynodrel: A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL. | 2.13 | 1 | 0 | oxo steroid | |
| 17-alpha-hydroxyprogesterone 17alpha-hydroxyprogesterone : A 17alpha-hydroxy steroid that is the 17alpha-hydroxy derivative of progesterone. | 2.13 | 1 | 0 | 17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone | human metabolite; metabolite; mouse metabolite; progestin |
| chlorpromazine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride; phenothiazines | anticoronaviral agent; phenothiazine antipsychotic drug |
| ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group. | 2.13 | 1 | 0 | beta-lactam antibiotic; penicillin allergen; penicillin | antibacterial drug |
| cytarabine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. | 2.13 | 1 | 0 | nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor |
| 4-hydroxypropiophenone [no description available] | 2.13 | 1 | 0 | acetophenones | |
| medroxyprogesterone acetate [no description available] | 2.13 | 1 | 0 | 20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester | adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive |
| isopropamide iodide isopropamide iodide: was heading 1965-94; use AMMONIUM COMPOUNDS to search ISOPROPAMIDE IODIDE 1966-94 | 2.13 | 1 | 0 | diarylmethane | |
| mestranol [no description available] | 2.13 | 1 | 0 | 17beta-hydroxy steroid; aromatic ether; terminal acetylenic compound | prodrug; xenoestrogen |
| lidocaine hydrochloride lidocaine hydrochloride : The anhydrous form of the hydrochloride salt of lidocaine. | 2.13 | 1 | 0 | hydrochloride | anti-arrhythmia drug; local anaesthetic |
| triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections. | 2.39 | 2 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone | anti-allergic agent; anti-inflammatory drug |
| dehydrocholic acid Dehydrocholic Acid: A semisynthetic bile acid made from cholic acid. It is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid.. 3,7,12-trioxo-5beta-cholanic acid : An oxo-5beta-cholanic acid in which three oxo substituents are located at positions 3, 7 and 12 on the cholanic acid skeleton. | 2.13 | 1 | 0 | 12-oxo steroid; 3-oxo-5beta-steroid; 7-oxo steroid; oxo-5beta-cholanic acid | gastrointestinal drug |
| methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone. | 2.13 | 1 | 0 | 6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic |
| 9,10-phenanthrenequinone 9,10-phenanthrenequinone: structure | 2.13 | 1 | 0 | phenanthrenes | |
| phenothiazine 10H-phenothiazine : The 10H-tautomer of phenothiazine. | 2.13 | 1 | 0 | phenothiazine | ferroptosis inhibitor; plant metabolite; radical scavenger |
| mecoprop mecoprop: RN given refers to cpd without isomeric designation; structure. 2-(4-chloro-2-methylphenoxy)propanoic acid : A monocarboxylic acid that is lactic acid in which the hydroxyl hydrogen is replaced by a 4-chloro-2-methylphenyl group.. mecoprop : A racemate comprising equimolar amounts of (R)- and (S)-mecoprop. | 2.13 | 1 | 0 | aromatic ether; monocarboxylic acid; monochlorobenzenes | |
| 2-methyl-4-chlorophenoxyacetic acid 2-Methyl-4-chlorophenoxyacetic Acid: A powerful herbicide used as a selective weed killer.. (4-chloro-2-methylphenoxy)acetic acid : A chlorophenoxyacetic acid that is (4-chlorophenoxy)acetic acid substituted by a methyl group at position 2. | 2.13 | 1 | 0 | chlorophenoxyacetic acid; monochlorobenzenes | environmental contaminant; phenoxy herbicide; synthetic auxin |
| arsanilic acid Arsanilic Acid: An arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. | 2.13 | 1 | 0 | organoarsonic acid | |
| 3-aminobenzoic acid 3-aminobenzoic acid: RN given refers to parent cpd. 3-aminobenzoic acid : An aminobenzoic acid carrying an amino group at position 3. | 2.13 | 1 | 0 | aminobenzoic acid | |
| pyridostigmine bromide Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. | 2.13 | 1 | 0 | pyridinium salt | |
| thiodipropionic acid thiodipropionic acid: structure | 2.13 | 1 | 0 | dicarboxylic acid | |
| imipramine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | antidepressant |
| flavaspidic acid flavaspidic acid: isolated from rhizomes of male fern; structure | 1.99 | 1 | 0 | ||
| neostigmine bromide neostigmine bromide : The bromide salt of neostigmine. | 2.13 | 1 | 0 | bromide salt | |
| edrophonium chloride edrophonium chloride : The chloride salt of edrophonium. A reversible inhibitor of cholinesterase with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes), it is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals. | 2.13 | 1 | 0 | chloride salt; quaternary ammonium salt | antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor |
| maltol maltol: found in bark of young larch trees; isolated from Passiflora incarnata; possesses depressant properties in mice; potentiates hexobarbital-induced narcosis & inhibits spontaneous motor activity; structure | 2.13 | 1 | 0 | 4-pyranones | metabolite |
| cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94 | 2.13 | 1 | 0 | quinolines | |
| methapyrilene hydrochloride methapyrilene hydrochloride : A hydrochloride that is the monohydrochloride salt of methapyrilene. | 2.13 | 1 | 0 | hydrochloride | anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative |
| phenazopyridine hydrochloride phenazopyridine hydrochloride : A hydrochloride obtained by combining phenazopyridine with one equivalent of hydrochloric acid. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. | 2.13 | 1 | 0 | hydrochloride | carcinogenic agent; local anaesthetic; non-narcotic analgesic |
| tetrracaine hydrochloride leocaine: a crystal beta-modification of the beta-dimethylaminoethyl ether of n-butylaminobenzoic acid hydrochloride | 2.13 | 1 | 0 | benzoate ester | |
| protocatechualdehyde protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure | 2.13 | 1 | 0 | dihydroxybenzaldehyde | |
| 20-alpha-dihydroprogesterone 20-alpha-Dihydroprogesterone: A biologically active 20-alpha-reduced metabolite of PROGESTERONE. It is converted from progesterone to 20-alpha-hydroxypregn-4-en-3-one by the 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE in the CORPUS LUTEUM and the PLACENTA. | 2.13 | 1 | 0 | 20-hydroxypregn-4-en-3-one | human metabolite; mouse metabolite |
| 2-chloroadenosine 5-chloroformycin A: structure given in first source | 2.13 | 1 | 0 | purine nucleoside | |
| diphenhydramine hydrochloride Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine. | 2.13 | 1 | 0 | hydrochloride; organoammonium salt | anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative |
| quinestrol Quinestrol: The 3-cyclopentyl ether of ETHINYL ESTRADIOL. After gastrointestinal absorption, it is stored in ADIPOSE TISSUE, slowly released, and metabolized principally to the parent compound. It has been used in ESTROGEN REPLACEMENT THERAPY. (From AMA Drug Evaluations Annual, 1992, p1011) | 2.13 | 1 | 0 | 17-hydroxy steroid; terminal acetylenic compound | xenoestrogen |
| tripelennamine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| propantheline bromide [no description available] | 2.13 | 1 | 0 | xanthenes | |
| chlormadinone acetate Chlormadinone Acetate: An orally active synthetic progestational hormone used often in combinations as an oral contraceptive (CONTRACEPTIVES, ORAL). | 2.13 | 1 | 0 | corticosteroid hormone | |
| ethamivan ethamivan: minor descriptor (65-72); major descriptor (73-86); on-line search BENZAMIDES (66-86); INDEX MEDICUS search BENZAMIDES (65-72); ETHAMIVAN (73-86). etamivan : Phenol substituted at C-2 and C-4 by a methoxy group and an N,N-diethylaminocarbonyl group respectively. A respiratory stimulant drug related to nikethamide, it has now fallen largely into disuse. | 2.13 | 1 | 0 | methoxybenzenes; phenols | |
| pargyline hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| orphenadrine hydrochloride orphenadrine hydrochloride : A hydrochloride comprising equimolar amounts of ophenadrine and hydrogen chloride. | 2.13 | 1 | 0 | hydrochloride | antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic |
| fluocinonide Fluocinonide: A topical glucocorticoid used in the treatment of ECZEMA. | 2.13 | 1 | 0 | organic molecular entity | |
| fluorometholone Fluorometholone: A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). fluorometholone : A member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; tertiary alpha-hydroxy ketone | anti-inflammatory drug |
| xanthinol niacinate Xanthinol Niacinate: A vasodilator used in peripheral vascular disorders and insufficiency. It may cause gastric discomfort and hypotension. | 2.13 | 1 | 0 | ||
| glycyrrhetinic acid [no description available] | 2.13 | 1 | 0 | cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid | immunomodulator; plant metabolite |
| podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA. | 2.13 | 1 | 0 | furonaphthodioxole; lignan; organic heterotetracyclic compound | antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator |
| medroxyprogesterone [no description available] | 2.13 | 1 | 0 | 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone | contraceptive drug; progestin; synthetic oral contraceptive |
| tetrahydrozoline hydrochloride tetrahydrozoline hydrochloride : The hydrochloride salt of tetryzoline. It is used as a nasal decongestant. | 2.13 | 1 | 0 | hydrochloride | nasal decongestant; sympathomimetic agent; vasoconstrictor agent |
| 1,2-naphthoquinone naphthalene-1,2-dione: structure given in first source. 1,2-naphthoquinone : The parent structure of the family of 1,2-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 2 of the naphthalene ring. It is a metabolite of naphthalene and is found in diesel exhaust particles. | 2.13 | 1 | 0 | 1,2-naphthoquinones | aryl hydrocarbon receptor agonist; carcinogenic agent |
| amitriptyline hydrochloride [no description available] | 2.13 | 1 | 0 | organic tricyclic compound | |
| naphazoline hydrochloride [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| 4,4'-bipyridyl 4,4'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-4 and C-4'. | 2.13 | 1 | 0 | bipyridine | |
| doxylamine succinate [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| monoacetyldapsone monoacetyldapsone: used in leprosy chemotherapy. monoacetyldapsone : A secondary carboxamide resulting from acetylation of one of the amino groups of dapsone. | 2.13 | 1 | 0 | acetamides; anilide; secondary carboxamide; sulfone | |
| formestane [no description available] | 2.13 | 1 | 0 | 17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid | antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor |
| chlorotrianisene Chlorotrianisene: A powerful synthetic, non-steroidal estrogen. | 2.13 | 1 | 0 | chloroalkene | antineoplastic agent; estrogen receptor modulator; xenoestrogen |
| aminacrine [no description available] | 2.13 | 1 | 0 | ||
| isoxsuprine hydrochloride [no description available] | 2.13 | 1 | 0 | alkylbenzene | |
| bethanechol chloride bethanechol chloride : The chloride salt of bethanechol. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention. | 2.13 | 1 | 0 | carbamate ester; chloride salt; quaternary ammonium salt | muscarinic agonist |
| megestrol acetate [no description available] | 2.13 | 1 | 0 | 20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester | antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive |
| 2-hydroxyacetanilide 2-acetamidophenol : A member of the class of phenols that is 2-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. A positional isomer of paracetamol which possesses anti-inflammatory, anti-arthritic and anti-platelet aggregation properties. | 2.13 | 1 | 0 | acetamides; phenols | anti-inflammatory agent; antineoplastic agent; antirheumatic drug; apoptosis inducer; platelet aggregation inhibitor; xenobiotic metabolite |
| acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine. | 2.13 | 1 | 0 | acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid | antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary |
| clopamide Clopamide: A sulfamoylbenzamide piperidine. It is considered a thiazide-like diuretic. | 2.13 | 1 | 0 | sulfonamide | |
| phosmet Phosmet: An organothiophosphorus insecticide that has been used to control pig mange. | 2.13 | 1 | 0 | organic thiophosphate; organothiophosphate insecticide; phthalimides | acaricide; agrochemical; EC 3.1.1.7 (acetylcholinesterase) inhibitor |
| levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. | 2.13 | 1 | 0 | 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound | contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive |
| malononitrile dimer Malononitrile dimer: has antithyroid activity; inhibits conversion of monoiodotyrosine to diiodotyrosine | 2.13 | 1 | 0 | ||
| diphenyl disulfide [no description available] | 2.13 | 1 | 0 | benzenes | |
| cyproheptadine hydrochloride (anhydrous) cyproheptadine hydrochloride (anhydrous) : The hydrochloride salt of cyproheptadine. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate. | 2.13 | 1 | 0 | hydrochloride | |
| estradiol valerate [no description available] | 2.13 | 1 | 0 | steroid ester | |
| tetramethylpyrazine tetramethylpyrazine: found in Ligusticum chuanxiong. tetramethylpyrazine : A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii). | 2.13 | 1 | 0 | alkaloid; pyrazines | antineoplastic agent; apoptosis inhibitor; bacterial metabolite; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent |
| 2,2'-dipyridylamine dipyridin-2-ylamine: structure in first source | 2.13 | 1 | 0 | ||
| pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage. | 2.13 | 1 | 0 | aliphatic nitrile | |
| flurandrenolone Flurandrenolone: A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733) | 2.13 | 1 | 0 | 21-hydroxy steroid | |
| diethylcarbamazine citrate [no description available] | 2.13 | 1 | 0 | piperazinecarboxamide | |
| azacyclonol azacyclonol: major descriptor (65-84); on-line search PIPERIDINES (65-84); Index Medicus search AZACYCLONOL (65-84); RN given refers to parent cpd | 2.13 | 1 | 0 | diarylmethane | |
| 5 alpha-androstane-3 alpha,17 beta-diol 5alpha-androstane-3alpha,17beta-diol : The 5alpha-stereoisomer of androstane-3alpha,17beta-diol. | 2.13 | 1 | 0 | androstane-3alpha,17beta-diol | Daphnia magna metabolite; human metabolite |
| guaiacoxyacetic acid guaiacoxyacetic acid: structure given in first source | 2.13 | 1 | 0 | ||
| methylene diphosphonate medronic acid : A 1,1-bis(phosphonic acid) consisting of methane substituted by two phosphonic acid groups. | 2.13 | 1 | 0 | 1,1-bis(phosphonic acid) | bone density conservation agent; chelator |
| amiloride hydrochloride, anhydrous amiloride hydrochloride : A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid. | 2.13 | 1 | 0 | hydrochloride | diuretic; sodium channel blocker |
| pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group. | 2.13 | 1 | 0 | benzimidazoles; heteroarylpiperidine; organofluorine compound | antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist |
| flumethasone Flumethasone: An anti-inflammatory glucocorticoid used in veterinary practice. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | anti-inflammatory drug |
| azaribine azaribine: pyrimidine analogue; anti-metabolite used in psoriasis & mycosis fungoides;. azaribine : A N-glycosyl-1,2,4-triazine that is 6-azauridine acetylated at positions 2', 3' and 5' on the sugar ring. It is a prodrug for 6-azauridine and is used for treatment of psoriasis. | 2.13 | 1 | 0 | acetate ester; N-glycosyl-1,2,4-triazine | antipsoriatic; prodrug |
| antazoline hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| mebeverine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase | 2.13 | 1 | 0 | dihydrofuran; nucleoside analogue; organic molecular entity | antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor |
| clidinium bromide clidinium bromide : The bromide salt of clinidium. It is used for the symptomatic treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | 2.13 | 1 | 0 | ||
| diloxanide furoate diloxanide furoate: structure. diloxanide furoate : A carboxylic ester resulting from the formal condensation of the carboxy group of furan-2-carboxylic acid with the hydroxy group of 2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide. It is a drug used for the treatment of asymptomatic amebiasis. | 2.13 | 1 | 0 | carboxylic ester; furans; organochlorine compound; tertiary carboxamide | antiamoebic agent; prodrug |
| nitroxoline nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5. | 2.13 | 1 | 0 | C-nitro compound; monohydroxyquinoline | antifungal agent; antiinfective agent; antimicrobial agent; renal agent |
| cladribine [no description available] | 2.13 | 1 | 0 | organochlorine compound; purine 2'-deoxyribonucleoside | antineoplastic agent; immunosuppressive agent |
| beclomethasone [no description available] | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | anti-asthmatic drug; anti-inflammatory drug |
| alverine citrate [no description available] | 2.13 | 1 | 0 | citrate salt; organoammonium salt | antispasmodic drug; cholinergic antagonist |
| cyclogyl cyclopentolate hydrochloride : The hydrochloride salt of cyclopentolate. It is used to produce mydriasis (excessive dilation of the pupil) and cycloplegia (paralysis of the ciliary muscle of the eye) for opthalmic diagnostic procedures. It acts more quickly than atropine and has a shorter duration of action. | 2.13 | 1 | 0 | ||
| metoclopramide hydrochloride metoclopramide hydrochloride : A hydrate that is the monohydrate form of metoclopramide monohydrochloride. | 2.13 | 1 | 0 | ||
| isoetharine mesylate [no description available] | 2.13 | 1 | 0 | ||
| 6-nitroindazole [no description available] | 2.13 | 1 | 0 | ||
| hydrocortisone-17-butyrate cortisol 17-butyrate : Cortisol esterified with butyric acid at the 17-hydroxy group. | 2.13 | 1 | 0 | butyrate ester; cortisol ester; primary alpha-hydroxy ketone | dermatologic drug; drug allergen |
| benserazide hydrochloride benserazide hydrochloride : A hydrochloride that is the monohydrochloride salt of benserazide. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide hydrochloride has no antiparkinson actions when given alone. | 2.13 | 1 | 0 | hydrochloride | antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor |
| pentamethylmelamine pentamethylmelamine: RN given refers to parent cpd | 2.13 | 1 | 0 | ||
| eedq EEDQ: peptide coupling reagent | 2.13 | 1 | 0 | ||
| ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections. | 2.13 | 1 | 0 | C-nitro compound; imidazoles; organochlorine compound; secondary alcohol | antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope |
| tetridamin tetridamin: do not confuse with tetrodamine; structure | 2.13 | 1 | 0 | ||
| metergoline Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7. | 2.13 | 1 | 0 | carbamate ester; ergoline alkaloid | dopamine agonist; geroprotector; serotonergic antagonist |
| capobenic acid [no description available] | 2.13 | 1 | 0 | benzamides | |
| thymolphthalein Thymolphthalein: Used as a pH indicator and as a reagent for blood after decolorizing the alkaline solution by boiling with zinc dust. | 2.13 | 1 | 0 | terpene lactone | |
| clobetasol propionate Clobetasol Propionate: This is the form in trademark preparations.. clobetasol propionate : The 17-O-propionate ester of clobetasol. A potent corticosteroid, it is used to treat various skin disorders, including exzema and psoriasis. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; fluorinated steroid; glucocorticoid | anti-inflammatory drug |
| frentizole frentizole: RN given refers to parent cpd | 2.13 | 1 | 0 | ||
| eterobarb [no description available] | 2.13 | 1 | 0 | barbiturates | |
| oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy. | 2.13 | 1 | 0 | cyclic ketone; dibenzoazepine | anticonvulsant; drug allergen |
| moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride. | 2.13 | 1 | 0 | hydrochloride | anti-arrhythmia drug |
| zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase. | 2.13 | 1 | 0 | azide; pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor |
| proroxan hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| etomidate ethnor: an adsorbable haemostatic bone sealant | 2.13 | 1 | 0 | imidazoles | |
| buspirone hydrochloride buspirone hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of buspirone and hydrogen chloride. | 2.13 | 1 | 0 | hydrochloride | anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist |
| propafenone hydrochloride propafenone hydrochloride : A hydrochloride that is the monohydrochloride salt of propafenone. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used in the management of supraventricular and ventricular arrhythmias. | 2.13 | 1 | 0 | hydrochloride | anti-arrhythmia drug |
| bezafibrate [no description available] | 2.13 | 1 | 0 | aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes | antilipemic drug; environmental contaminant; geroprotector; xenobiotic |
| sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol. | 2.13 | 1 | 0 | ||
| picobenzide [no description available] | 2.13 | 1 | 0 | ||
| flecainide acetate flecainide acetate : An acetate salt obtained by combining flecainide with one molar equivalent of acetic acid. An antiarrhythmic agent used to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart). | 2.13 | 1 | 0 | acetate salt | anti-arrhythmia drug |
| nicardipine hydrochloride [no description available] | 2.13 | 1 | 0 | dihydropyridine | geroprotector |
| triadimenol triadimenol : A member of the class of triazoles that is 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butane-1,2-diol substituted at position O1 by a 4-chlorophenyl group. A fungicide for cereals, beet and brassicas used to control a range of diseases including powdery mildew, rusts, bunts and smuts. | 2.13 | 1 | 0 | aromatic ether; conazole fungicide; hemiaminal ether; monochlorobenzenes; secondary alcohol; triazole fungicide | antifungal agrochemical; EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor; xenobiotic metabolite |
| captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug. | 2.13 | 1 | 0 | alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor |
| terazosin hydrochloride anhydrous [no description available] | 2.13 | 1 | 0 | ||
| pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. | 2.13 | 1 | 0 | methanesulfonate salt | antiparkinson drug; dopamine agonist; geroprotector |
| cerm-1978 bepridil hydrochloride : The hydrochloride of bepridil. | 2.13 | 1 | 0 | hydrochloride | |
| dazoxiben hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). | 2.13 | 1 | 0 | delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring) | anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug |
| mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME. | 2.13 | 1 | 0 | 3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound | abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive |
| tobramycin sulfate [no description available] | 2.13 | 1 | 0 | ||
| benzylaminopurine benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group. | 2.13 | 1 | 0 | 6-aminopurines | cytokinin; plant metabolite |
| fluoxetine hydrochloride fluoxetine hydrochloride : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine hydrochloride. A selective serotonin reuptake inhibitor (SSRI), it is used for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder. | 2.13 | 1 | 0 | hydrochloride; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | |
| diltiazem hydrochloride Carex: fluoride (1.8%) containing varnish; no further information available 8/91. diltiazem hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension. | 2.13 | 1 | 0 | hydrochloride | antihypertensive agent; calcium channel blocker; vasodilator agent |
| trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride. | 2.13 | 1 | 0 | hydrochloride | adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor |
| verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride. | 2.13 | 1 | 0 | ||
| doxazosin mesylate Cardura: Trade name in United States. | 2.13 | 1 | 0 | methanesulfonate salt | geroprotector |
| amantadine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | antiviral agent; dopamine agonist; NMDA receptor antagonist |
| norharman norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring. | 2.13 | 1 | 0 | beta-carbolines; mancude organic heterotricyclic parent | fungal metabolite; marine metabolite |
| desipramine hydrochloride desipramine hydrochloride : The hydrochloride salt of desipramine. | 2.13 | 1 | 0 | hydrochloride | drug allergen |
| ticlopidine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | |
| dopamine hydrochloride P 498: structure in first source; do not confuse with dopamine chloride, also known as P 498 | 2.13 | 1 | 0 | catecholamine | |
| sulconazole, mononitrate, (+-)-isomer [no description available] | 2.13 | 1 | 0 | conazole antifungal drug; imidazole antifungal drug; organic nitrate salt | |
| acetylcholine bromide acetylcholine bromide : The bromide salt of acetylcholine. | 2.13 | 1 | 0 | bromide salt; quaternary ammonium salt | |
| aloxistatin aloxistatin: a membrane-permeable cysteine protease inhibitor. aloxistatin : An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide. | 2.13 | 1 | 0 | epoxide; ethyl ester; L-leucine derivative; monocarboxylic acid amide | anticoronaviral agent; cathepsin B inhibitor |
| tryptamide tryptamide: structure given in first source | 2.13 | 1 | 0 | ||
| trihexyphenidyl hydrochloride [no description available] | 2.13 | 1 | 0 | aralkylamine | |
| oxyphencyclimine hydrochloride [no description available] | 2.13 | 1 | 0 | pyrimidines | |
| thioridazine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | first generation antipsychotic; geroprotector |
| diphenylpyraline hydrochloride diphenylpyraline hydrochloride : The hydrochloride salt of diphenylpyraline. A sedating antihistamine, it is used as the hydrochloride for the symptomatic relief of allergic conditions including rhinitis and hay fever, and in pruritic skin disorders. | 2.13 | 1 | 0 | hydrochloride | cholinergic antagonist; H1-receptor antagonist |
| procainamide hydrochloride procainamide hydrochloride : A hydrochloride which has procainamide as the amino component. | 2.13 | 1 | 0 | hydrochloride | anti-arrhythmia drug |
| siquil [no description available] | 2.13 | 1 | 0 | hydrochloride | anticoronaviral agent |
| mepivacaine hydrochloride mepivacaine hydrochloride : The hydrochloride salt of mepivacaine. It is used as a local anaesthetic. | 2.13 | 1 | 0 | hydrochloride; piperidinecarboxamide | local anaesthetic |
| oxymetazoline hydrochloride oxymetazoline hydrochloride : A hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal congestion. | 2.13 | 1 | 0 | hydrochloride | alpha-adrenergic agonist; nasal decongestant; sympathomimetic agent; vasoconstrictor agent |
| diphenidol hydrochloride [no description available] | 2.13 | 1 | 0 | diarylmethane | |
| alprenolol hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | |
| edoxudin [no description available] | 2.13 | 1 | 0 | pyrimidine 2'-deoxyribonucleoside | |
| 2-methoxyestradiol 2-methoxy-17beta-estradiol : A 17beta-hydroxy steroid, being 17beta-estradiol methoxylated at C-2. | 2.13 | 1 | 0 | 17beta-hydroxy steroid; 3-hydroxy steroid | angiogenesis modulating agent; antimitotic; antineoplastic agent; human metabolite; metabolite; mouse metabolite |
| 6-ketoestradiol [no description available] | 2.13 | 1 | 0 | ||
| 17 beta-estradiol hemisuccinate [no description available] | 2.13 | 1 | 0 | ||
| amizyl [no description available] | 2.13 | 1 | 0 | ||
| salicylhydroxamic acid [no description available] | 2.13 | 1 | 0 | hydroxamic acid; phenols | antibacterial drug; EC 1.11.2.2 (myeloperoxidase) inhibitor; EC 3.5.1.5 (urease) inhibitor; trypanocidal drug |
| 1,7-phenanthroline [no description available] | 2.13 | 1 | 0 | phenanthroline | |
| 3-fluoro-4-hydroxyphenylacetic acid [no description available] | 2.13 | 1 | 0 | ||
| dyclonine hydrochloride dyclonine hydrochloride : The hydrochloride salt of dyclonine. | 2.13 | 1 | 0 | hydrochloride | topical anaesthetic |
| clomipramine hydrochloride clomipramine hydrochloride : A hydrochloride resulting from the reaction of equimolar amounts of clomipramine and hydrogen chloride. One of the more sedating tricyclic antidepressants, it is used for the treatment of depression as well as obsessive-compulsive disorder and phobias. | 2.13 | 1 | 0 | hydrochloride | anticoronaviral agent; antidepressant; serotonergic antagonist; serotonergic drug |
| prazosin hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | |
| mianserin hydrochloride mianserin hydrochloride : The hydrochloride salt of mianserin, a tetracyclic compound with antidepressant effects. | 2.13 | 1 | 0 | hydrochloride | geroprotector |
| miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. | 2.13 | 1 | 0 | ||
| econazole nitrate econazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-econazole nitrate. Used to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. | 2.13 | 1 | 0 | ||
| 2,4-dimethoxybenzaldehyde [no description available] | 2.13 | 1 | 0 | ||
| enrofloxacin Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets. | 2.13 | 1 | 0 | cyclopropanes; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone | antibacterial agent; antimicrobial agent; antineoplastic agent |
| clobetasone butyrate [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| loxapine succinate [no description available] | 2.13 | 1 | 0 | succinate salt | geroprotector |
| guanfacine hydrochloride [no description available] | 2.13 | 1 | 0 | acetamides | geroprotector |
| labetalol hydrochloride [no description available] | 2.13 | 1 | 0 | salicylamides | |
| diflorasone diacetate diflorasone diacetate : The 17,21-diacetate derivative of diflorasone. It is used topically for its anti-inflammatory and antipruritic properties in the treatment of various skin disorders. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; fluorinated steroid; glucocorticoid | anti-inflammatory drug; antipruritic drug |
| acecainide hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| loperamide hydrochloride loperamide hydrochloride : A hydrochloride obtained by combining loperamide with one equivalent of hydrochloric acid. Used for treatment of diarrhoea resulting from gastroenteritis or inflammatory bowel disease. | 2.13 | 1 | 0 | hydrochloride | anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist |
| maprotiline hydrochloride [no description available] | 2.13 | 1 | 0 | anthracenes | |
| hydroxyzine dihydrochloride [no description available] | 2.13 | 1 | 0 | ||
| betamipron [no description available] | 2.13 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| secnidazole [no description available] | 2.13 | 1 | 0 | C-nitro compound; imidazoles; secondary alcohol | epitope |
| zidovudine triphosphate [no description available] | 1.99 | 1 | 0 | ||
| ergocornine ergocornine: a component of ergotoxine; minor descriptor (75-86); on-line & INDEX MEDICUS search ERGOLINES (75-86); RN given refers to ((5'alpha)-isomer). ergocornine : Ergotaman bearing a hydroxy group at the 12' position, isopropyl groups at the 2' and 5'alpha positions, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid. | 2.13 | 1 | 0 | ergot alkaloid | |
| pramoxine hydrochloride [no description available] | 2.13 | 1 | 0 | aromatic ether | |
| butyrylcholine chloride [no description available] | 2.13 | 1 | 0 | ||
| 1-benzylimidazole 1-benzylimidazole: inhibits human thromboxane synthetase | 2.13 | 1 | 0 | ||
| chloropyramine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| 6-aminoindazole 6-aminoindazole: depresses gastric acid secretion; structure given in first source | 2.13 | 1 | 0 | indazoles | |
| 5-aminoindazole [no description available] | 2.13 | 1 | 0 | ||
| phentolamine mesylate [no description available] | 2.13 | 1 | 0 | ||
| oxybutynin hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | |
| 2-methylhippuric acid 2-methylhippuric acid: urinary metabolite of o-xylene. o-methylhippuric acid : An N-acylglycine that is the ortho-methyl derivative of hippuric acid. | 2.13 | 1 | 0 | N-acylglycine | metabolite |
| prilocaine hydrochloride prilocaine hydrochloride : The monohydrochloride salt of prilocaine. | 2.13 | 1 | 0 | hydrochloride | local anaesthetic |
| meclizine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| 11-hydroxyprogesterone, (11alpha)-isomer 11alpha-hydroxyprogesterone : A 11alpha-hydroxy steroid that is pregn-4-ene-3,20-dione substituted by a hydroxy group at position 11. | 2.13 | 1 | 0 | 11alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid | |
| malic acid, (r)-isomer (R)-malic acid : An optically active form of malic acid having (R)-configuration. | 2.13 | 1 | 0 | malic acid | |
| 21-deoxycortisol 21-deoxycortisol: RN given refers to (11beta)-isomer; structure. 21-deoxycortisol : A deoxycortisol that is 17xi-pregn-4-ene-3,20-dione substituted by a beta-hydroxy group at position 11 and an alpha-hydroxy group at position 17. It is a marker of virilizing adrenal hyperplasia caused by 21-hydroxylase deficiency. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 17alpha-hydroxy-C21-steroid; deoxycortisol; tertiary alpha-hydroxy ketone | human blood serum metabolite; mouse metabolite |
| estrone 3-methyl ether estrone 3-methyl ether: RN given refers to cpd with unspecified isomeric designation; structure | 2.13 | 1 | 0 | ||
| e-250 [no description available] | 2.13 | 1 | 0 | ||
| rac-glycerol 1-monodecanoate rac-glycerol 1-monodecanoate: a monoglyceride of capric acid. 1-monodecanoylglycerol : A 1-monoglyceride that has decanoyl (capryl) as the acyl group.. rac-1-monodecanoylglycerol : A rac-1-monoacylglycerol composed of equal amounts of 3-decanoyl-sn-glycerol and 1-decanoyl-sn-glycerol. | 2.13 | 1 | 0 | rac-1-monoacylglycerol | |
| nipecotic acid amide nipecotic acid amide: RN & N1 form 9th CI Form Index; RN given refers to cpd without isomeric designation. nipecotamide : The amide resulting from the formal condensation of nipecotic acid with ammonia. | 2.13 | 1 | 0 | piperidinecarboxamide | |
| levcromakalim [no description available] | 2.13 | 1 | 0 | 1-benzopyran | |
| tachistin tachistin: a synthetic analog of dihydrotachysterol | 2.13 | 1 | 0 | ||
| cortisol octanoate [no description available] | 2.13 | 1 | 0 | corticosteroid hormone | |
| armepavine [no description available] | 2.13 | 1 | 0 | ||
| n(6)-phenyladenosine [no description available] | 2.13 | 1 | 0 | purine nucleoside | |
| pregnan-3,6-diol-20-one pregnan-3,6-diol-20-one: RN given refers to (3alpha,5beta,6alpha)-isomer | 2.03 | 1 | 0 | corticosteroid hormone | |
| mizoribine [no description available] | 2.13 | 1 | 0 | imidazoles | anticoronaviral agent |
| alphaxalone alphaxalone: RN given refers to (3alpha,5alpha)-isomer; structure | 2.13 | 1 | 0 | corticosteroid hormone | |
| bicuculline methiodide [no description available] | 2.13 | 1 | 0 | ||
| beta-carboline-3-carboxylic acid ethyl ester beta-carboline-3-carboxylic acid ethyl ester: isolated from brain tissue & urine; extremely potent displacer of diazepam from brain benzodiazepam receptors; structure in first source | 2.13 | 1 | 0 | beta-carbolines | |
| tryptoline tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure | 2.13 | 1 | 0 | beta-carbolines | |
| gamma-fagarine gamma-fagarine: active alkaloid of Chinese medicines from Dictamni radicis cortex (Rutaceae); structure given in first source | 2.13 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| betaxolol hydrochloride betaxolol hydrochloride : The hydrochloride salt of betaxolol. | 2.13 | 1 | 0 | hydrochloride | antihypertensive agent; beta-adrenergic antagonist |
| Zearalanone [no description available] | 2.13 | 1 | 0 | macrolide; resorcinols | |
| butethamate citrate [no description available] | 2.13 | 1 | 0 | ||
| 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol: structure in first source | 2.13 | 1 | 0 | piperidines | |
| gallopamil hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| histamine dihydrochloride [no description available] | 2.13 | 1 | 0 | ||
| 1,3-dimethylbenzimidazoline-2-thione 1,3-dimethylbenzimidazoline-2-thione: structure given in first source | 2.13 | 1 | 0 | ||
| n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine: inhibits calcium-activated neutral protease; see also record for E-64; RN given refers to (2-S-(2alpha,3beta)(R*)-isomer) | 2.13 | 1 | 0 | leucine derivative | |
| desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. | 2.13 | 1 | 0 | benzocycloheptapyridine | anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist |
| 3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer [no description available] | 2.13 | 1 | 0 | ||
| levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase. | 2.11 | 1 | 0 | 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic | antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor |
| dichloro-1,2-diaminocyclohexane platinum complex [no description available] | 2.13 | 1 | 0 | ||
| 1,4-di(2'-thienyl)-1,4-butadione 1,4-di(2'-thienyl)-1,4-butadione: structure given in first source | 2.13 | 1 | 0 | ||
| idazoxan hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| methyl 5-aminolevulinate hydrochloride methyl 5-aminolevulinate hydrochloride : The hydrochloride salt of methyl 5-aminolevulinate. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. | 2.13 | 1 | 0 | hydrochloride | antineoplastic agent; dermatologic drug; photosensitizing agent; prodrug |
| antazoline phosphate [no description available] | 2.13 | 1 | 0 | ||
| pridinol mesylate [no description available] | 2.13 | 1 | 0 | ||
| 17 alpha-hydroxyprogesterone caproate 17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS. | 2.13 | 1 | 0 | corticosteroid hormone | |
| atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3. | 2.13 | 1 | 0 | ||
| 5-fluorotryptamine monohydrochloride [no description available] | 2.13 | 1 | 0 | ||
| piribedil mesylate [no description available] | 2.13 | 1 | 0 | ||
| serc [no description available] | 2.13 | 1 | 0 | ||
| procyclidine hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | |
| (7R)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one [no description available] | 2.13 | 1 | 0 | macrolide | |
| cortisone [no description available] | 2.13 | 1 | 0 | 11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | human metabolite; mouse metabolite |
| equilin Equilin: An estrogenic steroid produced by HORSES. It has a total of four double bonds in the A- and B-ring. High concentration of euilin is found in the URINE of pregnant mares. | 2.13 | 1 | 0 | 17-oxo steroid; 3-hydroxy steroid | |
| adrenosterone adrenosterone : A 3-oxo Delta(4)-steroid that is androst-4-ene carrying three oxo-substituents at positions 3, 11 and 17. | 2.13 | 1 | 0 | 11-oxo steroid; 17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid | androgen; EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor; human urinary metabolite; marine metabolite |
| gossypol acetic acid [no description available] | 2.13 | 1 | 0 | ||
| epinastine dexamethasone acetate: RN given refers to (11beta,16alpha)-isomer | 2.13 | 1 | 0 | corticosteroid hormone | |
| benzatropine methanesulfonate [no description available] | 2.13 | 1 | 0 | ||
| 4',6-dihydroxy-5,7-dimethoxyflavone 4',6-dihydroxy-5,7-dimethoxyflavone : A dimethoxyflavone that is the 5,7-dimethyl ether derivative of scutellarein. | 2.13 | 1 | 0 | dihydroxyflavone; dimethoxyflavone | |
| 2-hydroxyestradiol 2-hydroxyestradiol: catechol estrogen; RN given refers to (17 beta)-isomer. 2-hydroxy-17beta-estradiol : A 2-hydroxy steroid that consists of 17beta-estradiol having an additional hydroxy group at position 2. | 2.13 | 1 | 0 | 17beta-hydroxy steroid; 2-hydroxy steroid | carcinogenic agent; human metabolite; metabolite; mouse metabolite; prodrug |
| medrysone [no description available] | 2.13 | 1 | 0 | corticosteroid hormone | |
| artisone acetate [no description available] | 2.13 | 1 | 0 | corticosteroid hormone | |
| chondocurine (1beta)-(+-)-isomer curine: structure in first source | 2.13 | 1 | 0 | aromatic ether | |
| 4-methoxyxanthone 4-methoxyxanthone: a vasodilator; structure in first source | 2.13 | 1 | 0 | ||
| 2-methyl-N-[4-(propan-2-ylamino)phenyl]-2-propenamide [no description available] | 2.13 | 1 | 0 | amine | |
| ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus. | 2.13 | 1 | 0 | 11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone | anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite |
| mandelic acid, (s)-isomer [no description available] | 2.13 | 1 | 0 | (2S)-2-hydroxy monocarboxylic acid; mandelic acid | |
| tosylphenylalanyl chloromethyl ketone Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone. | 2.13 | 1 | 0 | alpha-chloroketone; sulfonamide | alkylating agent; serine proteinase inhibitor |
| cortodoxone Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.. 11-deoxycortisol : A deoxycortisol that is cortisol in which the hydroxy group at position 11 has been replaced by a hydrogen. | 2.13 | 1 | 0 | deoxycortisol; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | human metabolite; mouse metabolite |
| acebutolol hydrochloride acebutolol hydrochloride : The hydrochloride salt of acebutolol, prepared using equimolar amounts of acebutolol and hydrogen chloride. | 2.13 | 1 | 0 | hydrochloride | anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent |
| amiodarone hydrochloride [no description available] | 2.13 | 1 | 0 | aromatic ketone | |
| dicyclomine hydrochloride dicyclomine hydrochloride : The hydrochloride salt of dicyclomine. An anticholinergic, it is used to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome. | 2.13 | 1 | 0 | hydrochloride | antispasmodic drug; muscarinic antagonist |
| nortriptyline hydrochloride [no description available] | 2.13 | 1 | 0 | organic tricyclic compound | geroprotector |
| difluprednate difluprednate: RN given refers to (6alpha,11beta)-isomer | 2.13 | 1 | 0 | butyrate ester; corticosteroid hormone | |
| dironyl dironyl: pronounced antifertility agent in rats; lactation suppressor in other species; serotonin antagonist; RN given refers to parent cpd; structure | 2.13 | 1 | 0 | organic molecular entity | |
| vinpocetine vinpocetine: whole issue of Arzneim Forsch (23 articles) discuss this drug; Arzneim Forsch 26(10a);1976; RN given refers to parent cpd with unspecified isomeric designation | 2.13 | 1 | 0 | alkaloid | geroprotector |
| amcinonide amcinonide: structure | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; acetate ester; corticosteroid; fluorinated steroid; spiroketal | anti-inflammatory drug |
| flumethasone pivalate flumethasone pivalate: structure | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; pivalate ester; tertiary alpha-hydroxy ketone | anti-inflammatory drug; antipruritic drug |
| dihydroergocristine monomesylate dihydroergocristine mesylate : The methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia. | 2.13 | 1 | 0 | methanesulfonate salt | alpha-adrenergic antagonist; geroprotector; vasodilator agent |
| tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry. | 2.13 | 1 | 0 | retinoic acid; vitamin A | anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule |
| resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration. | 2.13 | 1 | 0 | resveratrol | antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger |
| adenosine-5'-(n-ethylcarboxamide) Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group. | 2.13 | 1 | 0 | adenosines; monocarboxylic acid amide | adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent |
| histidyl-proline diketopiperazine cyclo(L-His-L-Pro) : A homodetic cyclic peptide resulting from the formal condensation of both the amino and acid groups of L-histidine with the acid and amino groups of L-proline. It is a metabolite of thyrotropin-releasing hormone (TRH). | 2.13 | 1 | 0 | dipeptide; homodetic cyclic peptide; imidazoles; pyrrolopyrazine | anti-inflammatory agent; dopamine uptake inhibitor; human blood serum metabolite |
| afimoxifene afimoxifene : A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen. | 2.13 | 1 | 0 | phenols; tertiary amino compound | antineoplastic agent; estrogen receptor antagonist; metabolite |
| ketoconazole (2R,4S)-ketoconazole : A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2R,4S)-configuration. | 2.13 | 1 | 0 | cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine | |
| aphidicolin Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication. | 2.13 | 1 | 0 | tetracyclic diterpenoid | antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite |
| azaserine Azaserine: Antibiotic substance produced by various Streptomyces species. It is an inhibitor of enzymatic activities that involve glutamine and is used as an antineoplastic and immunosuppressive agent.. azaserine : A carboxylic ester resulting from the formal condensation of the carboxy group of diazoacetic acid with the alcoholic hydroxy group of L-serine. An antibiotic produced by a Streptomyces species. | 2.13 | 1 | 0 | carboxylic ester; diazo compound; L-serine derivative; non-proteinogenic L-alpha-amino acid | antifungal agent; antimetabolite; antimicrobial agent; antineoplastic agent; glutamine antagonist; immunosuppressive agent; metabolite |
| maltitol maltitol : An alpha-D-glucoside consisting of D-glucitol having an alpha-D-glucosyl residue attached at the 4-position. Used as a sugar substitute. | 2.13 | 1 | 0 | alpha-D-glucoside; glycosyl alditol | laxative; metabolite; sweetening agent |
| chalcone trans-chalcone : The trans-isomer of chalcone. | 2.13 | 1 | 0 | chalcone | EC 3.2.1.1 (alpha-amylase) inhibitor |
| thermospine thermospine: structure given in first source | 2.13 | 1 | 0 | ||
| dibenzylidene acetone dibenzylidene acetone: structure in first source | 2.13 | 1 | 0 | ||
| 4-methoxy-1,3-dimethyl-6-thiophen-2-yl-8-cyclohepta[c]furanone [no description available] | 2.13 | 1 | 0 | cycloheptafuran | |
| 5-[(5-methoxycarbonyl-2-methyl-3-furanyl)methoxy]-2-methyl-3-benzofurancarboxylic acid 2-methoxyethyl ester [no description available] | 2.13 | 1 | 0 | 2-methoxyethyl ester; benzofurans | |
| 5,6,7-trimethoxy-1-methyl-2-indolecarboxylic acid [no description available] | 2.13 | 1 | 0 | indolyl carboxylic acid | |
| haplamine haplamine: isolated from Haplophyllum acutifolium; structure in first source | 2.13 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| octotropine methylbromide octotropine methylbromide: minor descriptor (65-86); on line & INDEX MEDICUS search TROPANES (69-86); RN given refers to endo-isomer. anisotropine methylbromide : A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide. | 2.13 | 1 | 0 | ||
| diethylstilbestrol dipropionate diethylstilbestrol dipropionate: RN given refers to parent cpd | 2.13 | 1 | 0 | ||
| (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available] | 2.13 | 1 | 0 | alkylbenzene | |
| glycerylphosphorylcholine choline alfoscerate : A member of the class of phosphocholines that is the choline ester of sn-glycero-3-phosphate. It is one of the major osmolyte in the renal medullary cells.. glycerophosphocholine : The glycerol phosphate ester of a phosphocholine. A nutrient with many different roles in human health. | 2.13 | 1 | 0 | phosphocholines; sn-glycerol 3-phosphates | Escherichia coli metabolite; human metabolite; mouse metabolite; neuroprotective agent; parasympatholytic; Saccharomyces cerevisiae metabolite |
| n-methylscopolamine nitrate [no description available] | 2.13 | 1 | 0 | ||
| propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group. | 2.13 | 1 | 0 | pyrimidinethione | antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist |
| phenytoin sodium [no description available] | 2.13 | 1 | 0 | ||
| nsc 4347 NSC 4347: structure in first source | 2.13 | 1 | 0 | ||
| ipratropium bromide anhydrous [no description available] | 2.13 | 1 | 0 | ||
| 4-methoxy-N1,N3-bis(3-pyridinyl)benzene-1,3-dicarboxamide [no description available] | 2.13 | 1 | 0 | benzamides | |
| methamilane methiodide [no description available] | 2.13 | 1 | 0 | ||
| physostigmine salicylate [no description available] | 2.13 | 1 | 0 | azaheterocycle salicylate salt; salicylates | |
| pilocarpine nitrate [no description available] | 2.13 | 1 | 0 | ||
| n(6)-cyclopentyladenosine [no description available] | 2.13 | 1 | 0 | ||
| methylatropine nitrate [no description available] | 2.13 | 1 | 0 | ||
| 1-[1-oxo-2-[(4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl)oxy]ethyl]-4-piperidinecarboxylic acid [no description available] | 2.13 | 1 | 0 | coumarins | |
| prothionamide Prothionamide: Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents. | 2.13 | 1 | 0 | pyridines | |
| 2-(2,3,4-trimethoxyphenyl)-2,3-dihydro-1,3-benzoxazin-4-one [no description available] | 2.13 | 1 | 0 | benzoxazine | |
| dienestrol Dienestrol: A synthetic, non-steroidal estrogen structurally related to stilbestrol. It is used, usually as the cream, in the treatment of menopausal and postmenopausal symptoms.. dienestrol : An olefinic compound that is hexa-2,4-diene substituted by 4-hydroxyphenyl groups at positions 3 and 4 respectively. | 2.13 | 1 | 0 | ||
| methylthiouracil Methylthiouracil: A thiourea antithyroid agent that inhibits the synthesis of thyroid hormone. It is used in the treatment of hyperthyroidism. | 2.13 | 1 | 0 | pyrimidone | |
| 4-methoxy-N-(3-pyridinylmethyl)benzamide [no description available] | 2.13 | 1 | 0 | benzamides | |
| caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid. | 2.13 | 1 | 0 | caffeic acid | geroprotector; mouse metabolite |
| 5-methyl-4-[(2-oxo-1-benzopyran-7-yl)oxymethyl]-2-furancarboxylic acid methyl ester [no description available] | 2.13 | 1 | 0 | coumarins | |
| 2-(1,3-dioxo-2-isoindolyl)-N-(3-nitrophenyl)acetamide [no description available] | 2.13 | 1 | 0 | phthalimides | |
| urocanic acid Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration. | 2.13 | 1 | 0 | urocanic acid | human metabolite |
| 2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone [no description available] | 2.13 | 1 | 0 | stilbenoid | |
| 3-(4-methoxyphenyl)-5-(2-phenylethyl)-1,2,4-oxadiazole [no description available] | 2.13 | 1 | 0 | oxadiazole; ring assembly | |
| 3-(3,5-dimethyl-7-oxo-6-furo[3,2-g][1]benzopyranyl)propanoic acid [no description available] | 2.13 | 1 | 0 | psoralens | |
| 1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione [no description available] | 2.13 | 1 | 0 | pyrimidotriazine | |
| thiothixene [no description available] | 2.13 | 1 | 0 | N-methylpiperazine | anticoronaviral agent |
| curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa. | 2.13 | 1 | 0 | aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol | anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger |
| 9-hydroxy-4-[1-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-[1]benzopyrano[3,4-b]pyridin-5-one [no description available] | 2.13 | 1 | 0 | pyridochromene | |
| 5-bromo-3-pyridinecarboxylic acid [3-(3-methylphenoxy)-4-oxo-1-benzopyran-7-yl] ester [no description available] | 2.13 | 1 | 0 | chromones | |
| 5-methyl-4-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-1-yl)oxymethyl]-2-furancarboxylic acid [no description available] | 2.13 | 1 | 0 | coumarins | |
| 4-methyl-3-(phenylmethyl)-7-[(3,4,5-trimethoxyphenyl)methoxy]-1-benzopyran-2-one [no description available] | 2.13 | 1 | 0 | coumarins | |
| [2-(4-methoxyphenyl)-6-methyl-4-quinolinyl]-(4-morpholinyl)methanone [no description available] | 2.13 | 1 | 0 | quinolines | |
| 5-(3,3-dimethyl-2-oxobutoxy)-3,4,7-trimethyl-1-benzopyran-2-one [no description available] | 2.13 | 1 | 0 | coumarins | |
| N-[4-(4-morpholinyl)phenyl]-5-(2-nitrophenyl)-2-furancarboxamide [no description available] | 2.13 | 1 | 0 | aromatic amide; furans | |
| 2-(8-methoxy-2-methyl-4-oxo-1-quinolinyl)-N-(2-methoxyphenyl)acetamide [no description available] | 2.13 | 1 | 0 | quinolines | |
| N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-N-propan-2-yl-2-furancarboxamide [no description available] | 2.13 | 1 | 0 | quinolines | |
| cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS. | 2.13 | 1 | 0 | diarylmethane; N-alkylpiperazine; olefinic compound | anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist |
| 2-(4-bromophenyl)-1-(2,4-dihydroxyphenyl)ethanone [no description available] | 2.13 | 1 | 0 | stilbenoid | |
| 1-cyclohexyl-3-(6-ethoxy-1,3-benzothiazol-2-yl)urea [no description available] | 2.13 | 1 | 0 | benzothiazoles | |
| N-[(3,5-dimethoxyphenyl)methyl]-1-(2,3,4-trimethoxyphenyl)methanamine [no description available] | 2.13 | 1 | 0 | dimethoxybenzene | |
| 2-[[5-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]-4-oxo-2-phenyl-1-benzopyran-7-yl]oxy]acetic acid tert-butyl ester [no description available] | 2.13 | 1 | 0 | flavones; tert-butyl ester | |
| ethylenethiourea Ethylenethiourea: A degradation product of ethylenebis(dithiocarbamate) fungicides. It has been found to be carcinogenic and to cause THYROID hyperplasia. | 2.13 | 1 | 0 | imidazolidines | |
| tacrine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| p-aminosalicylic acid monosodium salt [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. | 2.13 | 1 | 0 | cardenolide glycoside; steroid saponin | anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope |
| mecysteine hydrochloride [no description available] | 2.13 | 1 | 0 | alpha-amino acid ester | |
| ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide. | 2.13 | 1 | 0 | pyridines; thiocarboxamide | antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug |
| 2-(2-furanyl)-4-thiazolidinecarboxylic acid [no description available] | 2.13 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| dihydrosamidine [no description available] | 2.13 | 1 | 0 | ||
| N-(2-methoxycyclohexyl)-3,4-dimethylaniline [no description available] | 2.13 | 1 | 0 | methylbenzene | |
| eskazine [no description available] | 2.13 | 1 | 0 | ||
| 2-(3,4-dimethylphenyl)-5-ethyl-5-phenyl-1,2,4-triazolidine-3-thione [no description available] | 2.13 | 1 | 0 | methylbenzene | |
| 2-[3-oxo-1-[[[oxo(thiophen-2-yl)methyl]amino]-sulfanylidenemethyl]-2-piperazinyl]acetic acid propan-2-yl ester [no description available] | 2.13 | 1 | 0 | isopropyl ester; piperazines | |
| zeranol Zeranol: A non-steroidal estrogen analog. | 2.13 | 1 | 0 | macrolide | |
| monooctanoin monooctanoin: dissolution agent for retained cholesterol bile duct stones; RN in Chemline for octanoic acid, ester with 1,2,3-propanetriol, MF unknown: 11140-04-8; RN for octanoic acid, 2,3-dihydroxypropyl ester (1-monooctanoin): 502-54-5; RN in 9th CI Form Index for (+-)-1-monooctanoin: 19670-49-6. rac-1-monooctanoylglycerol : A rac-1-monoacylglycerol comprising equal amounts of 1-octanoyl-sn-glycerol and 3-octanoyl-sn-glycerol.. 1-monooctanoylglycerol : A 1-monoglyceride that has octanoyl as the acyl group. | 2.13 | 1 | 0 | 1-monoglyceride; octanoate ester; rac-1-monoacylglycerol | |
| trimethoprim [no description available] | 2.13 | 1 | 0 | ||
| 4-hydroxy-1-[1-oxo-2-(phenylmethoxycarbonylamino)propyl]-2-pyrrolidinecarboxylic acid [no description available] | 2.13 | 1 | 0 | peptide | |
| N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(2,3-dimethoxyphenyl)acetamide [no description available] | 2.13 | 1 | 0 | dimethoxybenzene | |
| 3-acetyl-6-methyl-1H-quinolin-4-one [no description available] | 2.13 | 1 | 0 | quinolines | |
| 3-(phenylthio)-1-(1-pyrrolidinyl)-1-propanone [no description available] | 2.13 | 1 | 0 | aryl sulfide | |
| N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide [no description available] | 2.13 | 1 | 0 | imidazolidines | |
| Anthraniloyllycoctonine [no description available] | 2.13 | 1 | 0 | diterpene alkaloid | |
| N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide [no description available] | 2.13 | 1 | 0 | aromatic amide | |
| 1-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid [no description available] | 2.13 | 1 | 0 | harmala alkaloid | |
| diclofenac sodium Diclofenac Sodium: The sodium form of DICLOFENAC. It is used for its analgesic and anti-inflammatory properties.. diclofenac sodium : The sodium salt of diclofenac. | 2.13 | 1 | 0 | organic sodium salt | |
| biochanin a [no description available] | 2.13 | 1 | 0 | 4'-methoxyisoflavones; 7-hydroxyisoflavones | antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor |
| prostaglandin b1 prostaglandin Bx: phospholipase A2 inhibitor; polymeric derivative of diketo-PGB1; mean MW 2,200. prostaglandin B1 : A member of the class of prostaglandins B that is prosta-8(12),13-dien-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 13E,15S-stereoisomer). | 2.13 | 1 | 0 | prostaglandins B | human metabolite |
| prostaglandin f1 prostaglandin F1: was EN to PROSTAGLANDINS F (75-81); RN given refers to (9 alpha,11 alpha,13E,15S)-isomer | 2.13 | 1 | 0 | prostaglandins Falpha | human metabolite |
| pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone | anti-inflammatory drug; bronchodilator agent; drug allergen |
| timolol maleate (S)-timolol maleate : The maleic acid salt of the active (S)-enantiomer of timolol, comprising equimolar amounts of (S)-timolol and maleic acid. | 2.13 | 1 | 0 | maleate salt | anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist |
| brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis. | 2.13 | 1 | 0 | maleate salt | anti-allergic agent |
| zearalenone Zearalenone: (S-(E))-3,4,5,6,8,10-Hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione. One of a group of compounds known under the general designation of resorcylic acid lactones. Cis, trans, dextro and levo forms have been isolated from the fungus Gibberella zeae (formerly Fusarium graminearum). They have estrogenic activity, cause toxicity in livestock as feed contaminant, and have been used as anabolic or estrogen substitutes.. zearalenone : A macrolide comprising a fourteen-membered lactone fused to 1,3-dihydroxybenzene; a potent estrogenic metabolite produced by some Giberella species. | 2.13 | 1 | 0 | macrolide; resorcinols | fungal metabolite; mycoestrogen |
| estriol 17-glucuronide [no description available] | 2.13 | 1 | 0 | steroid saponin | |
| tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group. | 2.13 | 1 | 0 | amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide | anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent |
| 4-hydroxyestradiol 4-hydroxyestradiol: catechol estrogen. 4-hydroxy-17beta-estradiol : A 4-hydroxy steroid that consists of 17beta-estradiol having an additional hydroxy group at position 4. | 2.13 | 1 | 0 | 4-hydroxy steroid | metabolite |
| menatetrenone menaquinone-4 : A menaquinone whose side-chain contains 4 isoprene units in an all-trans-configuration. | 2.13 | 1 | 0 | menaquinone | anti-inflammatory agent; antioxidant; bone density conservation agent; human metabolite; neuroprotective agent |
| xylometazoline hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug. | 2.13 | 1 | 0 | organoammonium salt | anti-asthmatic drug; H1-receptor antagonist |
| dinoprost tromethamine [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| hydrocortisone valerate hydrocortisone valerate: used in treatment of atopic dermatitis; RN given refers to 11beta-isomer | 2.13 | 1 | 0 | cortisol ester; glucocorticoid; primary alpha-hydroxy ketone; valerate ester | |
| prostaglandin f2 methyl ester prostaglandin F2 methyl ester: has ocular hypotensive effect; RN given refers to (5Z,9alpha,11alpha,13E,15S)-isomer | 2.13 | 1 | 0 | prostanoid | |
| 2-bromoergocryptine mesylate [no description available] | 2.13 | 1 | 0 | ||
| perhexiline maleate [no description available] | 2.13 | 1 | 0 | ||
| phenoxybenzamine hydrochloride [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| phenylephrine hydrochloride Nose: A part of the upper respiratory tract. It contains the organ of SMELL. The term includes the external nose, the nasal cavity, and the PARANASAL SINUSES.. phenylephrine hydrochloride : A hydrochloride that is the monohydrochloride salt of phenylephrine. | 2.13 | 1 | 0 | hydrochloride | |
| mepyramine maleate histosol: proprietary mixture of synthetic aromatic hydrocarbons forming an extremely nonpolar organic solvent | 2.13 | 1 | 0 | ||
| ethisterone Ethisterone: 17 alpha-Hydroxypregn-4-en-20-yn-3-one. A synthetic steroid hormone with progestational effects.. ethisterone : A 17beta-hydroxy steroid that is testosterone in which the 17beta hydrogen is replaced by an ethynyl group. Ethisterone was the first orally active progestin and is a metabolite of danazol. | 2.13 | 1 | 0 | 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol | drug metabolite; progestin |
| nalmefene nalmefene: RN given refers to 5-alpha isomer | 2.13 | 1 | 0 | morphinane alkaloid | |
| 6alpha-hydroxy-17beta-estradiol 6alpha-hydroxy-17beta-estradiol : A 4-hydroxy steroid that consists of 17beta-estradiol bearing an additional 6alpha-hydroxy substituent. | 2.13 | 1 | 0 | 6alpha-hydroxy steroid | |
| desoximetasone Desoximetasone: A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.. desoximetasone : Dexamethasone in which the hydroxy group at the 17alpha position is substituted by hydrogen. A synthetic corticosteroid with glucocorticoid activity, it is used as an anti-inflammatory and anti-pruritic in the treatment of various skin disorders, including skin allergies and psoriasis. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone | anti-inflammatory drug; antipruritic drug |
| cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments. | 2.13 | 1 | 0 | cytochalasin; lactam; lactone; organic heterotricyclic compound | actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor |
| u-44619 thromboxane A2 agonist : An agonist that binds to and activates thromboxane A2 receptors. | 2.13 | 1 | 0 | ||
| furazolidone [no description available] | 2.13 | 1 | 0 | ||
| tyrphostin ag 555 [no description available] | 2.13 | 1 | 0 | ||
| nifuroxazide nifuroxazide: structure | 2.13 | 1 | 0 | benzoic acids | |
| molsidomine [no description available] | 2.13 | 1 | 0 | ethyl ester; morpholines; oxadiazole; zwitterion | antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent |
| rg 13022 RG 13022: structure given in first source | 2.13 | 1 | 0 | ||
| styrylquinoline styrylquinoline: structure in first source | 2.13 | 1 | 0 | 2-styrylquinoline | |
| kavain [no description available] | 2.13 | 1 | 0 | racemate | glycine receptor antagonist |
| enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. | 2.13 | 1 | 0 | maleate salt | antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug |
| trimebutine maleate salt [no description available] | 2.13 | 1 | 0 | trihydroxybenzoic acid | |
| vinblastine sulfate [no description available] | 2.13 | 1 | 0 | ||
| vincristine sulfate [no description available] | 2.13 | 1 | 0 | ||
| 3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one [no description available] | 2.13 | 1 | 0 | isoflavones | |
| (2R)-2-[[(2R,3R,4R)-2-amino-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-2-[(2S,3R,4S,5S)-5-(2,4-dioxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]acetic acid [no description available] | 2.13 | 1 | 0 | peptide | |
| n-methylscopolamine bromide scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide. | 2.13 | 1 | 0 | ||
| naltrexone hydrochloride naltrexone hydrochloride : A hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid. it is a mu-opioid receptor antagonist that is used to treat alcohol dependence. | 2.13 | 1 | 0 | hydrochloride | antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist |
| guanabenz acetate [no description available] | 2.13 | 1 | 0 | dichlorobenzene | geroprotector |
| nylidrin hydrochloride [no description available] | 2.13 | 1 | 0 | alkylbenzene | |
| triprolidine hydrochloride anhydrous triprolidine hydrochloride (anh.) : A hydrochloride resulting from the formal reaction of equimolar amounts of triprolidine and hydrogen chloride. Its monohydrate is used for the symptomatic relief of uticaria, rhinitis, and various pruritic skin disorders. | 2.13 | 1 | 0 | hydrochloride | H1-receptor antagonist |
| phentolamine [no description available] | 2.13 | 1 | 0 | ||
| fendiline hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| tiapridex Tiapride Hydrochloride: A benzamide derivative that is used as a dopamine antagonist. | 2.13 | 1 | 0 | benzamides | |
| nab-365 clenbuterol hydrochloride : A hydrochloride that is the monohydrochloride salt of clenbuterol. | 2.13 | 1 | 0 | hydrochloride | beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent |
| dithiazanine iodide [no description available] | 2.13 | 1 | 0 | benzothiazoles; organic iodide salt | anthelminthic drug; fluorochrome |
| sinequan [no description available] | 2.13 | 1 | 0 | dibenzooxazepine | |
| buflomedil hydrochloride [no description available] | 2.13 | 1 | 0 | aromatic ketone | |
| moxisylyte hydrochloride [no description available] | 2.13 | 1 | 0 | monoterpenoid | |
| dirithromycin [no description available] | 2.13 | 1 | 0 | macrolide antibiotic | prodrug |
| fluphenazine [no description available] | 2.13 | 1 | 0 | ||
| homochlorocyclizine monohydrochloride [no description available] | 2.13 | 1 | 0 | ||
| butoxamine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| scopolamine hydrobromide scopolamine hydrobromide (anhydrous) : A hydrobromide that is obtained by reaction of scopolamine with hydrogen bromide. | 2.13 | 1 | 0 | ||
| protriptyline hydrochloride [no description available] | 2.13 | 1 | 0 | hydrochloride | antidepressant |
| emetine hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| epinephrine bitartrate [no description available] | 2.13 | 1 | 0 | ||
| bicuculline methobromide [no description available] | 2.13 | 1 | 0 | ||
| 6 beta-hydroxycortisol 6 beta-hydroxycortisol: RN given refers to the (6beta,11beta)-isomer; see also record for 6 alpha-hydrocortisol. 6beta-hydroxycortisol : A C21-steroid that is cortisol bearing an additional hydroxy substituent at the 6beta-position. In humans, it is produced as a metabolite of cortisol by cytochrome p450-3A4 (CYP3A4, an important enzyme involved in the metabolism of a variety of exogenous and endogenous compounds) and can be used to detect moderate and potent CYP3A4 inhibition in vivo. | 2.13 | 1 | 0 | 11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; 6beta-hydroxy steroid; C21-steroid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | human metabolite; mammalian metabolite; probe |
| butylscopolammonium bromide Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract. | 2.13 | 1 | 0 | ||
| androst-16-en-3-one androst-16-en-3-one: boar taint steroid; RN given refers to (5alpha)-isomer. 5alpha-androst-16-en-3-one : An androstanoid that is 5alpha-androst-16-ene substituted by an oxo group at position 3. It is a steroid pheromone found in high concentrations in the saliva of male pigs,. | 2.13 | 1 | 0 | 3-oxo steroid; androstanoid | mammalian metabolite; pheromone |
| butaclamol hydrochloride [no description available] | 2.13 | 1 | 0 | ||
| dihydroouabain [no description available] | 2.13 | 1 | 0 | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; radiosensitizing agent |
| LSM-6455 [no description available] | 2.13 | 1 | 0 | peptide ergot alkaloid | |
| estradiol 17-acetate [no description available] | 2.13 | 1 | 0 | steroid ester | |
| (3aR,6aR)-5-(3-methoxyphenyl)-3-[oxo(2-pyrazinyl)methyl]-3a,6a-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione [no description available] | 2.13 | 1 | 0 | pyrrolidines | |
| chlorhexidine Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge. | 2.11 | 1 | 0 | biguanides; monochlorobenzenes | antibacterial agent; antiinfective agent |
| 3-morpholino-sydnonimine monohydrochloride [no description available] | 2.13 | 1 | 0 | ||
| cefotaxime sodium [no description available] | 2.13 | 1 | 0 | organic sodium salt | |
| N-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)-4-pyrazolyl]methyl]-2-(2-pyridinyl)ethanamine [no description available] | 2.13 | 1 | 0 | pyrazoles; ring assembly | |
| 8-hydroxyserrulat-14-en-19-oic acid 8-hydroxyserrulat-14-en-19-oic acid: antimicrobial compound from the Australian desert plant Eremophila neglecta; structure in first source | 2.11 | 1 | 0 | ||
| bucladesine Bucladesine: A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed). bucladesine : A 3',5'-cyclic purine nucleotide that is the 2'-butanoate ester and 6-N-butanoyl derivative of 3',5'-cyclic AMP. | 2.13 | 1 | 0 | 3',5'-cyclic purine nucleotide | |
| ampicillin sodium [no description available] | 2.13 | 1 | 0 | organic sodium salt | |
| penicillin g potassium benzylpenicillin potassium : Organic potassium salt of benzylpenicillin. | 2.13 | 1 | 0 | organic potassium salt | |
| piperacillin sodium [no description available] | 2.13 | 1 | 0 | organic sodium salt | |
| cefoxitin sodium [no description available] | 2.13 | 1 | 0 | organic molecular entity | |
| nafcillin sodium [no description available] | 2.13 | 1 | 0 | organic sodium salt | |
| cefamandole nafate cefamandole sodium : An organic sodium salt that is the sodium salt of cefamandole. | 2.13 | 1 | 0 | organic sodium salt | antibacterial drug |
| sodium diatrizoate histopaque: used for separating mononuclear & other cells. sodium amidotrizoate : The sodium salt of a benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, often as a mixture with the meglumine salt, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography. | 2.13 | 1 | 0 | organic sodium salt; organoiodine compound | radioopaque medium |
| estrone sulfate, potassium salt [no description available] | 2.13 | 1 | 0 | ||
| cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups. | 2.13 | 1 | 0 | organic sodium salt | |
| naproxen sodium naproxen sodium : An organic sodium salt consisting of equimolar amounts of naproxen(1-) anions and sodium anions. | 2.13 | 1 | 0 | organic sodium salt | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae. | 2.13 | 1 | 0 | ||
| piroxicam [no description available] | 2.13 | 1 | 0 | benzothiazine; monocarboxylic acid amide; pyridines | analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug |
| acenocoumarol Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. | 2.13 | 1 | 0 | C-nitro compound; hydroxycoumarin; methyl ketone | anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor |
| mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. | 2.13 | 1 | 0 | 1,3-thiazoles; benzothiazine; monocarboxylic acid amide | analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
| mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries. | 2.13 | 1 | 0 | heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| nsc 158393 NSC 158393: structure given in first source | 1.99 | 1 | 0 | ||
| demeclocycline hydrochloride demeclocycline hydrochloride : The hydrochloride salt of demeclocycline. A tetracycline antibiotic, it is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective. | 2.13 | 1 | 0 | ||
| acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections. | 2.13 | 1 | 0 | 2-aminopurines; oxopurine | antimetabolite; antiviral drug |
| inosine [no description available] | 2.13 | 1 | 0 | inosines; purines D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia. | 2.13 | 1 | 0 | benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound | adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic |
| ganciclovir [no description available] | 2.13 | 1 | 0 | 2-aminopurines; oxopurine | antiinfective agent; antiviral drug |
| kf38789 KF38789: a non-carbohydrate low MW cpd that Inhibits P-selectin specific cell adhesion; structure in first source | 2.13 | 1 | 0 | ||
| allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring. | 2.13 | 1 | 0 | nucleobase analogue; organic heterobicyclic compound | antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger |
| pralidoxime iodide pralidoxime iodide : An organic iodide salt that has pralidoxime as the cation. | 2.13 | 1 | 0 | organic iodide salt; pyridinium salt | cholinergic drug; cholinesterase reactivator |
| pralidoxime chloride [no description available] | 2.13 | 1 | 0 | organic chloride salt; pyridinium salt | cholinergic drug; cholinesterase reactivator |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Innate Inflammatory Response [description not available] | 0 | 2.05 | 1 | 0 |
| Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. | 0 | 2.05 | 1 | 0 |
| Benign Neoplasms [description not available] | 0 | 3.03 | 1 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 3.03 | 1 | 0 |
| Infections, Staphylococcal [description not available] | 0 | 2.11 | 1 | 0 |
| Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS. | 0 | 2.11 | 1 | 0 |
| Anemia, Fanconi [description not available] | 0 | 2.13 | 1 | 0 |
| Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004) | 0 | 2.13 | 1 | 0 |
| Cystic Fibrosis of Pancreas [description not available] | 0 | 2.13 | 1 | 0 |
| Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. | 0 | 2.13 | 1 | 0 |